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ABSTRACT 
With each passing decade, pancreatic cancer (PanC) is consistently emerging as an 
imminent threat to human population. Conventional therapies are proving to be of marginal 
relevance given that PanC associated fatalities are steadily rising and 5-year survival rates 
continue to plunge. Improvements in the prevention and intervention approaches are highly 
desired to diagnose the disease in its relatively early phase and prevent it from progressing to 
advanced stages of pancreatic ductal adenocarcinoma (PDAC). Of late, the focus is shifting more 
towards increased intake of dietary agents linked to reduced cases of cancer incidences in certain 
populations worldwide. One such natural agent under study for its anticancer potential is Bitter 
Melon. Previously, we have reported Bitter Melon Juice (BMJ) efficacy in activating AMPK 
(AMP-activated protein kinase) leading to apoptotic death in PanC cell and mouse models. 
Additionally, BMJ also displayed elevated potential in targeting molecular mechanisms 
responsible for gemcitabine (GEM) resistance in PanC cells. To further investigate the potential 
mechanisms of BMJ efficacy in PanC, we designed four study aims: (1) To determine the 
efficacy of BMJ in targeting and inhibiting PanC- associated cancer stem cell (CSC) pool, in 
addition to the bulk tumor population, (2) To establish the effect of BMJ in altering PanC cell 
metabolome using cell and animal models of PanC, (3) To assess the therapeutic potential of 
BMJ in combination with gemcitabine using PanC-patient derived xenografts, and finally (4) To 
determine the potential of BMJ as an effective intervention agent at various stages of PanC 
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progression in LSLKRASG12D/+;p48Cre/+ transgenic animals for enhanced translational relevance. 
Regarding study aim 1, we used sorted PanC cells (using triple positive markers for isolating 
PanC-CSCs) and tested the efficacy of BMJ in FACS sorted versus unsorted PanC cell 
populations. BMJ proved efficacious against the CSC-enriched as well as the bulk tumor cell 
populations via targeting various PanC-CSC associated transcription factors and regulatory 
markers. In study aim 2, we sought to determine the effect of BMJ in altering PanC cell 
metabolome. NMR metabolomics analysis of BMJ treated PanC cells displayed changes in 
metabolites, particularly lactate and glycolytic pathway components. The validation studies were 
further performed in a mouse model of PanC, where again BMJ showed its potential by 
significantly decreasing the tumor volumes as well as glucose and lactate transporter expression. 
Next, to address BMJ potential in combination therapy for specific aim 3, we tested the potency 
of BMJ in combination with a popular chemotherapeutic GEM, in a patient derived xenograft 
(PDX) model of PanC. The results established increased efficacy of a combination of BMJ with 
GEM in overcoming GEM resistance in PanC-PDX tumors compared to tumors treated with 
GEM alone. Furthermore, for specific aim 4, we also employed a transgenic mouse model 
LSLKRASG12D; p48Cre+/-, mimicking the progression of PanC as seen in human disease state, to 
test the efficacy of BMJ when administered at different stages of PanC progression. Collectively, 
these results highlight the value of BMJ as an effective intervention agent to target and 
modulate/regulate multiple molecular mechanisms involved in PanC tumorigenesis. 
 
The form and content of this abstract are approved. I recommend its publication. 
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With each passing decade, pancreatic cancer (PanC) is emerging as a serious threat to 
mankind; it is currently the fourth leading cause of cancer related deaths (both sexes combined) 
in the United States, and estimated to be the second most threatening form of cancer by 2030 [1]. 
It shows poor prognosis and has a disappointing 5-year survival rate of 3-5%; median survival of 
<6 months [1]. A variety of risk factors are recognized to be associated with PanC 
initiation/tumorigenesis, such as obesity, smoking, type 2 diabetes, chronic pancreatitis, age, 
gender, ethnicity, genetic mutations (inherited or acquired), alcohol consumption and infections 
[2]. However, in earlier stages, PanC remains undiagnosed owing to the symptomless 
progression of the disease to its metastatic and invasive forms. Endoscopic ultrasonography and 
endoscopic ultrasonography-guided fine needle aspiration is the available diagnostic tool for 
PanC detection [3]. Surgical resection of tumor continues to be the preferred option, which is 
possible only in the initial localized stage of this disease (only 20% of the PanC patient 
population) and does not guarantee a complete disease-free state. There are also alarmingly high 
cases (~80%) of tumor recurrence following surgical removal, chemotherapy, radiation therapy 
and even adjuvant therapies. Additionally, although improvements in surgical/ neo-adjuvant 
therapies are being made with successful increase in response rates of the patients and modest 
survival, it however accompanies increased incidences of resistance to the frontline 
chemotherapeutic drugs. A leading example is the growing number of cases of resistance to 
gemcitabine, the most widely used chemotherapeutic against PanC in clinic [3]. Even with the   
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available agents for PanC treatment, there is less survival benefit in patients at advanced stages 
of the disease and is often associated with severe side effects. Under these dire circumstances, 
there is a constant need for improvement and incorporation of newer and alternative strategies 
that aid in overcoming the current shortcomings and drawbacks in PanC management.  
More than 95% of all PanCs are manifested as pancreatic ductal adenocarcinomas (PDACs). 
There are numerous genetic events and modulations involved in PDAC initiation. A sequence of 
events occurs, starting from normal pancreatic ductal epithelium to low grade precursor lesions, 
pancreatic intraepithelial neoplasms (PanINs), mainly PanIN1, intermediate grade PanIN2A and 
PanIN2B, high grade PanINs like PanIN3 before culminating into metastatic and invasive forms 
of advanced PDAC. PanIN3 is usually concomitant with invasive stage. The accumulation of 
mutations to development of PDACs is slow and takes upto ~20 years for the generation of 
invasive form of PanC. Major genetic events are identified at each step of disease progression; 
most initial mutation to occur early on in the process is HER2 (erbB2), a member of epithelial 
growth factor receptor (EGFR) family, which is seen in PanIN1 and 2. Also, >90% of PanINs 1 
and 2 have mutated V-Ki-ras2 kirsten rat sarcoma virus (KRAS) accompanied by telomere 
shortening resulting in chromosomal abnormalities. This constitutively active KRAS protein 
favors cancer cell growth, proliferation, and survival. Towards PanIN2 stages, p16/ cyclin 
dependent kinase inhibitor 2A (CDKN2A) mutation is observed in ~85-90% cases, which has cell 
cycle regulatory and tumor suppressor functions. With advancement to PanIN2B, there is 
accumulation of TP53 mutation, accounting for ~50-75% cases and finally BRCA2 (tumor 
suppressor) and SMAD4/DPC mutations occurring at the later stages [4]. In addition to the 
frequently mutated players like KRAS, CDKN2A, TP53 and SMAD4, there are also other less 
frequently mutated genes associated with PanC, such as PTEN, CDK4, MDM2, MYC, FOXA2, 
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and SMURF1. Pancreatic tumorigenesis and progression also involve dysregulation of vital 
genes and proteins responsible for maintaining key signaling pathways associated with cell 
growth and differentiation [5]. There are 12 core cell signaling pathways and regulatory 
processes that are recognized to be aberrant in PanC (as observed in 60-100% PanC patients); 
these are mainly Hedgehog pathway, Notch pathway, Wnt/ β-catenin pathway, TGF-β pathway, 
KRAS signaling, apoptosis, DNA damage control, cell adhesion, regulation of G1-S phase 
transition, integrin signaling, and regulation of invasion and small GTPase dependent signaling 
(other than KRAS). Since these pathways work in cohorts and are interconnected with areas of 
overlaps, to aid in advancement of the disease, therefore, there is a high possibility of alterations 
in different components leading to similar effects [6]. Discussed below are the aberrant signaling 
pathways that serve as potential targets for PanC management (Fig. 1.1).  
Hedgehog pathway 
Hedgehog pathway is a core signaling pathway, under tight regulation, involved in 
normal embryonic growth and development. It helps maintain cell differentiation and 
proliferation, body patterning (anterior-posterior positioning) and stem cell maintenance. In 
postnatal cases and mature individuals, it is mostly inactive except for its role in tissue 
maintenance and repair [7]. However, it is dysregulated and reported to be involved in initiation 
and progression of a variety of cancer types such as, medulloblastoma as well as cancers of skin, 
colon, lung, prostate, breast and pancreas [8]. This signaling pathway works via its two arms; the 
canonical arm and the non-canonical arm. The canonical arm is associated with Sonic hedgehog 
(SHH) ligand initiating the cascade by binding to patched (PTCH). PTCH is a 12-span 
transmembrane receptor protein, which, in the presence of auto-processed (post translational 





















Figure 1.1: Chemopreventive agents target core signaling pathways in pancreatic cancer. 
Hh: Hedgehog, PTCH: Patched, SMO: Smoothened, SuFu: Suppressor of fused, GLI: 
Glioblastoma, JAG: Jagged, NICD: NOTCH intracellular domain, FDZ: Frizzled, Dvl: 
Dishevelled, TGF-β: Transforming growth factor beta, TβR: TGF-β receptor, IGF: Insulin like 
























































activity and physically interacts to activate 7-span transmembrane protein smoothened (SMO) 
that travels to the cell membrane [9]. Activated SMO thereby acts on suppressor of fused (SuFu) 
protein, dissociating it from the SuFu-Gli complex and renders Gli (family of zinc finger 
transcription factors) protein free. Gli translocates to the nucleus and activates the downstream 
transcription factors of Gli family such as, Gli1, Gli2 and Gli3. Thus, loss of SuFu renders the 
pathway inactive [9, 10]. In the inactive state, Gli proteins have low basal expression levels and 
are present in their repressor forms. Gli1 expression is observed along with matrix 
metalloproteinase 9 (MMP9) expression in PanC patients that correlates to reduced survival 
rates. The non-canonical arm does not require Gli mediated pathway progression and is 
categorized into Type 1 and Type 2 [10]. Type 1 includes PTCH-dependent and Type 2 refers to 
the SMO-dependent pathway progression. Generally, there are three different ligands that work 
differently to mediate hedgehog activation; desert hedgehog (DHH), Indian hedgehog (IHH) and 
Sonic hedgehog (SHH) [10]. SHH is the most extensively studied ligand in mammalian systems. 
SHH has been shown to be overexpressed in > 70% of PDACs [11]. Additionally, SHH secreted 
by tumor cells also serves as a ligand for the stromal compartment, that helps in the tumor 
progression. Under normal conditions, SHH levels are undetected at protein and mRNA levels in 
pancreatic ductal epithelium; however, the levels seem to increase with progression of the 
disease from intraepithelial lesions stages to the full-blown ductal adenocarcinoma stage [11]. 
PTCH specifically acts as tumor suppressor by catalytically inhibiting SMO but is a potential 
oncogene when mutated. This pathway has been linked to a variety of diseases linked to 
mutations in elements at each step; mutated PTCH (1 & 2) and SMO lead to basal cell carcinoma 
and medulloblastoma [12]. SMO activation is a common occurrence in PanC promotion. Gli 
proteins are the most downstream in this pathway and are responsible for activation of 
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transcription factors/ target gene expression in response to SHH ligand. These proteins act by 
regulating a balance between their activator and repressor forms. Gli1 and Gli2 act as pathway 
activators and Gli3 acts as the repressor for majority of the cases [11]. Interestingly, recent 
studies have revealed that hedgehog pathway also mediates PanC tumorigenesis by paracrine 
signaling in conjunction with the adjacent pancreatic stromal compartment and cancer stem cells 
(CSCs) [13]. It is responsible for the self-renewal potential of CSCs in multiple forms of cancer, 
including PanC [13]. Also, findings have suggested an important role of hedgehog ligand in 
dysfunctional drug transporters which hamper the uptake of chemopreventive agents/ 
therapeutics and thereby lead to PanC resistance [14]. Consequently, hedgehog pathway also 
promotes epithelial to mesenchymal transition (EMT) and helps in PanC progression and 
increased invasiveness by upregulating SNAIL family of transcription factors and 
downregulating E-cadherin levels. The pathway works individually or in sync with other 
signaling pathways like mitogen activated protein kinase (MAPK) and phosphatidylinositol-4,5-
bisphosphate 3-kinase (PI3K) cascades, to induce EMT in PanC [15].  
There are a variety of FDA approved chemotherapeutic agents or small molecules in 
preclinical settings/clinical trials that target hedgehog signaling in PanC regulation. 
Pharmacologically, the most actively targeted molecule of hedgehog pathway is SMO. 
Cyclopamine is a naturally occurring teratogenic alkaloid, a SMO antagonist. SMO antagonists 
act by targeting the desmoplastic stroma. Cyclopamine acts as a hedgehog pathway inhibitor that 
has also been shown to limit CD133+ population in PanC cells. It is known to downregulate 
target genes, Ptch1, Gli1 and Gli2 levels [16]. It has been extensively used in clinical trials for 
abrogating the metastatic form of the disease. KAAD-cyclopamine is a chemical derivative of 
cyclopamine which shows higher efficacy and reduced toxicity. A small molecule agent 
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Vismodegib (also called GDC-0449) is undergoing phase 1 and phase 2 studies in patients with 
solid tumors; it is a SMO inhibitor, actively used in PanC. It is commonly used for treating cases 
with PDAC recurrence and with progressive stages of the disease. The suggested mechanism of 
action is via caspase 3-mediated apoptosis induction, and reduced cell viability with a decrease 
in Gli-DNA binding. Its potency against PanC CSCs mediated by reduced expression of SHH 
receptors is also well established with acceptable safety/tolerance data in patients. Vismodegib 
related side effects include weight loss, alopecia, diarrhea, muscle spasms, severe birth defects 
and fetal deaths [17]. GANT58 and GANT61 are synthetically derived small molecules that act 
downstream of SMO by reducing the SHH associated alkaline phosphatase activity. GANT61 
specifically works by modulating Gli expression. Another synthetically derived small molecule 
inhibitor of SHH pathway is robotnikinin. It acts upstream of SMO and inhibits Gli transcription. 
Next in line is a SMO specific inhibitor IPI-926 (Sardegib). It affects and downregulates Gli1 
mRNA levels in PanCs. Its antitumor effect against PanC has also been observed in genetically 
engineered mouse models where it depletes the dense desmoplastic stroma that makes up the 
advanced PDACs [18]. LDE-225 (Sonidegib) is another SMO antagonist employed in PanC 
therapeutics and acts on Gli transcription factor family to produce its effects. Its efficacy has 
been observed in a variety of clinical trials in patients with advanced PDACs.   
Notch pathway 
Notch signaling is one of the regulatory pathways responsible for normal stem cell 
differentiation and maintenance. It is important in embryonic pancreas development for 
maintaining undifferentiated precursor cells. In mature individuals, this pathway is restricted to 
the centroacinar cells [19]. In PanC, it is associated with cell growth, differentiation, stem cell 
self-renewal, and tumor angiogenesis. Under normal developmental conditions, Notch pathway 
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is activated by jagged (JAG) and Delta-like family ligands, on a cell, binding to Notch receptors 
on a neighboring cell. In mammalian systems, there are four types of Notch transmembrane 
receptors present as heterodimers, namely Notch 1-4 and five types of Jagged ligands that cause 
pathway initiation by binding of these receptor ligand pairs. JAG2 is highly expressed in cells of 
PDAC; promoting cell migration and invasion leading to cancer progression [20]. Cell surface 
receptors undergo sequential cleavages, firstly by ‘a disintegrin and metalloprotease domain’ 
(ADAM) family of secretases to produce Notch C-terminal fraction and second cleavage 
mediated by γ-secretase to release the notch intracellular domain (NICD). NICD translocates to 
the nucleus, binds to cofactors and induces basic helix-loop-helix transcriptional repressors, 
hairy enhancer of split (HES) and hairy- related transcription factor (HEY) families of 
transcription factor activation. The other key downstream targets here are p21/Waf1/Cip1 and 
nuclear factor-kappa B (NF-κB) [5]. In carcinogenesis, Notch pathway is activated by receptor 
ligand interaction between adjacent cells. The ligands and receptors can be overexpressed or can 
both be expressed by the tumor cells themselves, for pathway progression. Activated Notch 
signaling has been reported in both, PanINs and full blown PDAC stages. In vivo studies have 
also employed the use of a γ-secretase inhibitor to successfully inhibit the Notch pathway in 
KPC mice, affecting PanC progression to invasive forms [21]. Notch1 deletion accelerates PanIN 
development and decreases the median survival [22]. Activation of multiple Notch pathway 
components like Notch 2-3, JAG1 and DLK1 has been observed in PDACs. Downstream genes 
like Hes1 is also known to be overexpressed in PanINs and advanced metastatic forms of PanCs 
compared to normal pancreas. Various mechanisms have been attributed to Notch activation in 
PDACs. Majorly, EGFR and mutational status of Ras have been linked to Notch initiation. Also, 
NF-κB activity has been associated with Notch 1 overexpression, which in turn leads to PanC 
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growth and promotion. Elevated Notch 1 levels are seen in pancreatic CSCs [23, 24]. This 
pathway leads to EMT phenotype acquisition in mesenchymal cells of PanC, resulting in 
metastasis and invasion. Results from completed and ongoing clinical studies also provide 
evidence for Notch pathway being actively involved in resistance to chemotherapy of PanC [25].  
Agents developed to target Notch signaling mostly focus on inhibiting the Notch 
receptors and ligands. Additionally, drugs/agents also target the receptor-ligand binding, γ-
secretase activity and the nuclear transcriptional complex. Antibody therapies include Notch 
ligand inhibitor OMP-21 M18 (demcizumab), a DLL4 monoclonal antibody being tested in 
phase 1 clinical trials for PanC patients. DLL4 specific antibodies have been shown to bind and 
regress tumor growth in patients with solid pancreatic tumors [26]. Cetuximab, a monoclonal 
antibody directed towards growth factor receptor ErbB1 has been successful resulted from phase 
2 and phase 3 clinical studies when used alone or in combination with other PanC drugs [27]. 
OMP-59 R5 (tarextumab) reduces PanC CSCs when used with other chemotherapeutic agents 
like gemcitabine and nab-paclitaxel, by inhibiting Notch 2 and Notch 3 [28, 29]. RO4929097 is a 
γ-secretase inhibitor (GSI) administered orally to PanC patients; it has shown successful anti-
tumor efficacy in both in vitro and in vivo studies. It acts by inducing apoptosis and regressing 
tumor progression in PDAC mouse models (orthotropic and transgenic mouse models). It has 
also proved to be highly potent with lesser side effects in early phase clinical trials in PDAC 
patients [30]. Other GSIs like PF-03084014, GSI-18, and MRK-003 have high efficacy against 
PanC [19]. PF-03084014 is a non-competitive small molecule, when used in combination with 
docetaxel, leads to enhanced anticancer efficacy by increasing tumor latency. PF-03084014 has 
human safety data with increased tolerability in patient population with solid tumors and suitable 
pharmacokinetic (PK) profile. MRK-003 when used in combination with gemcitabine attacks 
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tumor endothelial cells and causes hypoxic necrosis and slows tumor progression in PanC 
patients [31]. In PanC patient derived xenograft (PDX), MRK-003 efficiently downregulates 
Notch target genes and causes tumor growth inhibition. In vitro studies with PanC cell lines 
showed decreased CSCs with MRK-003 exposures. Combination therapies involving MRK-003 
and gemcitabine treatments prolong survival in PanC patients [32]. γ-Secretase ends up cleaving 
a plethora of substrates in addition to Notch receptors, leading to subsequent disadvantages 
associated with the use of its inhibitors. Also, there is no distinction between the different Notch 
receptor subtypes for the GSIs to cause their specific effect. There are side effects linked to the 
use of GSIs, mainly cardiovascular toxicities, diarrhea and several types of infections.  
WNT pathway 
Wnt signaling is another important regulatory pathway for embryonic development and 
adult tissue and organ proliferation, differentiation, development, and stem cell homeostasis. It is 
involved in body patterning and germ layer formation. Epigenetic modifications lead to 
unregulated pathway activation where Wnt inhibitors become hypermethylated. The pathway can 
be activated in PanC by various mechanisms, such as excessive mutations in pathway members, 
increased ligand expression levels or decreased levels/inactivity of pathway inhibitors leading to 
EMT and PanC progression [33]. Mutations arise in various components of Wnt pathway such as 
APC (adenomatous polyposis coli), Axin, and β-catenin, as seen in PDACs. Wnt is upregulated 
in PDACs and there is an aberrant localization of β-catenin (nuclear/cytosolic). Clinical results 
from PDAC patients show increased levels of Axin2 [34]. Wnt signaling proceeds by its 
canonical and non-canonical arms. Wnt5a is the ligand responsible for activating the non-
canonical branch in PanC. Studies have also shown that Wnt2 is involved in PanC metastasis. 
The canonical arm is β-catenin dependent, more common and extensively studied in PDACs, 
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compared to the non-canonical arm that works independent of β-catenin [35]. In the absence of 
Wnt ligands, a cytosolic complex of glycogen synthase kinase 3 (GSK3), casein kinase 1α 
(CK1α), Axin and adenomatous polyposis coli (APC) is intact and responsible for 
phosphorylation and subsequent degradation of β-catenin. Wnt ligand binds to the 
transmembrane Frizzled (FDZ) receptor / low density lipoprotein receptor related protein (LRP) 
5 or 6 receptor, and this interaction activates downstream molecule Disheveled (Dvl) by 
phosphorylation and polyubiquitination to release β-catenin which freely translocates to the 
nucleus. In the nucleus, it binds to and activates the downstream lymphoid enhancer binding 
factor (LEF) and T-cell factor (TCF) transcription factors [36]. This pathway is commonly active 
in majority of the PanC cell lines and confers anti-apoptotic properties to these cells for disease 
advancement. Wnt pathway has also been implicated in CSC maintenance in PanC. In certain 
PDAC cases, Wnt alone is not solely responsible for carcinogenesis but becomes activated in the 
presence of KRAS mutation to give rise to PanINs and invasive PanC [33], [37]. Axin2 and 
transcriptional co-activators like TCF1 and LEF1 under ideal circumstances, act as pathway 
inhibitors upon activation as target genes and contribute to regulation of the pathway. β-catenin 
has also been shown to support PDAC cell proliferation and tumor progression in certain mouse 
xenograft models [38]. Activated Wnt signaling in PanC patients is an important biomarker 
which correlates to poor survival rates and therefore serves as a potential therapeutic target. 
Since Wnt signaling pathway is commonly dysregulated in PDACs, therefore, a variety 
of therapeutic agents have been developed to target its various components. PRI-724 is a β-
catenin modulator, undergoing clinical trials in PanC patients. It is generally used in combination 
with gemcitabine in PDAC patients with metastatic tumors, or as second in line during 
treatments. Small molecule inhibitor of β-catenin/TCF4 pathway, ICG-001, works by causing G1 
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cell cycle arrest in PDAC patient tumors. However, its specificity towards Wnt pathway 
inhibition is still unclear. OMP-18R5, a Wnt inhibitor, is a monoclonal antibody that mediates its 
anti-tumor efficacy against PanC by binding to FDZ1, FDZ2, FDZ5, FDZ7 and FDZ8, and 
blocks β-catenin efficiently. It has been tested in vivo in mouse xenograft studies and displayed 
significant tumor inhibition and tumor latency. For clinical trials, it is often combined with 
paclitaxel for increased tumor inhibition [38]. OMP-54F28 is another Wnt ligand and receptor 
inhibitor that successfully inhibits PanC growth and progression. It is commonly used with 
gemcitabine in phase 1 and 2 clinical studies in PDAC patients. Results from pancreatic 
xenograft studies in mice point to better efficacy of OMP-54F28 alone than in combination with 
gemcitabine; OMP-54F28 was also found to target PanC CSCs. However, certain side effects 
linked to OMP-54F28 use in clinical studies are muscle spasms, nausea and fatigue, and its 
safety and toxicity levels are yet to be determined [39]. 
TGF-β pathway 
Transforming growth factor- beta (TGF-β) pathway is an important regulator of cellular 
proliferation, differentiation, adhesion, survival, microenvironment, and tissue homeostasis. 
Under ideal circumstances, TGF-β pathway acts as a tumor suppresser, however, its mutant form 
is an active component of tumorigenesis and is found to be deregulated in various cancer types, 
including PDACs (≥50%) [40, 41]. Modification of this pathway is critical to the functioning of 
both tumor cell and stromal cell compartments. TGF-β has three mammalian isoforms, viz., 
TGF-β1, TGF-β2, and TGF-β3; TGF-β1 being the most common and extensively studied. The 
pathway is activated by receptor-ligand interaction and dimerization of the serine/threonine 
kinase receptors TGF-β type 1 receptor (TβRӀ) and TGF-β type 2 receptor (TβRӀӀ) that are 
commonly found to be mutated in PanCs [42]. TβRӀӀ kinase in turn trans-phosphorylates and 
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activates TβRӀ kinase, which results in receptor-regulated SMADS (R-SMAD)/small and 
mothers against decapentaplegic (SMAD4) complex to translocate to the nucleus and kick starts 
a signaling cascade involving (or independent of) SMAD family of proteins. SMAD4 is a key 
player and major target in canonical form of the pathway and is often seen to be inhibited in 
PanINs, its activity is lost in the advanced forms of PDACs but is seen to be intact during early 
PanIN stages [43-45]. It complexes with SMAD2 or SMAD3 and is regulated by E3 ubiquitin 
ligase SMURF1 for increased invasiveness of the disease [46]. In the tumor cell compartment, 
TGF-β generally acts as a tumor suppressor in normal/ early tumor phase; however, as the tumor 
progresses, TGF-β adds to the oncogenecity [47]. The difference in the functions is dependent on 
SMAD mediated or SMAD independent pathways. Elevated TGF-β levels have been reported in 
PanC and are linked to dismal patient survival by increased progression, invasion and liver 
metastasis. It also stimulates PanC cells in conjunction with activated KRAS to undergo EMT 
for increased aggressiveness. SMAD3 and SMAD4 overexpression has been associated with 
increased EMT; however, increased expression of SMAD7 results in the contrary. The tumors 
lacking SMAD4 are known to be more aggressive, therefore, SMAD-dependent signaling is a 
more appropriate candidate for directed therapeutics [48]. SMAD independent pathway works 
through activated TGF-β receptors, in accordance with MAPK and PI3K signaling pathways 
[49]. TGF-β signaling is not restricted to just the autocrine form but paracrine signaling has also 
been seen between the tumor and its microenvironment [50, 51]. TGF-β helps mediate the 
transition of fibroblasts to myofibroblasts to secrete growth factors, and causes a fibrous 
reaction, which also aids EMT and human PanC progression [52, 53]. GATA6 is another 
downstream target of this pathway. Ideally, GATA6 inhibits TGF-β1 promoter and complexes 
with SMAD2 during embryogenesis. Forkhead box A2 (FOXA2) is another major molecule that 
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inhibits and regulates the TGF-β signaling [46]. Therefore, an overexpression of GATA6 and 
FOXA2 is seen in altered TGF-β pathway for PanC progression.  
There are numerous ongoing clinical trials with inhibitors of the TGF-β pathway. AP 
12009 (trabedersen) is a synthetic 18-mer antisense phosphorothioate oligodeoxynucleotide that 
specifically targets TGF-β2 biosynthesis [54] and is being actively investigated in phase 1/2 
clinical studies, since it is a key factor involved in malignant PanC [55, 56]. It has shown 
significant antitumor in vitro and in vivo studies involving PanC cell lines [56]. SD-208, a small 
molecule ATP competitive inhibitor of ALK5, a TGF-β receptor, actively inhibits PanC invasion 
in vitro, as observed in SMAD4 dependent PanC cell lines [5, 57]. It is a selective and highly 
effective pyridopyrimidine TβRӀ inhibitor which complexes with TβRӀ kinase and renders it 
inactive [58]. LY2157299 is another small molecule inhibitor of TβRӀ. It acts by affecting tumor 
migration and invasion in PanC. LY3022859 is also a TβRӀӀ inhibitor, currently being 
investigated in phase 1 trials for PanC [59]. Despite the trials for establishing potential 
therapeutic drugs for TGF-β pathway, there has been only modest progress. The survival rates 
and associated side effects are yet to be managed and no breakthrough has been achieved with 
the currently available agents. 
Insulin like growth factor (IGF) pathway 
This pathway plays an important part in normal cell growth regulation and apoptosis. In 
cancerous cells, this pathway is overexpressed/hyper activated to support cell survival and 
proliferation; it also mediates angiogenesis via vascular endothelial growth factor (VEGF) 
upregulation, to help in tumor progression. IGF complex comprises of polypeptide ligands IGF-I 
and IGF-II, cell membrane receptors IGF-IR and IGF-IIR, and six binding proteins IGFBPs. 
Ligands bind to the receptors, majorly IGF-IR, a tetrameric transmembrane receptor tyrosine 
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kinase with α and β subunits, to activate the signaling cascade, by causing receptor dimerization 
and cross-phosphorylation of the kinase domain [60]. Signaling progresses as the intracellular 
substrates are phosphorylated such as insulin receptor substrate 1-4 (IRS1-4) and Src homology 
collagen (Shc) which in turn activates the PI3K/Akt/mTOR, MAPK and STAT pathways. These 
pathways are responsible for maintaining cell proliferation, survival, differentiation, 
transformation, and apoptosis. Studies have reported 70-100% of the core metabolic pathways 
being targeted by IGF-IR in PDAC progression [6]. High degree of homology has been observed 
between other insulin receptors and IGF-IR [61]. Additionally, increased IGF-IR levels have 
been directly linked to greater risk of developing different kinds of neoplasms [62, 63]. Human 
PanC cells and tissues display high expression levels of IGF-I [64]. IGF-IR is also reported to be 
commonly expressed at increased concentrations in human PanC [65]. Its role has been shown to 
be of great importance in tumor growth and metastasis even in the absence of IGF-I, which could 
possibly be a result of other growth factors activating IGF-IR or its constitutive activation in 
tumors. Notably, PanC risk is also associated with increased serum concentrations of IGF-I and 
IGFBP-3. Results from in vitro and in vivo studies indicate a decrease in PanC tumorigenicity by 
favoring IGF-IR blocking.  
Currently there are close to 30 ongoing clinical trials testing the IGF-IR targeting agents; 
these include use of monoclonal antibodies designed to target the IGF ligands and receptors as 
well as IGF-IR tyrosine kinase inhibitors. Targeting IGF-IR with monoclonal antibodies seems 
like a very interesting option as it is the primary receptor for both IGF-I and IGF-II [60]. A small 
molecule tyrosine kinase inhibitor of IGF-IR family of kinases is BMS-754807, which acts by 
inhibiting the catalytic domain of the receptors. It has already been shown to be a potent 
anticancer agent in PanC cell and animal models [66, 67]. It is a dual inhibitor of IGF-IR/IR [67]. 
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It is currently being investigated in a variety of phase 1-2 trials with gemcitabine and cetuximab 
[68]. Another orally available, small molecule tyrosine kinase inhibitor specific to IGF-IR is 
NVP-AEW541 [69, 70]. Its anticancer efficacy has been reported in cells and orthotropic animal 
models of PanC. It inhibits migration, vascularization and metastasis, and STAT3 
phosphorylation [71]. However, in PanC patients, it causes adverse effects on the insulin receptor 
signaling pathways and induces significant weight loss. R1507 (teprotumumab) is a human IgG1 
type monoclonal antibody targeting IGF-IR and inhibits the signaling propagation. It specifically 
binds the extracellular domain of the receptor and displaces bound IGF-I. It is effective against 
PanC xenograft models and causes tumor inhibition [72, 73]. CP-751871 (figitumumab) is 
another highly specific human monoclonal antibody that acts by inhibiting ligand induced IGF-
IR autophosphorylation in human PanC. It is being tested in phase 1 clinical trials and 
demonstrates high efficacy and low dose limiting toxicities, alone or in combination therapies 
[74]. AMG 479 (ganitumab) is next in the list of human monoclonal IgG1 antibodies designed to 
target IGF signaling. It binds and inhibits IGF-IR homodimers [75]. It acts by preventing the 
binding of IGF-I and IGF-II to IGF-IR and has acceptable toxicity data from phase 1 and 2 
clinical trials [76, 77]. There are a variety of other inhibitors designed to target this pathway that 
are undergoing patient trials for PanC. However, majority of these trials, even with combinatorial 
strategies have failed to improve patient survival in PanC patients, mainly due to development of 
drug resistance by activation of other survival pathways [76, 78].  
Pancreatic cancer management using other chemotherapeutic drugs/techniques 
Apart from the above mentioned aberrant signaling pathways and chemotherapeutic agents 
targeting the associated mechanisms, there are many other clinical drugs and strategies (in use 
and under investigation) that have different targets and decent survival statistics when used alone 
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in monotherapies or in combination therapies against PanC. Briefly, some of these strategies and 
targeted therapies directed towards PanC management are detailed below; Table 1.1 also 
summarizes their molecular targets and associated toxicities.  
Surgical resection of the tumor in patients with initial localized stage of PanC is deemed 
fit. This approach along with adjuvant therapies has been proven to increase overall patient 
survival [79]. Gemcitabine is the drug of choice for PanC patients with locally advanced or 
metastatic PDACs, where tumor resection is not an option. It is a nucleoside analogue of 
cytidine, and the frontline drug of choice for PanC based on the results of phase 3 clinical trials, 
wherein it showed modest patient survival with lower toxicity levels, in comparison to other 
comparable anti-cancer agents like 5-fluorouracil (5-FU). Post cellular uptake, it is 
phosphorylated and metabolized to its active form difluorodeoxycytidine diphosphate (dFdCDP) 
and difluorodeoxycytidine triphosphate (dFdCTP). Both of these metabolites are highly capable 
of interfering with DNA transcription and help inhibit PanC progression [80]. However, 
increased therapeutic efficacy is observed with combination therapies involving gemcitabine and 
targeted agents in PanC patients, like erlotinib, as opposed to using gemcitabine alone as 
monotherapy [81]. To date, erlotinib is the only approved and clinically accepted standard drug 
used in combination with gemcitabine for PDAC patients [82]. Erlotinib is an orally 
administered small molecule inhibitor of EGFR tyrosine kinase activity. It was approved by FDA 
in 2007 and is a targeted agent that acts by blocking autophosphorylation of the receptor dimer 
and inhibiting the downstream targets. It is commonly used for locally advanced, unresectable 
PanCs. However, when used as individual agents, gemcitabine and erlotinib are capable of 
causing interstitial lung disease (ILD) [83, 84]. Next, FOLFIRINOX is another combination of 
chemotherapeutic drugs folinic acid, 5-FU, irinotecan and oxaliplatin, used for treating PDACs,  
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Table 1.1: Targeted therapies for pancreatic cancer management 
 
Agent Targets PanC clinical studies Toxicities/Side effects 
Gemcitabine 
(Gem) 
Inhibits hedgehog and 
EGFR pathway in PanC. 
Causes cell cycle arrest by 
inhibiting ribonucleotide 
reductase. 
Completed (Gem with or w/o Erlotinib) 
NCT00026338. 
Phase 3 (Gem with or w/o Erlotinib) 
NCT01013649. 
Phase 3 (Gem + Masitinib) 
NCT00789633. 




interstitial pneumonitis, biliary 
tract infections, fever, fatigue, 
nausea and skin rashes. 
5-fluorouracil  
(5-FU) 
Targets DNA replication. 
Inhibits thymidylate 
synthase. 
Completed (5FU with or w/o adjuvant) 
NCT01494506. 
Phase 2 (5FU + Calcium levofolinate) 
NCT02697058. 
Completed (5FU + Radiation) 
NCT00424827. 
Phase 2 (5FU + Vitamin C) 
NCT01905150. 
Gastrointestinal and skin 
toxicities, myelosuppression, 
fatigue, diarrhea, mucositis, 
nausea and loss of appetite. 
Erlotinib Small molecule (EGFR) 
tyrosine kinase inhibitor. 
Phase 3 (Erlotinib + Gem) [86]. 
Phase 2 (Erlotinib + Gem) in patients 
with metastatic PanC [86]. 
Completed (Erlotinib + Bevacizumab) 
NCT00614653. 
Severe lung and skin toxicity, 
interstitial lung disease, 
diarrhea, fatigue and vomiting. 
Nab-paclitaxel Causes inhibition of 
mitosis leading to cell 
cycle arrest, and apoptosis 
induction. Possible targets 
include Notch and Wnt 
signaling pathways. 
Completed (Nab-paclitaxel + Gem) 
NCT01442974. 
Phase 2 (Nab-paclitaxel + 
FOLFIRINOX) NCT02241551. 
Phase 1 (Nab-paclitaxel + 
Enzalutamide) NCT02138383. 
Grade 3 hematologic toxicities 
(neutropenia, anemia, 
thrombocytopenia), 
neuropathy and fatigue. 
Cetuximab Monoclonal antibody 
against EGFR. Prevents 
ligand binding, increases 
EGFR degradation and 
causes G1 arrest. 
Completed (Cetuximab + 
Cyclophosphamide) NCT00305760. 
Phase 2 (Cetuximab + Intraoperative 
imaging) NCT02736578. 
Completed (Cetuximab + Irinotecan + 
Oxaliplatin) NCT00871169. 
Acne like rash, asthenia, 
dyspnea, abdominal pain, 
diarrhea and leucopenia. 
Bevacizumab Monoclonal antibody 
against VEGF A. 
Completed (Bevacizumab + Erlotinib) 
NCT00614653. 
Phase 2 (Bevacizumab + Gem + 
Radiation) NCT00460174. 
Completed (Bevacizumab + Gem + 
Oxaliplatin) NCT00112528. 
Neutropenia, neuropathy, high 
blood pressure/ hypertension, 
gastrointestinal perforations, 








both locally advanced and metastatic PanCs [85]. It is the more popular treatment of choice in 
the UK at present for patients with PDAC. Results from its use shows prolonged survival but 
poor quality of life. It has a greater anticancer efficacy compared to gemcitabine but is associated 
with systemic and neuro toxicities [87, 88]. Nab-paclitaxel is another chemotherapeutic drug, a 
taxane compound used in PanC management since 2013. It is a nanoparticle albumin bound 
paclitaxel prepared with human serum albumin, which provides substantial antitumor activity 
against PDACs [89]. It is a hydrophobic drug that binds to β subunits of tubulin and causes 
mitotic blockage with cell cycle arrest, leading to apoptosis. Results from preclinical and early 
clinical studies also point to its potential as a chemotherapeutic agent. It is used mainly in 
combination with gemcitabine where it improves the overall survival by 8.5 months compared to 
gemcitabine monotherapy [90, 91]. Cetuximab is a chimeric human monoclonal antibody 
directed against EGFR and alters cell growth and differentiation in PanC. It is known to enhance 
radiosensitivity and induce apoptosis, as seen in various in vitro and in vivo studies [92]. 
Bevacizumab, a human monoclonal antibody specific for VEGF A epitope site and an anti-
angiogenic agent, inhibits the ligand-receptor interaction in PanC tumors [93]. These antibodies 
are used individually, together or in combination with gemcitabine for phase 2 clinical studies 
and have shown better overall survival with gemcitabine addition [94]. Despite the moderate 
success rate in the patient overall survival, there are multiple mechanisms responsible for 
developing resistance against these drugs, rendering them ineffective.  
Chemoprevention with natural non-toxic compounds/agents 
Chemoprevention is essentially the ability of products/agents to delay or prevent the 
development and progression of pre-cancerous lesions to advanced forms of the disease. These 
agents exhibit potency in populations that are predisposed and have a greater risk of developing 
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cancer in their lifetime [95, 96]. An ideal candidate that qualifies for being a chemopreventive 
agent should have its specific targets overexpressed in cancerous cells, exert its effect on the 
tumor cells and be nontoxic to the healthy/normal surrounding cells and tissue. Both synthetic 
and natural compounds have been tested for their chemopreventive properties in vitro, in vivo 
and in clinical trials. Natural agents generally act by targeting multiple pathways of 
carcinogenesis as opposed to synthetic agents that usually have a specific target. These agents 
are being evaluated individually or in combination with the chemotherapeutic agents to study the 
nature of drug interactions in patient populations [97, 98]. Although individuals rely heavily on 
FDA approved drugs for PanC containment, these compounds do succeed to a certain degree but 
not without the side effects. Therefore, the current focus is shifting more towards the use of 
plant/dietary derived agents that have increased potential for PanC chemoprevention with 
minimal to no side effects in human population (Table 1.2) [99, 100]. Importantly, they can also 
serve as great candidates for combination therapies in the clinic, in conjunction with therapeutic 
agents.  
Curcumin 
Curcumin (diferuloyl methane) is a natural bioactive compound isolated from the rhizome of a 
spice Curcuma longa (turmeric plant). It belongs to the class of polyphenols and is a routinely 
used agent for coloring and flavoring in Asian cuisines with various health benefits resulting 
from its anti-inflammatory, antioxidant, and anticancer properties. It targets cellular growth, 
proliferation, survival, apoptosis, metastasis, migration and angiogenesis in various cancer types, 
including PanC [101, 102]. It has been reported that curcumin targets Notch pathway in PanC to 
inhibit cell growth and induce apoptosis. In vitro studies have also shown the role of curcumin in 
inhibiting PanC cell proliferation and suppression of NF-κB activation [103].  
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Table 1.2: Natural agents in pancreatic cancer chemoprevention 
 




↓NF-κB, growth inhibition & 
apoptosis. 
↑FOXO1, inhibits PI3K/Akt. 
Reversal of EMT & COX-2 
suppression. 
Targets Notch, WNT, EGFR & 
STAT signaling. 
Phase 1/2 (in Gem 
resistant patients) [104]. 
Phase 1/2 (Curcumin + 
Gem) [105]. 








Source: Cruciferous vegetables 
Apoptosis induction, ↓NF-κB,  
VEGF & Cyclin D. 
Blocks cell proliferation & 
induces cell cycle arrest and 
reduces EMT. 
↑ROS generation and decreases 
phospho-Akt. 
Targets PanC CSCs and hedgehog 
pathway. 








Inhibits cell growth & invasion, 
induces apoptosis, ↓ NF-κB. 
Targets PanC CSC renewal, 
↓EMT, cell migration & 
clonogenecity. 
Inhibits FOXM1, hedgehog & 
Notch signaling. 
Chemosensitizes PanC cells to 
Gem & cisplatin. 
Phase 1 (Genistein + 
Gem) [108]. 
Phase 2 (Genistein + 
Gem + Erlotinib) [109]. 
Phase 1 (Gem + 







Source: Green tea 
Inhibits cell growth & 
proliferation and hedgehog 
pathway. 
Targets Hsp -70 & Hsp-90. 
↓ phospho Akt, KRAS gene, 
↓ MMPs & PanC CSC associated 
regulatory molecules. 
Phase 1 (Gem + 











































Table 1.2 cont’d 
 




Targets hedgehog and MAPK 
signaling cascades. 
Induces mitochondrial dependent 
apoptosis. 
↓ phospho ERK, c-Jun, and ↑ROS 
mediated JNK activation. 









Source: Grapes, berries, plums, and peanuts. 
Targets Wnt, Hh and PI3K/Akt 
pathways. 
↓ β-catenin localization to the 
nucleus. 
↓ Notch 1 protein & phosphor 
ERK, Akt. 
Decreases EMT and modulates 





Bitter Melon juice 
Source: Bitter Melon 
a) Cucurbitane type triterpenoids 
Kuguacin J 
 
b) Cucurbitane type triterpene glycosides, such 
as Charantoside 
 
↓cell viability and ↑apoptosis in 
PanC cells. ↓Survivin and XIAP, 
↑p21, CHOP, MAPKs. 
Activates AMPK. 
↓Akt and pERK1/2 in Gem 
resistant PanC cells. 
Targets PanC CSCs and 




































NF-κB has an established role in conferring chemoresistance to PanC cells by inhibition of 
apoptosis [110, 111]. It is constitutively active in PanC cells but not in normal ductal epithelial 
cells, and the expression is also present in in vivo models and human PanC tissue. Therefore, 
targeting NF-κB in PanC progression could lead to the development of a potent chemopreventive 
agent. Curcumin helps to downregulate the NF-κB gene products’ expression, which in turn 
affects NF-κB mediated apoptosis, invasion, proliferation and metastasis. It promotes apoptosis 
in PanC cells via caspase activation and subsequent release of cytochrome c. Results from cell 
and animal studies point to the efficacy of curcumin in reducing angiogenesis and cell growth in 
a dose and time dependent trend [112]. Another molecule that is downregulated in the presence 
of curcumin is cyclooxygenase 2 (COX-2), which is overexpressed in human PDACs, and 
associated with increased cell proliferation, metastasis, angiogenesis, and VEGF production 
[113]. Results from PanC cell treatments with curcumin show decreased EGFR expression and 
hampered ERK1/2 activity [114]. It also dysregulates specific miRNAs; upregulates a few and 
downregulates some in human PanC cells to exert its anticancer efficacy [115]. It also selectively 
targets CSCs in different cancer types and significantly inhibits the sphere forming ability of 
PanC cells, verified by downregulation of CSC associated markers like CD44 and EpCAM 
[116]. Gemcitabine resistance has been observed in a variety of PDACs, which is thought to be 
exerted via NF-κB dysregulation. Curcumin exposure affected cell proliferation and 
angiogenesis and enhanced the antitumor activity of gemcitabine in MiaPaCa2 orthotropic 
xenograft mouse model [103]. PK-phamacodynamic (PD) analysis of curcumin shows its low 
bioavailability with nil dose-limiting toxicities. Data from these studies hints at microgram levels 
of the phytochemical required for efficacy in PanC carcinogenesis [117]. Issues with 
bioavailability of this natural agent have led to development of its synthetic analogues FLLL11, 
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FLLL12 and difluoro compound CDF. Additionally, different routes and forms of exposure are 
being evaluated to increase its bioavailability to the cancer site. Studies have incorporated 
liposome encapsulated curcumin for intravenous drug delivery to MiaPaCa2 and BxPC3 
xenografts; it causes reduction in the tumor volume by increasing apoptotic cell death and 
inhibiting angiogenesis [112]. In different combination therapy studies, curcumin was dosed 
together with gemcitabine, celecoxib, and paclitaxel. These treated PanC cells showed elevated 
sensitization to the chemotherapeutic agents when given with curcumin [103, 114, 118]. For the 
clinical trials with PDAC patients with locally advanced or metastatic disease, curcumin is used 
in monotherapies or in combination with gemcitabine or nonsteroidal anti-inflammatory drugs 
(NSAIDs). In phase 2 and 3 clinical studies with curcumin, the results indicated towards 
increased anticancer efficacy/biological activity associated with decreased NF-κB, COX-2 and 
pSTAT3 levels, but poor oral bioavailability in patients with advanced PanC [106, 119]. There 
was no visible toxicity observed with an oral dose of 12gm/day of curcumin in both, healthy 
individuals and PanC patients [95, 120]. Although it does have minimal side effects like diarrhea 
and nausea, curcumin still shows great potential as a chemopreventive agent in PanC 
management [121].  
Sulforaphane 
Sulforaphane is a naturally occurring isothiocyanate derived from cruciferous vegetables 
and exists as conjugate in family Brassicaceae, mainly broccoli, cauliflower, cabbage, garlic, etc. 
In these vegetables, isothiocyanates are readily enzymatically hydrolyzed from glucosinolates; 
glucoraphanin. The basic structure contains a β-D-thioglucose group, a sulfonated oxime group 
and a variable side chain. The chemopreventive effect is attributed largely to the isothiocyanates 
than the parent glucosinolates. It causes cell cycle arrest, suppresses cellular proliferation and 
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induces apoptosis in PanC cells as well as PanC associated CSCs by targeting the hedgehog 
pathway and affecting their self-renewal potential and EMT [122-124]. Results from in vivo 
studies have shown its anticancer potential against carcinogen-induced cancer in rodents. The 
mechanism of action is thought to be inhibiting activation of signaling molecules such as 
STAT3, NF-κB, Akt, MAPK, as well as p53 and COX-2 levels [125]. Data from PK analysis of 
dietary absorbed sulforaphane shows its improved bioavailability and µmol/L blood 
concentration [126, 127]. Its chemopreventive potential is exerted by apoptosis induction and 
cell cycle arrest [128]. It also primarily affects and reduces the expression of NF-κB and 
associated genes mediating cell adhesion, inflammation, apoptosis and growth factors [129]. It is 
also known for its ability to target and inhibit the Nrf2-Keap1 pathway [126]. It acts by targeting 
and complexing with the thiols on Keap1, assisting in Nrf2 dissociation from the complex, and 
activation of this pathway by binding to ARE (antioxidant response element) in the nucleus and 
causing transcriptional upregulation. This triggers the downstream gene expression of phase 2 
biotransformation pathway enzymes for carcinogen elimination from the body. It inhibits 
CYP450 phase 1 enzymes and induces the activation of phase 2 enzymes. Sulforaphane has 
impressive results from studies involving resistance of PanC to chemotherapeutics. In vitro 
studies incorporating use of sulforaphane in combination with other chemotherapeutic drugs in 
various cell lines, showed its enhanced effect in overcoming drug resistance in cancer cells 
[129]. Treatment of PanC cells with three different agents, namely sulforaphane, wogonin, and 
resveratrol, was capable of overcoming treatment resistance in pancreatic tumor initiating cells 
(TICs) with the maximum observed effect in the presence of sulforaphane. In vivo models of 
MiaPaCa2 xenografts when exposed to sulforaphane showed apoptosis induction in the TICs 
without any cytotoxic effects on the surrounding normal cells. Sulforaphane and its thiol 
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conjugates have a plasma concentration of 2-6 µM within a couple hours of dosing but relatively 
shorter half- lives of ~2.2 hours [126]. It is an ideal chemopreventive agent owing to its 
properties of serving as an antioxidant, anti-proliferative, anticancer and antiangiogenic agent. 
Monotherapies and combination therapies of sulforaphane are tested in completed or ongoing 
clinical trials which ensure its potential as a novel chemopreventive agent in PanC [107].   
Genistein 
Genistein (4’,5,7-trihydroxyisoflavone) is a dietary agent, an isoflavone derived from 
soybean and soy products. It has a heterocyclic, diphenolic structure: as known for estrogen. Soy 
isoflavones have been included in a variety of PanC and other cancer studies for their established 
potential as strong anticancer agents. Genistein causes apoptosis induction and cell growth 
inhibition in PanC cells by inhibiting tyrosine kinases, protein kinases, DNA topoisomerase II 
and by targeting nonoxidative ribose synthesis, as seen in different tumor models including 
PanC. It also increases the sensitivity of these cells towards chemotherapeutics by targeting the 
core signaling pathways and their downstream molecules like PI3K/Akt, TGF-β and NF-κB. The 
other aspects of its mechanism of action involve cancer cell cycle arrest, suppression of 
angiogenesis and metastatic capability of human PanC, as seen in BxPC3 cells. It has shown 
great potential as a chemopreventive agent in combination with docetaxel and cisplatin by 
causing increased growth inhibition in cancerous BxPC3 cells with reduced cytotoxicity in 
normal cells. The induction of apoptosis by genistein has been associated with NF-κB inhibition, 
which in turn can confer heightened chemosensitivity to PanC cells and orthotropic mouse 
models [130-132]. Studies on PANC1 cells exposed to genistein also revealed EMT suppression 
with reduced invasion and migration [133]. Genistein acts by a variety of pathways to inhibit 
carcinogenesis, with one of the targets being miRNAs. It causes downregulation of mi233 
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expression levels which suppresses PanC cell growth and migration [134]. Certain in vitro 
studies have reported its role in modulating EMT in chemoresistant PanC cells. Other studies 
have linked the beneficial anti-cancer effect of genistein to FoxM1 expression [133, 135]. Its 
chemopreventive and inhibitory effects have also been observed against PanC associated CSCs, 
which has been attributed to its potential to suppress Notch pathway. Combination therapies with 
TRAIL/Apo2L, a tumor necrosis factor (TNF) superfamily member and genistein helped 
overcome the drug resistance in AsPC1 cells by activating caspase-3 and in part by affecting 
PI3K/Akt pathway. It also improves the efficacy of erlotinib in a variety of PanC cell lines by 
significantly suppressing Akt and NF-κB [136, 137]. Reduction in pSTAT3 levels with genistein 
treatment is also known to be mediated through inhibition of protein tyrosine kinases. In animal 
models of PanC, genistein was successful in decreasing tumorigenesis (with increased apoptosis 
observed in treated tumor tissue) and increasing animal survival [138]. Genistein has proven to 
be effective in not only in vitro and in vivo pre-clinical studies, but also in PanC clinical studies, 
when administered in combination with other drugs. A phase 1 clinical trial involving AXP107-
11, a crystalline form of genistein, in combination with gemcitabine, resulted in increased overall 
survival compared to when gemcitabine was given alone. The benefits included improved 
bioavailability and no toxicity to the healthy tissues [108]. In a phase 2 study of patients with 
locally advanced or invasive PDAC, combination therapy with gemcitabine, erlotinib, and 
genistein improved overall patient survival (although not significantly) with no toxic effects 
[109]. 
Epigallocatechin-3-gallate (EGCG)  
EGCG is the main polyphenolic compound extracted from green tea and constitutes 
~59% of the total catechins. It inhibits adhesion and proliferation of cancer cells and thus 
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suppresses carcinogenesis in a wide variety of cancers [139-141]. It has shown efficacy against 
angiogenesis by largely targeting and inhibiting VEGF. Dietary phytochemicals are well known 
to be pleiotropic agents, and EGCG is no exception to that. The mechanism of action includes its 
antioxidant properties, modifying cell signaling pathways, apoptosis induction and inhibition of 
MMPs, proteasome, etc. [142]. A lot of cellular studies suggest caspase activation, Bcl-2 
regulation and MAPK modification for the growth inhibitory and apoptotic effect of EGCG, and 
it is considered highly efficacious in tumors of gastrointestinal origins. In vitro combination and 
monotherapies of EGCG with other drugs resulted in improved growth inhibition and cell death 
in MiaPaCa2 and PANC1 cells, in a dose dependent fashion. The anti-proliferative effect of 
EGCG is attributed to G1 arrest, and it also causes dissociation of p23, Hsp-70 and Hsp-90 
complex [143]. Production of ROS is associated with EGCG induced cell death in PanC cell 
lines. It also inhibits JAK3 and STAT3 molecules and the associated downstream genes of the 
pathway to cause inhibition of cell migration and invasion and induction of apoptosis by caspase 
activation in AsPC1 and PANC1 cell lines [144]. Furthermore, additional studies on PanC cells 
showed the inhibition of Focal adhesion kinase (FAK1) and IGF-IR by EGCG to be responsible 
for the deceased tumorigenicity [145]. EGCG targets and inhibits PanC CSCs by inhibiting the 
major CSC associated transcription factors and regulatory molecules such as Nanog, c-Myc, 
Oct4 and hedgehog pathway, thereby affecting the CSC self-renewal potential [144]. The PK-PD 
analysis from in vivo studies shows wide bioavailability of EGCG in the pancreas and other 
major organs [146]. Studies with EGCG treated AsPC1 and PANC1 PanC xenograft models 
confirmed the in vitro observations where EGCG caused dysregulation of PI3K/Akt and MAPK 
pathways, and reduction in VEGF, CD31, MMPs and pERK levels [147, 148]. However, 
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additional clinical studies in human PanC patients are required to address the problems 
associated with non-uniform bioavailability of EGCG and the observed side effects.  
Other dietary phytochemicals/agents in pancreatic cancer chemoprevention 
In addition to the above detailed dietary agents with significant potential against PanC 
development and progression, there are numerous other agents that have been also investigated 
for their efficacy against PanC. A lot of phytochemicals are routinely incorporated in the diets of 
Asian and African natives that have disclosed great potential in alternative / folk medicines 
thereby eliciting interest to harvest their health benefits in PanC.  
Several natural agents in their raw/crude form have been used for disease treatment since ages; 
however, not only the parent compound alone, but also their derivatives are gaining high 
importance in the field of cancer chemoprevention and therapeutics. These agents are widely 
accepted as alternative strategies and evaluated alone or in combination with other agents and 
anticancer drugs for their efficacy against PanC. The resulting effects can either be synergistic or 
additive, which can both be beneficial for mankind. Resveratrol is a very popular natural 
chemopreventive agent isolated from grapes, berries and pines. It is a polyphenol synthesized by 
a lot of plants in response to damages caused by UV and fungi [149]. The most potent source of 
resveratrol is the red grape skin. In the mainstream scientific cell culture studies and PanC 
animal models, it serves as an efficacious anticancer molecule and suppresses the activities of 
NF-κB, COX-2, MMP9, Akt, etc [150]. Its mechanism of apoptosis induction in PanC is driven 
by the mitochondrial dependent pathway [151]. Its role in chemosensitizing the drug resistant 
cells, particularly gemcitabine resistant PanC cells, is also investigated, where it is speculated to 
mediate the effect via inhibiting NF-κB, STAT3 and drug transporters [152]. Silibinin (a 
flavonolignan from milk thistle Silybum marianum), is another widely consumed dietary 
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supplement [153, 154], which has shown strong anti-cancer efficacy in cell culture and animal 
models of various malignancies including prostate, skin, lung, colon, bladder, liver, etc. [155-
158]. Notably, silibinin has a long history of human use and is considered exceptionally safe 
[158-160]. Regarding PanC, studies conducted by us and others have shown strong preventive 
and therapeutic efficacy of silibinin in different pre-clinical models [161-164]. In PanC BxPC3 
and PANC1 xenografts silibinin-fed group tumors showed decreased cell proliferation and 
angiogenesis and an increased apoptosis [163]. Silibinin was also found to reduce tumor growth 
and proliferation in an orthotopic mouse model of PanC and induce metabolic reprogramming of 
PanC cells to attenuate tumor growth [164]. In another study, a combination treatment of the 
histone deacetylase inhibitor Trichostatin A and silibinin exerted additive growth inhibitory 
effect on PanC cells [161], which was associated with significant reduction in the expression of 
cyclinA2, cyclinB1/Cdk1 and survivin, indicating therapeutic potential of this novel combination 
against PanC growth. 
COX-2 inhibitors are of much value and key targets since COX-2 is overexpressed in 
PanC [165]. A commonly used COX-2 specific inhibitor in PanC is celecoxib. In vitro and in 
vivo studies have shown its efficacy in inhibiting VEGF and SP1 family of transcription factors, 
thus leading to tumor volume inhibition with reduced invasion and metastasis. Combinatorial 
experiments with gemcitabine and curcumin have shown synergistic effects in PanC 
management. Clinical studies of phase2 and 3 grades are still under investigation for determining 
the effective dose and accompanying cytotoxic effects if any [166-168]. Vitamins D and E are 
other commonly used chemopreventive agents in PanC. Vitamin D analogue 1α, 25-dihydroxy 
vitamin D3 has shown growth inhibitory effect in the PanC cells and xenografts; however, the 
clinical studies have not yet proven anything substantial [169, 170]. Vitamin E on the other hand 
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is not effective in all PanC studies, while animal studies expand on the ability of Vitamin E as an 
anticancer agent, human data was converse of the results obtained in cell culture and animal 
studies [171-173].  
Bitter melon juice 
In addition to the remarkable diet-derived agents listed above, a novel natural agent, 
bitter melon juice (hereafter referred as BMJ), is gaining interest in its anticancer potential 
against PanC. BMJ derived from the fruits of Bitter melon (Momordica charantia, 
Cucurbitaceae family) is a tropical fruit, and its juice (BMJ) and extracts as well as bitter melon 
itself are routinely used in folk medicine for several decades [174]. Bitterness of the fruit has 
been associated with the presence of cucurbitane-like alkaloid momordicine as well as the 
triterpene glycoside contents; the characterized bitter components are momordicosides K and L, 
and momordicines Ӏ and Ⅱ [175-177]. Component analysis revealed the presence of several 
bioactive compounds like saponins, alkaloids, glycosides, triterpenes, triterpene glycosides and 
steroids, in addition to various minerals, vitamins and proteins [177-179]. Traditionally, the 
intake of bitter melon fruit as vegetable or as juice is one of the most common home-remedial 
approaches in non-developed and developing countries for its several health benefits including 
presumed anti-diabetic effects [179, 180]. It is widely used in several parts of India, China, 
Thailand, Vietnam, Cuba, Mexico, Peru, etc. for a variety of benefits including its roles as a 
anthelmintic, abortifacient, contraceptive, as well as for its effects against gout, kidney stones, 
rheumatism, and primarily its presumed anti-diabetic effects [179-181]. Bitter melon’s anti-
diabetic effect is thought to be associated with improved glucose tolerance and reduced blood 
glucose levels [182]. While the exact mechanism for hypoglycemic effect of bitter melon 
remains under investigation, various studies report upregulated peripheral skeletal muscle 
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glucose utilization, suppressed gluconeogenic enzymes, inhibition of intestinal glucose uptake 
together with preservation of pancreatic islet cells with bitter melon intake [179, 180]. Bioassay-
guided fractionations of bitter melon have attributed the anti-diabetic benefits to a mixture of 
steroidal saponins (e.g. charantin), alkaloid (vicine), polypeptide-p (also known as plant insulin), 
and other cucurbitane-type triterpenoids present therein [176, 177, 183-187]; while the efforts to 
identify the critical anti-cancer compounds in bitter melon are ongoing in our and other labs 
[188, 189].  
Moreover, several studies have also shown anti-cancer efficacy of bitter melon against 
various cancers, including our work in pancreatic cancer (PanC) [181, 184, 188, 190-193]. 
Notably, our studies have shown significant growth inhibitory effects of BMJ in a panel of PanC 
cell lines in culture and mouse xenografts, detailed in the following chapters [188, 190, 192]. 
Also, in pre-clinical studies, BMJ alone or in combination with gemcitabine, has exhibited 
significant sustained therapeutic efficacy against patient derived-PanC tumor xenografts 
(unpublished data, Dhar et al.). Mechanistically, we found that BMJ activates cellular energy 
sensor AMP-activated protein kinase causing apoptotic cell death [190]. Importantly, BMJ also 
targets the self-renewal and kinetics of CSC pool expansion and bulk tumor cell population via 
targeting various regulatory signals associated with their survival and multiplication leading to 
its efficacy against PanC cells and their resistant phenotypes [190, 192, 194, 195]. In other 
studies, the probable mechanism of action for bitter melon efficacy against cancers has been 
linked to effective inhibition of DNA, RNA and protein synthesis [181, 196]. Published reports 
also point to bitter melon efficacy by inhibition of guanylate cyclase activity and it also serves as 
an activator of natural killer cells [197-199]. Bitter melon extracts have also been shown to 
interact with and amplify the effect of chemotherapeutic agents with improved bioavailability, 
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possibly mediated via interaction of bitter melon with drug transporter P-glycoprotein [200]. 
Based on these key findings, BMJ is a novel agent that can be tested for its efficacy in human 
PanC populations, in conjunction with effective clinical chemotherapeutics. 
In the subsequent chapters, we highlight BMJ efficacy in targeting PanC by evaluating the 
underlying mechanisms, involvement of key molecules and pathways, to establish vital BMJ 
targets using various cell and animal models of PanC.  
Purpose and significance of our studies 
Currently there is no specific curative therapy for treatment of PanC. Evidently, it is 
primarily due to the undiagnosed advancement to the invasive form of the disease, which has 
been a consistent scenario for the past few decades. With the use of clinically approved drugs 
like gemcitabine, erlotinib and 5-FU, there has been modest improvement in the overall survival 
rate of patients, with an increased possibility of tumor recurrence. Importantly, the increased 
survival comes with a heavy price in the form of expansively discomforting slew of side effects.  
The chemopreventive natural agents mentioned here provide a great window of opportunity for 
PanC management. These compounds are not only effective against PanC when used alone but 
have also proven to be ideal candidates when used together with chemotherapeutic drugs by 
eliciting synergistic responses with minimal incidences of associated toxicities in patients [97-
100]. Although the data from the studies conducted on human patients has shown positive 
results, there remains a need for more intense and exhaustive clinical trials with more drug 
combinations and better PK-PD analysis for improved strategies. This might in part be possible 
by developing formulation or isolating isoforms of these agents that are more compatible in drug 
combinations and with improved bioavailability. Various routes of drug administration are also 
under consideration, e.g., nanoparticles loaded with drugs, might help advance the response 
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rates. Once achieved, chemopreventive intervention can prove to be significantly beneficial in 
human populations at an increased risk of developing PanC in their lifetime.  
Lately, natural agents have demonstrated significant anticancer potential against a variety 
of cancers in preclinical studies, including PanC, as discussed previously. BMJ is a relatively 
novel dietary agent steadily gaining importance in mainstream therapeutics based on its 
associated health benefits. Our preliminary studies pointed out the role of BMJ activated AMPK 
in PanC cells and its efficacy in MiaPaCa2 xenografts. However, further investigation is required 
to test BMJ efficacy along with mechanistic studies to reveal the underlying mechanisms of 
action involving CSCs, metabolic reprogramming and overcoming drug resistance and establish 
key molecular targets of BMJ mediated PanC intervention. Therefore, following study aims were 
proposed in cell and murine models of PanC with BMJ treatment for subsequent disclosure of 
the associated drug targets and related pathways: 
(1) To determine the role of BMJ in targeting PanC associated cancer stem cells and bulk 
tumor cell populations. Human PanC cells were used to define the ability of BMJ in 
targeting and inhibiting both PanC associated cancer stem cells and the related 
transcription factors and regulatory molecules. We further examined the aforementioned 
molecules from in vitro models of PanC in MiaPaCa2 xenograft tissues for added in vivo 
relevance. 
(2) To support our previously published findings of BMJ-mediated AMPK activation in 
PanC, we sought to further investigate the underlying mechanisms of BMJ directed 
changes in PanC cell metabolome and establish the major metabolic targets involved in 
BMJ efficacy. We also performed validation studies post NMR-spectroscopy analysis of 
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BMJ treated PanC cells and explored the significance of our findings in a PANC1 
xenograft mouse model. 
(3) To establish BMJ efficacy alone and in combination with gemcitabine; the 
chemotherapeutic and standard of care in the clinic. We utilized PanC cells and patient 
derived xenograft bearing animals to test BMJ potential and nature of drug combinations. 
Additionally, following increased response to gemcitabine with BMJ addition, we 
analyzed gemcitabine resistance pathway associated molecules to determine the possible 
contribution of BMJ in rescuing gemcitabine resistant tumor cells, thereby providing 
better translational relevance for supporting future clinical studies. 
(4) To determine BMJ potential as an intervention agent in an age-based disease progression 
of PanC using a transgenic mouse model – LSLKRASG12D/+;p48Cre/+. BMJ efficacy was 
tested in the early stages of PanC initiation with different doses of BMJ. Also, the 
progression-based approach was employed to govern histological differences in PanC 







BITTER MELON JUICE EXERTS ITS EFFICACY AGAINST PANCREATIC CANCER 
VIA TARGETING BOTH BULK AND CANCER STEM CELLS 
Introduction 
Over the past few decades, pancreatic cancer (PanC) has steadily emerged as a serious 
threat to mankind, being the fourth leading cause of cancer-related deaths within the United 
States, accounting for 3% of all cancers [201]. It is a highly aggressive disease linked to a poor 
prognosis and resulting in a dismal 5-year survival rate of <5%, owing to its rapid and 
symptomless progression to advanced stages. Key survival statistics for the year 2018 reveal 
~55,440 new incidences and ~44,330 PanC associated fatalities within the United States [1]. 
Majority of PanC linked symptoms appear in under 3 years prior to metastasis including 
heartburn, bloating, abdominal pain, altered bowel schemes, etc., accompanied by extreme 
fatigue and weight loss [202]. A variety of risk factors are known to be associated with PanC 
development namely smoking, age, onset of diabetes, chronic pancreatitis, excessive alcohol 
consumption and high fat diet [203]. Surgical resection is the only available current curative 
treatment option for PanC patients; however, not entirely reliable with the imminent risk of 
tumor relapse. Apart from surgery, as majority of the clinical cases present themselves as 
metastasized or unresectable forms of PanC, the frontline chemotherapeutic agent currently used 
in clinic is gemcitabine, a nucleoside analogue. Gemcitabine is extensively applied in PanC 
therapy alone or in combination with other approved cytotoxic agents (5-fluorouracil, cisplatin, 
oxaliplatin, etc.) and biological agents (erlotinib, bevacizumab, etc.) [204]. However, there has  
been a constant increase in resistance to gemcitabine therapy in PanC patients and the survival 
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outcome is recurrently poor [205]. PanC usually arises as noninvasive precursor lesion namely 
pancreatic intraepithelial neoplasia (PanIN) and gradually evolves to the advanced metastatic 
form of pancreatic ductal adenocarcinoma (PDAC). PDACs are the most commonly occurring 
form of PanC (90%), with mutated KRAS expressed in ≥ 95% of cases. Other frequently mutated 
genes present in ≥ 50% of PanC types are p16/CDKN2A, TP53 and SMAD4 [206].  
Other than genetic alterations, in recent years, cancer stem cells (CSCs) have been 
identified to play a major role in cancer progression and recurrence in pancreatic as well as other 
cancers [207, 208]. PanC-CSCs were first identified in 2007 by Li et al., in established human 
PanC xenografts of NOD/SCID mice [207]. CSCs are the cells comprising a very small part 
(~1%) of the entire tumor mass, with the ability to self-renew and give rise to phenotypically and 
functionally heterogeneous cancer cell lineages found within the tumor itself [209]. While they 
share the core regulatory pathways with normal stem cells, CSCs are known to undergo 
reprograming and transformation, resulting in their multi-lineage differentiation and self-renewal 
potential [210]. Owing to their stem cell like properties, although a small population, CSCs are 
known to mediate initiation, progression, metastasis, relapse and drug resistance in variety of 
cancers including PanC [211]. It has been frequently reported that CSCs are responsible in 
inducing chemo-resistance and lead to accelerated progression of PanC to its more aggressive 
and invasive forms [212]. The idea therefore remains to target the PanC-CSC pool using novel 
agents with elevated anticancer and therapeutic potential and negligible toxicity to the 
surrounding normal tissue.  
Taken together, it is clear that several efforts are being made to control, manage, and treat 
PanC; however, conventional chemotherapeutic drugs have drug-resistance and often fail to 
effectively target and eliminate CSCs, thereby resulting in tumor relapse and metastasis. This 
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feature is further emphasized in PanC particularly; mainly credited to its high intrinsic resistance 
resulting from relatively higher percentage and enrichment of CSCs following chemotherapeutic 
regimes [213]. Clearly, better approaches as well as agents are needed to target the mechanisms 
and/or pathways driving both PanC and PanC-CSCs, with minimal associated toxicity to healthy 
cells. In this regard, in recent years, our focus is predominantly on the efficacy of Bitter melon 
juice (BMJ) in PanC therapy and preventive intervention. BMJ is isolated from Bitter melon 
(Momordica charantia, Family: Cucurbitaceae), a vegetable widely consumed in Asia, Africa 
and parts of South America. In recent years, bitter melon has shown efficacy against a variety of 
diseases and medical conditions including inflammation, hypoglycemia and various cancers, 
such as head and neck, ovarian, lung, leukemia, bladder, hepatocellular, breast, and prostate 
[214, 215]. Regarding PanC, our published studies have shown promising anticancer activity of 
BMJ against PanC cells in both culture and nude mice xenografts, via Adenosine 
monophosphate-activated protein kinase (AMPK) modulation, together with its efficacy in 
gemcitabine-resistant PanC cells [190, 192]. Based on these significant findings, here we 
assessed BMJ efficacy in targeting PanC-CSCs and associated mechanisms.  
Materials and methods 
Cell lines and reagents 
Human pancreatic adenocarcinoma cells MiaPaCa2, PANC1 and AsPC1, were purchased 
from ATCC (Manassas, VA, USA) and used at passage #10-15. MiaPaCa2 and PANC1 cells 
were grown under standard culture conditions (37°C, 95% humidified air and 5% CO2) with 10% 
FBS, 1% Penicillin-Streptomycin, and additional 2.5% horse serum for MiaPaCa2, in 
Dulbecco’s Modified Eagle’s Medium (DMEM) with high glucose, from ATCC. AsPC1 cells 
were grown in RPMI 1640 (1X) with 10% FBS, 1% Penicillin-Streptomycin and essential amino 
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acids. DMEM/F12 (1:1) 1X media supplemented with B27 (50X) and N2 (100X) from life 
technologies with 1% Penicillin-Streptomycin was used for spheroid generation assays. EGF and 
FGF were from Invitrogen (Grand Island, NY, USA). HPLC grade gemcitabine hydrochloride 
was purchased from Sigma. Antibody for PDX1 was from Abcam (Cambridge, MA, USA). 
SOX2 and NANOG antibodies were from Cell signaling (Beverly, CA), and OCT4 and CD44 
antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA).  
BMJ preparation 
Chinese variety of commercially available bitter melon was used for our study. The fruits 
were washed with water and air dried. Once the water was completely drained, the melons were 
cut open, deseeded and the remaining fruit was juiced using a household juicer. The juice was 
then subjected to centrifugation at 3000g for 30 mins. The supernatant was collected, sterile 
filtered and aliquoted for storage at -80ºC, while the pellet was discarded. The liquid supernatant 
was employed for all in vitro studies; for the in vivo studies, we employed the lyophilized BMJ 
powder stored at 4ºC as detailed earlier [190, 192]. 
FACS sorting 
PANC1 cells were trypsin digested and stained with CD44-FITC, CD24-APC, and 
EpCAM-PE antibodies from BD Pharmingen and then subjected to cell sorting by FACS using 
Flow Cytometry Shared Resources of the University of Colorado Cancer Center. Isolated 
CD44+/CD24+/EpCAM+ triple positive and CD44-/CD24-/EpCAM- triple negative populations 
were subjected to limiting dilution assays for sphere formation. Sorted triple positive cells and 
unsorted cells were seeded at varying densities (200 cells/well to 10,000 cells/well) in 6-well 
ultra-low attachment plates in DMEM/F12 (1:1) 1X media supplemented with B27 (50X) and 
N2 (100X) and 1% Penicillin-Streptomycin and observed for their sphere forming ability over a 
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course of 11 days. Consequently, the effect of BMJ (0.5%-2%, v/v) was examined on sorted 
triple positive cells versus unsorted PANC1 cells.  
Gemcitabine exposure 
PANC1 and AsPC1 cells were trypsin digested and seeded at 2500 cells/well density, in 
6-well ultra-low attachment plates in DMEM/F12 (1:1) 1X media supplemented with B27 (50X) 
and N2 (100X) and 1% Penicillin-Streptomycin. At 6 hours post seeding, cells were treated with 
2.5 and 5.0 µM gemcitabine. At 24 hours after gemcitabine treatments, cultures were treated 
with BMJ (0.5%-2%, v/v) without washing out any residual gemcitabine and sphere formation 
was followed for 11 days. EGF (20ng/ml) and FGF (10ng/ml) were added at every 72 hours. 
Cell viability and spheroid assay 
All three PanC cell lines MiaPaCa2, PANC1 and AsPC1 were seeded in 6-well plates 
(Corning, Inc.) for 24 hours and treated with varying concentrations of BMJ (2-4%, v/v) for 24, 
48 and 72 hours. For the control group, media lacking BMJ was added to the wells. The cell 
viability was determined by trypan blue exclusion assay. The cells stained blue were 
recorded/counted on the hemocytometer as dead cells. All experiments were done in triplicates. 
In the next set of the experiment, MiaPaCa2, PANC1 and AsPC1 cells were cultured in a 2D 
format/culture conditions (referred to as monolayer here after) and subjected to BMJ treatment 
(0.5%-2%, v/v) for a course of 9 days (single versus multiple BMJ treatments at every 72 hours). 
Thereafter, the remaining viable cells on day 9 were trypsin digested and resuspended in stem 
cell media (DMEM/F12 (1:1) 1X media supplemented with B27 (50X) and N2 (100X) and 1% 
Penicillin-Streptomycin) and seeded at a density of 2500 cells/well in 6-well ultra-low 
attachment plates (Costar). During seeding, caution was exerted to specifically seed individual 
cells and not cell clusters adhering to each other, to minimize the false positives. Additionally, 
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the seeded cells were followed as a function of time to carefully monitor for clumping, if any. 
The single cell derived spheroid forming ability of these CSCs was monitored over a course of 
11 days. Media was replenished and growth factors EGF (20ng/ml) and FGF (10ng/ml) were 
added at every 72 hours. 
In another set of the experiment, BMJ unexposed cells were seeded at a density of 2500 
cells/well in 6-well ultra-low attachment plates with DMEM/F12 (1:1) 1X media supplemented 
with B27 (50X) and N2 (100X) and 1% Penicillin-Streptomycin. At 6 hours post seeding, cells 
received either a single exposure of BMJ (0.5%-2%, v/v) for 72 hours or repeated exposures of 
BMJ (0.5%-2%, v/v) at every 72 hours for 9 days. The spheroid generation was monitored for 11 
days. Media was replenished, and EGF (20ng/ml) and FGF (10ng/ml) were added at every 72 
hours. In a parallel study, cells were allowed to generate spheroids for 4-5 days, which were then 
treated with exogenous addition of BMJ (2% and 4%, v/v; data not shown for 4%) for 11 days to 
study the effect of BMJ on mature spheroids. 
RT2qPCR array for human stem cell transcription factors 
MiaPaCa2 cells were treated with BMJ (2%, v/v) for 72 hours. The cells were collected, 
washed and RNA isolated (RNeasy Mini Kit, Qiagen). The cDNA conversion was carried out 
using RT2 First Strand Kit (Qiagen). Thermal amplification parameters were: initial denaturation 
for 5 min at 94°C; 30 cycles of denaturation for 30 s at 94°C, annealing for 30 s at 54°C and 
extension for 30 s at 72°C; and final extension for 5 min at 72°C. Quality control was assessed 
on the nanodrop and ~250ng of the starting material was loaded onto the PCR array plate 
(Human stem cell transcription factors array PCR, Qiagen). A two-step cycling protocol on ABI 
7500 cycler was used involving denaturation for 10 min at 95°C followed by 40 cycles of 15 sec 
at 95°C and 1 min at 60°C. The relative quantification of gene expression between the untreated 
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control and BMJ treated cells was conducted by normalization against endogenous GAPDH and 
β-Actin using the ∆∆CT method of quantification. For data analysis, ABI 7500 and Qiagen 
software was used to calculate the fold changes. 
Immunofluorescence 
All three PanC cell lines MiaPaCa2, PANC1 and AsPC1 were grown on coverslips in 6- 
well culture plates and treated with BMJ (2%, v/v) for 72 hours. Post treatment, cells were 
harvested and formalin (4% formalin in 1X PBS) fixed. For staining, cells were washed with 
0.1% triton X-100 in 1X PBS thrice, 5 min for each wash followed by permeabilization with 
0.3% Triton X-100 in 1X PBS for 1-2 hours. Next, cells were blocked with CAS block buffer 
(Invitrogen, 1:1 in PBS) for an hour at room temperature. Post blocking, primary antibody was 
added in dilution buffer (1% BSA in PBST) overnight at 4ºC in humidified chamber. Following 
day, cells were washed again with 0.1% triton X-100 in 1X PBS thrice, 5 min for each wash and 
fluorochrome conjugated secondary antibody was added and incubated in dark with DAPI at RT 
for 1 hour. Hereon, all steps were carried out in dark. Finally, cells were washed with high salt 
PBS and subsequent washes with 0.1% triton X-100 in 1X PBS. Lastly, the coverslips were 
mounted with Prolong® Gold Antifade Reagent /DAPI and allowed to dry. Nikon D-Eclipse C1 
confocal microscope (Nikon) was used for imaging and analysis by EZ-C1 Free viewer software. 
Immunofluorescence for spheres used matrigel as the embedding medium for immobilizing the 
spheres. Fixing, permeabilization, blocking and antibody incubation was carried out as described 
in previous publications from our group [216]. 
Immunohistochemistry 
MiaPaCa2 tumor xenograft samples from control (water only) and lyophilized BMJ 
(200mg/kg) exposed groups for 6 weeks from a recently completed study showing strong 
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efficacy of BMJ in inhibiting tumor xenograft growth [190], were processed per our previously 
published protocol [217]. Tissue samples were stained for transcription factors: SOX2, OCT4, 
NANOG and PDX1. Brown stained cells were counted positive for each molecule. There were 
seven animals per group and eight random regions per sample were considered. The final 
representation of the data is as percent positive cells. 
Statistical analysis 
All statistical analyses were performed using Sigma Stat software (version 3.5, Jandel 
Scientific). Quantitative data are presented as mean±SEM. Statistical significance of difference 
between control and treatment groups was determined through one-way analysis of variance 
(ANOVA) followed by Tukey’s test for multiple comparisons. P<0.05 was considered 
significant. P value of p ≤ 0.05 is denoted by *, p ≤ 0.01 is denoted by ** and p ≤ 0.001 is 
denoted by ***. 
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Results 
BMJ decreases the number and size of PanC spheroids generated by 
CD44+/CD24+/EpCAMHigh enriched CSCs and unsorted PanC cell populations 
CD44+/CD24+/EpCAMHigh markers have been validated in a variety of studies for CSC 
sorting from solid tumors, as the subpopulation of cells expressing the combination of these 
markers have an increased proliferation potential with poor glandular differentiation correlating 
























Figure 2.1: BMJ affects both unsorted and CSC enriched PanC cell spheroids. FACS 
sorting of untreated PANC1 cell line with CD44+/CD24+/EpCAM+ combination of CSC markers 
(A). The sorted CD44+/CD24+/EpCAM+ was subjected to limiting dilution assay to generate 
spheroids with cell number ranging from 200-10,000 cells per well for determining the stemness 
of triple positive population (B). The effect of BMJ was studied by exposing FACS sorted and 
unsorted cells to varying BMJ concentrations and recording the number of spheroids formed per 
well (C). p ≤ 0.05 is denoted by * and p ≤ 0.01 is denoted by ***. 
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of cells that accounted for only 0.2 to 0.8% of the total population of PanC cells [207]. However, 
this population had an enhanced capacity of tumor initiation compared to the non-tumorigenic/ 
bulk tumor population. Here we subjected human PANC1 cell line to FACS assay and 
CD44+/CD24+/EpCAMHigh triple marker was employed for isolating the triple positive 
population of CSCs (Fig. 2.1A). The CD44+/CD24+/EpCAMHigh enriched (FACS sorted) CSCs 
were then seeded for limiting dilution assays for spheroid formation, ranging from 200 to 10,000 
cells/well (Fig. 2.1B). Based on these results, appropriate seeding density of 2500 cells/well in a 
6-well ultra-low attachment plate was selected for all spheroid assays. The other subpopulation 
of isolated CD44-/CD24-/EpCAM- triple negative cells failed to generate any spheroids (data not 
shown). Addition of BMJ to the CD44+/CD24+/EpCAMHigh enriched CSC population showed a 
pronounced effect; a significant decrease in the generated spheroid number was observed with 
increasing doses of BMJ (0.5%-2%, v/v), whereby a minimal number of spheroids were formed 
with 2% BMJ, compared to the untreated control (Fig. 2.1C). Notably, BMJ treatment dose-
dependently decreased the number of spheroids formed by both, unsorted and sorted PANC1 
cells (Fig. 2.1C). BMJ addition targeted and decreased the PanC spheroid number, primarily 
reflecting its effect on CSC population which in turn is responsible for spheroid generation. A 
decrease in PanC spheroid size accompanied the decrease in spheroid number, thereby 
highlighting the potential of BMJ in targeting PanC-CSCs as well as the associated bulk tumor 
cells, which collectively account for the resulting spheroid mass. Together, these results 
underline the role of BMJ against CSC-mediated PanC stemness and proliferation.  Note: Given 
that percentage decrease in spheroids generated by either CSC enriched PanC cells or unsorted 
PanC population by BMJ was comparable, therefore, in all successive spheroid assays, we 
employed the unsorted PanC cells to generate spheroids. 
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BMJ exposure confers sensitivity to gemcitabine resistant PanC-CSCs 
Variety of cell subpopulations from solid tumors resistant to radio- and chemo-therapies 
and expressing CSC markers have been identified [218]. The most frequently used palliative 
chemotherapeutic against late stage PanC is gemcitabine. Gemcitabine is effective in PanC 
tumor volume reduction and delays the time to proliferation [219]. However, there have been 
increasing incidences of PanC resistance to gemcitabine treatment [220]. Chemoresistance in 
PanC might result from extreme desmoplasia, hypovasculariztion, aberrant activity of membrane 
transporters/drug efflux pumps and drug metabolizing enzymes and mostly, the CSCs [221]. 
CSCs have been shown to possess the properties of pro-survival and possible rapid efflux of 
drugs, thereby conferring chemoresistance [222]. Thus, on the lines of chemoresistance in PanC, 
we employed BMJ to test its ability in increasing PanC sensitivity to gemcitabine. PANC1 and 
AsPC1 cell lines resistant to 2.5µM (Fig. 2.2A) and 5µM (Fig. 2.2B) gemcitabine doses were 
subjected to spheroid assays and exposed to single BMJ treatment (0.5 and 2%). These cells 
were observed for 11 days in spheroid assays where BMJ was successful in rescuing cells from 
gemcitabine resistance at both 0.5 and 2% doses; cells from BMJ treated wells were able to form 
a smaller number of spheroids, where both BMJ doses showed inhibition in sphere formation. 
Additionally, both 2.5µM and 5µM gemcitabine resistant cells followed a similar trend in their 
response to treatment by showing a significant decrease in spheroid formation (number and size) 
with BMJ exposures. These results indicate the ability of BMJ to reverse CSC-associated 
gemcitabine resistance in PanC and increasing the sensitivity to the drug, thereby enhancing the 

























Figure 2.2: BMJ treatment helps confer sensitivity to gemcitabine resistant PanC cells 
generated spheroids. PANC1 and AsPC1 PanC cells surviving 2.5µM gemcitabine treatment 
(A), and 5 µM gemcitabine treatment (B), were exposed to 0.5 or 2% BMJ (v/v) treatments in 
spheroid assay, and the decrease in spheroid number and size was recorded after 11days.  







2.5 µM Gem      
2% BMJ 
0.5% BMJ - 
- 









5 µM Gem        
2% BMJ 
0.5% BMJ - 
- 



























2.5 µM Gem 
5 µM Gem 
2.5 µM  
Gem 
5 µM  
Gem 






































BMJ affects viability and stemness of human PanC cells 
PanC cell lines MiaPaCa2, PANC1 and AsPC1, which are aggressive cancer cell lines 
[223], were treated with BMJ (2-4%, v/v) and assessed for cell growth and death as well as 
stemness. The total cell number increased consistently with increasing time points in the 
controls, but there was a significant decrease in the 2 and 4% BMJ treatment groups (Fig. 2.3A). 
Specifically, the total cell number was decreased by 83 and 92% in case of MiaPaCa2, 69 and 
97% in case of PANC1, and 80 and 91%in case of AsPC1 cells, following 2 and 4% BMJ 
treatment for 72 hours, respectively (Fig. 2.3A). BMJ also strongly induced cell death (with 
increasing concentration and treatment time) in PANC1 and AsPC1 cells; cell death was induced 
by BMJ in MiaPaCa2 cells at 24 hours (even though the untreated controls showed higher 
percentage of dead cells compared to other PanC cells) (Fig. 2.3B). 
Next, we sought to determine the effect of BMJ on PanC-CSCs under different drug 
exposure conditions. MiaPaCa2, PANC1 and AsPC1 cells in monolayers were treated with 
single and multiple exposures of BMJ, and then observed for spheroid formation. Cells were 
treated with BMJ once (Single treatment with 0.5 - 2%, v/v) for 72 hours and seeded for spheroid 
formation. In parallel, cells were given repeated BMJ treatments (Multiple Treatments with 0.5% 
- 2%, v/v), every 72 hours until day 9 since study initiation, and the remaining viable cells were 
seeded for spheroid formation. For the BMJ single treatment assay (Fig. 2.3C), a dose-dependent 
decrease in the spheroid number and size per well was observed in all the cell lines with the least 
number of generated spheroids seen in the 2% BMJ group. The results from BMJ multiple 
treatments (Fig. 2.3D) followed similar trends as was seen with single BMJ exposure with 





Figure 2.3: BMJ affects the cell viability and stemness in PanC cell monolayers. Trypan blue 
exclusion assay was performed for PanC cell lines MiaPaCa2, PANC1 and AsPC1 with 2-4% 
BMJ (v/v). The decrease in total cell number (A) and increase in percent cell death (B), are 
shown in the top panels for 24, 48 and 72 hours. Also, BMJ effect on PanC stemness was 
assessed by spheroid assays for PanC cell lines MiaPaCa2, PANC1 and AsPC1 where the cell 
monolayers were treated with 0.5-2% BMJ (v/v) single (C), and multiple treatments (D) and 
observed for 11 days. Representative spheroid images are shown.  p ≤ 0.01 is denoted by ** and 
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BMJ affects PanC sphere formation with single and multiple exposures as well as pre-
formed pancreatic spheres 
To study the effect of single treatment of BMJ on PanC spheroid formation (not pre-
exposed to BMJ and/or gemcitabine), MiaPaCa2, PANC1 and AsPC1 cells were seeded in stem 
cell media to generate spheres and, 6 hours post seeding, were treated with BMJ (0.5% - 2%, 
v/v). Growth factors EGF (20 ng/ml) and FGF (10 ng/ml) were added every 72 hours until day 
11. The results show a significant decrease in the sphere number and size in a dose-dependent 
manner for all the cell lines, with the maximum effect at 2% BMJ, where a 95, 80 and 91% 
decrease was observed in the number of MiaPaCa2, PANC1 and AsPC1 spheres, respectively 
(Fig. 2.4A). Another set of experiments involved repeated treatments of PanC cells with BMJ, 
where cells were seeded and treated every 72 hours with 0.5%, 1% and 2% BMJ (v/v) until day 
11 in the presence of EGF (20ng/ml) and FGF (10ng/ml). Similar to the results seen with single 
treatment, multiple BMJ treatments also caused a significant reduction in the sphere number and 
size. By day 11, the 2% BMJ dose caused 91, 88 and 95% reduction in sphere number for 
MiaPaCa2, PANC1 and AsPC1, respectively (Fig. 2.4A). In simultaneous studies, spheres were 
allowed to develop, following exposure to exogenous dose of 2% BMJ and 4% BMJ (data not 
shown) for a course of 11 days. As shown (Fig. 2.4B), 2% BMJ dose for all PanC cells results in 
a significant decrease in spheroid size and number by day 11 compared to the control groups.  
BMJ downregulates mRNA and protein levels of CSC associated transcription 
factors/regulatory molecules in PanC cells and PanC-CSC spheroids 
To test BMJ potency in altering the expression of various stem cell transcription factors 




Figure 2.4: BMJ affects number and size of spheres formed by PanC-CSCs. PanC cells 
seeded for sphere formation were exposed to single and multiple treatments of BMJ (0.5-2% 
BMJ, v/v) and observed for 11 days (A). PanC cells were allowed to generate spheroids for 5 
days and then treated with 2% BMJ to observe the effects on pre-formed spheroid number and 
size (B). Representative spheroid images are shown. p ≤ 0.05 is denoted by *, p ≤ 0.01 is denoted 
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Figure 2.5: BMJ alters the mRNA levels of PanC-CSC associated regulatory molecules and 
transcription factors. MiaPaCa2 cells were exposed to 2% BMJ for 72 hours, thereafter 
harvested and subjected to RT2-qPCR array of human stem cell transcription factors for 
assessment of BMJ effects on gene expression of PanC-CSC associated transcription factors. 
Top panel depicts scatter plot showing BMJ vs untreated control group (1.5-fold level changes); 
downregulated genes are displayed as open circles (green). Bottom panel depicts genes 

























BMJ effect on human stem cell transcription factors – RT2qPCR array in MiaPaCa2 cells 
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for determining the changes in levels of ~84 genes linked to stem cells in spheroids generated 
from PanC cell lines after treatment with BMJ. MiaPaCa2 cells were exposed to 2% BMJ for 72 
hours, thereafter harvested and subjected to assessment of various PanC-CSC associated gene 
expression levels. BMJ treatment exhibited downregulation of a majority of genes as seen in the 
scatter plot (Fig. 2.5, top panel). The downregulated genes are displayed as open circles (green). 
BMJ exposure caused a major change in the expression levels of SOX2; it showed the maximum  
decrease in expression as made evident by the change in fold regulation, followed closely by 
OLIG2 and NR2F2 (Fig. 5, bottom panel). Additional genes contributing to stem cells associated  
with PanC-CSC that depicted decreased expression in the presence of BMJ, involved molecules 
such as GATA6, GLI2, ISL1, JUN, MYC, NANOG, NOTCH2 and PCNA. These results highlight 
the potential of BMJ in targeting especially SOX2 and NANOG levels, which are of utmost 
importance in their contribution to the CSC pool expansion in PanC [224, 225].  
Next, we assessed BMJ effect on protein levels of CSC associated transcription 
factors/regulatory molecules in PanC cells. MiaPaCa2, PANC1 and AsPC1 PanC cells in 
monolayers were seeded on coverslips in 6-well plates and treated with BMJ (2%) for 72 hours, 
then stained for transcription factors, namely SOX2, OCT4, NANOG, and stem cell surface 
marker CD44. Immunofluorescence imaging results followed by their densitometry analysis 
clearly depicted a significant decrease in the expression of SOX2, OCT4, NANOG and CD44 in 
all the cell lines following BMJ treatment, albeit at different levels (Fig. 2.6). Together, these 
results show BMJ activity in targeting CSC associated transcription factors/regulatory molecules 
in PanC cells at both mRNA and protein levels.  
In continuation with our results in PanC cell monolayers, we also assessed the effect of 






Figure 2.6: BMJ decreases the protein expression of CSC associated transcription factors 
and surface markers in PanC cell monolayers. Immunofluorescence staining of PanC cell 
monolayers treated with 2% BMJ for 72 hours shows a reduction in SOX2, OCT4, NANOG and 
CD44 protein expression levels in MiaPaCa2 (A), PANC1 (B), and AsPC1 (C) cells. The results 
from densitometry by Image J software are also provided and correlate to the data from the 
images. p ≤ 0.05 is denoted by *, p ≤ 0.01 is denoted by ** and p ≤ 0.001 is denoted by ***. 
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Figure 2.7: BMJ decreases the protein expression of CSC associated transcription factor 
SOX2 and CSC surface marker CD44 in PanC cell generated spheroids. PanC cells were 
treated with 2% BMJ (72 hours) and allowed to generate spheroids in stem cell media for 10 
days. On day 11, spheroids were harvested and stained by immunofluorescence for SOX2 and 
CD44 in MiaPaCa2 (A), PANC1 (B), and AsPC1 (C) spheroids. Z-stacking was performed for 
the spheroids. The results from densitometry by Image J software are also provided and correlate 





































































































































































Immunofluorescence analysis of BMJ treated PanC spheroids 
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PanC cells were exposed to 2% dose of BMJ and followed for spheroid generation for 11 days in 
stem cell media. Imaging results from Z-stacking of spheroids suggested BMJ to be effective in 
significantly decreasing the expression of SOX2 and CD44 in all three MiaPaCa2 (Fig. 2.7A), 
PANC1 (Fig. 2.7B) and AsPC1 (Fig. 2.7C) spheroids. Consistent with our PanC cells in 
monolayers data (Fig. 2.6), SOX2 was found to be most significantly downregulated in PanC 
spheroids as well.  
BMJ downregulates the expression of CSC associated transcription factors/regulatory 
molecules in MiaPaCa2 tumor xenografts  
To further establish the significance of our cell culture results in an in vivo scenario, 
paraffin embedded MiaPaCa2 xenograft tissues from control and BMJ-fed nude mice from a 
recently completed study [190] were processed and stained for transcription factors namely 
SOX2, OCT4, NANOG and PDX1. Role of transcription factors SOX2, OCT4 and NANOG in 
CSC driven pancreatic tumorigenesis has been detailed later in the discussion section. PDX1 is a 
transcription factor crucial for pancreatic development; it is the first transcription factor 
expressed in developing pancreas and its expression becomes confined to β-cells in adult 
pancreas. Increased PDX1 levels have been reported in PDACs, mainly in the precursor lesions 
irrespective of the degree of dysplasia, pointing to its role in PanC progression [226]. Consistent 
with the finding observed for the in vitro studies, there was a significant decrease in the 
expression of each of the transcription factors (in terms of positively stained cells) examined in 
the samples from BMJ-treated mice compared to controls (Fig. 2.8). Quantitative analyses 
showed a decrease in SOX2 expression by ~80% (Fig. 2.8A) and that of OCT4, NANOG and 
PDX1 by ~67% decrease in the samples from BMJ-fed mice compared to controls expression 






















Figure 2.8: BMJ targets and downregulates the expression of CSC associated transcription 
factors in MiaPaCa2 xenografts. Paraffin embedded MiaPaCa2 xenograft tumor sections from 
control and BMJ treated groups were subjected to immunohistochemical analysis for 
determining the in vivo effect on the protein levels of PanC-CSC associated transcription factors: 
SOX2 (A), OCT4 (B), NANOG (C), and PDX1 (D). The percent positive cells were quantitated 
by counting the brown stained nuclei for each molecule in control versus the BMJ treated groups. 
































































  *Brown (+) stained nuclei counted. 
**Minimal nuclear staining observed in BMJ groups. 
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expression of the CSC associated transcription factors in both cell culture and animal xenografts, 
thus signifying its possible efficacy as a novel PanC chemotherapeutic.  
Discussion 
Lately, the research surrounding CSCs is gaining momentum, mostly due to the 
preliminary progress achieved in targeting various solid tumors. CSCs possess variable 
histological characteristics which makes them prone to chemoresistance. Conventional 
chemotherapeutic agents target and attack the bulk population of cancer cells in a tumor, leaving 
CSCs unaffected and fully capable of giving rise to the relapsed tumor [227]. This attributes to 
CSCs being the ideal candidates for developing targeted chemotherapies with recent advances in 
the assay development [228]. PanC-CSCs were first established in 2007, and since then 
techniques have been developed to identify them as potential biomarkers of PanC [207].  
Phytochemicals have been known to regulate CSC survival by targeting their self-
renewal pathways [229]. The advantages of exploiting their chemopreventive and therapeutic 
efficacy are the minimal associated toxicities to surrounding normal healthy cells and cost 
effectiveness; particularly with PanC, there have been extensive studies connecting dietary 
agents to reduced PanC incidences [230, 231]. BMJ, a dietary agent extracted from the fruits of 
Momordica charantia, has numerous associated health benefits; antidiabetic, emetic and laxative 
[188]. Studies using BMJ/BMJ-extracts in animals show lower serum cholesterol levels, 
hypoglycemia and delayed onset of tumorigenesis, alongside improved glucose tolerance in 
human subjects without significant alterations to insulin levels with BMJ administration [232-
234]. Component analysis of bitter melon characterizes all the important constituents with 
multiple beneficial effects, mainly cucurbitane-type triterpenoids, triterpene glycoside, phenolic 
acid, flavonoids, essential oils, fatty acids, saponins and amino acids [188]. The toxicity data is 
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minimal with only evident side effects being diarrhea and abdominal pain that can be relatively 
easily managed [235]. Variety of bitter melon constituents have actively been screened for their 
anticancer potential in numerous cancer types [188]. Analysis of bitter melon methanolic extract 
showed cucurbitane-type triterpenoids to be associated with an elevated anticancer efficacy in a 
two-stage mouse skin carcinogenesis model [236]. Furthermore, purified fractions of bitter 
melon methanolic extract containing monogalactosyl diacylglycerol (MGDG, a 
glycoglycerolipid) also displayed DNA polymerase inhibition-mediated growth inhibitory effects 
in lung, leukemia, colon, cervical and stomach cancer cells; however, no such effects were 
observed in normal cells [237]. Kuguaoside A; momordicoside I, F1, and K; and goyaglycoside-b 
derived from bitter melon ethanolic extract have shown cytotoxicity in breast, colon, laryngeal 
and medulloblastoma cancer cells [184]. Another vital bitter melon component, cucurbitane-type 
triterpene 3β,7β-dihydroxy-25-methoxycucurbita-5,23-diene-19-al is reported to exert strong 
cytotoxic potential against breast cancer cells via targeting and activating/altering PPARγ and -
downstream signaling pathways along with inhibition of mTOR-p70S6K signaling mediated by 
downregulation of AKT and AMPK activation [193]. Our previously published works have also 
reported BMJ mediated modulation of key pathway molecules such as PI3/Akt and ERK1/2 
involvement in PanC associated gemcitabine resistance, and activation of AMPK (master 
metabolic regulator) leading to nutrient stress and eventually apoptosis in BMJ treated PanC 
cells and murine tumor xenografts [190, 192].  
The current study exclusively revolves around BMJ and its anticancer efficacy against 
PanC exerted through CSC modulation. We utilized a CD44+/CD24+/EpCAM+ triple positive 
marker for identifying the enriched subset of PanC-CSCs [207]. BMJ potential was evident by 
PanC growth inhibition observed with lower doses, of upto 2% BMJ, followed by massive cell 
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death inflicted by 4% BMJ over a course of 72 hours. 2% BMJ qualified as the biological dose, 
hence was selected as the peak concentration for all mechanistic evaluations. The spheroid 
assays with PanC cells showed a significant decrease in resulting spheroid number and size in 
BMJ pre-treated PanC cell monolayers and established spheroids, with drug exposures (single 
and multiple BMJ treatments), highlighting the potential of BMJ to effectively target the CSC 
pool in solid tumors. Further insight into the PanC-CSC associated transcription factors and 
regulatory molecules/surface markers by RT2qPCR array of BMJ treated MiaPaCa2 cells 
displayed altered/decreased fold regulation for key genes involved in PanC stemness. SOX2 and 
NANOG are of great significance to this study based on their contribution to the CSC pool in a 
variety of cancers, particularly PanC. They are specifically responsible for self-renewal, 
dedifferentiation and impart stemness characteristics by targeting cell cycle regulatory genes, 
eventually resulting in EMT [224, 225, 238, 239]. Other downregulated genes of interest with 
BMJ treatment included NR2F2; encodes COUP TFII, a downstream molecule in numerous CSC 
associated PanC progression pathways [240], GLI2; downstream molecule of hedgehog pathway 
and critical to CSC stemness and maintenance in PanC initiation and progression [241], ISL1; 
stage specific marker of pancreatic development/differentiation and highly upregulated in PanC-
CSCs [242], MYC; overexpressed in PanC and identified as a key determinant of oxidative 
phosphorylation dependency in PanC-CSCs [222]. Targeting these CSC genes responsible for 
stemness has been reported to diminish the tumorigenic potential and enhance sensitivity to 
chemotherapeutic agents by altering core CSC properties [203]. Analysis of protein levels of 
core molecules involved in PanC-CSC stemness and self-renewal exhibited significantly 
decreased expressions/fluorescence intensities of SOX2, OCT4, NANOG and CD44 in PanC cell 
monolayers and spheroids. SOX2, OCT4 and NANOG are embryonic stem cell transcription 
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factors aberrantly expressed in PanC-CSCs, responsible for their self-renewal and pluripotency 
[225]. CD44 is reported as the most enriched cell surface marker in relapsing PDAC; a suitable 
therapeutic target in multiple cancers. It is widely accepted on the panel of markers for PanC-
CSC isolation [243, 244]. Therefore, a reduced expression for these protein markers in PanC 
monolayers and spheroids correlates to BMJ efficacy in curbing CSC mediated PanC. Overall, 
BMJ efficiently targets and downregulates these PanC-CSC associated molecules, thereby 
pointing to inhibition of PanC progression. Lastly, translational relevance of BMJ was confirmed 
in vivo utilizing MiaPaCa2 xenografts where BMJ administration (via oral gavage) also caused a 
significant reduction in PanC- CSC associated transcription factors as examined by 
immunohistochemical staining of SOX2, OCT4, NANOG and PDX1, thus verifying the results 
noted from our in vitro studies.  
In summary, we were able to establish a novel activity of BMJ in targeting both PanC 
CSC pool as well as bulk tumor population, together with a decrease in the levels of CSC-
associated regulatory molecules. The effects observed in vitro were further corroborated in 
mouse xenograft tissue samples showing a decrease in PanC-CSC associated regulatory 
molecules in BMJ treated samples compared to controls.  Notably, these effects of BMJ warrant 
further studies to establish its efficacy in CSC-driven PanC models and define associated 










BITTER MELON JUICE MODULATES LACTATE TRANSPORT IN ITS EFFICACY 
AGAINST PANCREATIC CANCER 
Introduction 
Pancreatic cancer (PanC) is currently ranked as the fourth leading cause of cancer-related 
deaths across the US. The dismal statistics for the year 2018 estimates about 55,440 new 
incidences and 44,330 PanC-associated fatalities in men and women combined, with a 5-year 
survival rate of less than 10% [1]. The risk factor is elevated by the anatomically fairly 
inaccessible location of the pancreas for routine examination. To make matters worse, there has 
also been a marked increase in PanC patient population resistant to conventional 
chemotherapeutic agents; PanC is estimated to be the second leading cause of cancer-associated 
fatalities by the year 2020 [245]. PanC chemo-resistance has been attributed to the dense stromal 
environment and broad heterogeneity of mutations. This increasing repertoire of genetic and 
metabolic modifications further confers heightened proliferative ability and capacity to PanC for 
survival under unfavorable conditions [246]. 
Lately, there has been a keen interest in recognizing dysregulated cellular metabolism as 
a prime suspect of carcinogenesis. PanCs possess a very intricately designed metabolic profile 
favoring excess glycolysis in addition to altered glutamine metabolism, leading to PanC 
progression [247].  Glucose is the major metabolic precursor responsible for Warburg effect; a 
shift in ATP generation from oxidative phosphorylation to glycolysis, even when oxygen is not a 
limiting factor. Resulting amplified lactate production leads to enhanced tumorigenic potential 
characterized by tumor cell invasion, migration, metastasis and in turn, correlates with tumor 
reoccurrence [248]. Warburg effect is regulated via multiple pathways/factors, especially AMPK 
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that functions as a metabolic checkpoint by modulating and regulating cellular response to 
energy availability [249]. Under stressful conditions, AMPK is phosphorylated and activated in 
response to an elevated AMP/ATP ratio, shifting the cellular metabolism to an oxidative 
phosphorylation phenotype causing proliferation arrest [250]. Cancer cells typically experience a 
loss of AMPK activity which contributes to their glycolytic phenotype [251]. Oncogenic KRAS 
present in >90% pancreatic ductal adenocarcinomas (PDACs) is documented as the driver of 
glucose metabolism in PanC triggering key metabolic alterations downstream of its activation 
[252]. Together, accumulation of these pathway modifications for elevated nutrient requirements 
confers metabolic plasticity enabling PanC to accustom with these rapid metabolic changes. 
Due to the severity of PanC and its related complex metabolic profile, a variety of targeted 
therapies/therapeutic agents have proven unsuccessful or deemed ineffective in the clinic [253]. 
To overcome that, stronger chemotherapeutic agents are employed with improved efficacy for 
increasing patient life span by a few months, but not without numerous associated side effects; 
PanC patients undergoing chemotherapy display a very poor and dismal quality of life [254, 
255]. Recent times have witnessed a heightened interest in recognizing the potency of natural 
products as anticancer agents and their underlying mechanisms, particularly in PanC [256]. Bitter 
melon juice (BMJ), derived from the fruits of Bitter melon (Momordica charantia, Family-
Cucurbitaceae), is one such dietary agent gaining importance in mainstream therapeutics after 
having been exploited for its potential in alternative medicine for decades [188]. BMJ-associated 
health benefits include effectiveness against gout, kidney-stone, rheumatism; however, it is 
mainly used as an antidiabetic, anthelminthic, abortifacient, and even as a contraceptive [180, 
181]. Few short-term/uncontrolled clinical studies have indicated the efficacy of BMJ in type II 
diabetics; BMJ administration improves glucose tolerance and reduces blood glucose levels in 
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these patients [257, 258]. Different preparations of bitter melon including BMJ have been 
reported to possess significant anticancer efficacy against a wide variety of cancer types; e.g. 
skin, breast, prostate, colon, etc. [191, 236, 259-261]. In our studies, we have shown AMPK 
activation-mediated apoptotic cell death as a major mechanism in BMJ efficacy against PanC in 
cell culture and xenograft models [190]. We have also recently reported the BMJ potential in 
targeting PanC cancer stem- and bulk-cell populations; BMJ also facilitated the drug sensitivity 
in gemcitabine resistant PanC cells by targeting the underlying molecular pathways [192, 261]. 
These findings directed us to study the potential of this natural agent on PanC metabolism; 
specifically, we assessed whether BMJ modulates PanC cell metabolome, together with 
establishing the molecular metabolomic targets to better understand the relevance of altered 
metabolism in PanC management by BMJ. 
Materials and methods 
Cell lines and reagents 
Human PanC PANC1 and BxPC3 cell lines were purchased from ATCC (Manassas, VA, 
USA) and snap frozen in batches (used at passage #10-15). PANC1 cells were grown under 
standard culture conditions (37°C, 95% humidified air and 5% CO2) with 10% FBS and 1% 
Penicillin-Streptomycin in Dulbecco’s Modified Eagle’s Medium (DMEM) with high glucose, 
from ATCC. BxPC3 cells were grown in RPMI 1640 (1X) media from Life technologies, 
supplemented with 10% FBS and 1% Penicillin-Streptomycin. Trypan blue dye was purchased 
from Gibco by Life Technologies (Carlsbad, CA) and crystal violet dye from Sigma-Aldrich (St. 
Louis, MO). Primary antibodies used for immunohistochemistry (IHC): Ki67 (#16667), CD31 
(#28364) and LDH (#47010) were from abcam (Cambridge, MA), C-caspase 3 antibody (#9661) 
was from cell signaling technologies (Danvers, MA), and pAMPK antibody (#PA5-37821) was 
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from Invitrogen (Carlsbad, CA). Secondary antibodies were: anti-rabbit (#31820) from 
Invitrogen (Carlsbad, CA) and anti-mouse (#E0433) from Dako (Denmark). The DAB kit 
(#SK4100) was from Vector Laboratories, Inc. (Burlingame, CA). Primary antibodies for 
immunofluorescence (IF) were: GLUT1 (#652) from abcam (Cambridge, MA) and MCT4 
(#376140) from Santa Cruz Biotechnology (Dallas, TX). The secondary antibodies for IF were: 
anti-rabbit (#A11032) and anti-mouse (#A11008) from Life Technologies (Carlsbad, CA). BMJ 
preparation and characterization were as reported by us earlier [190]. 
Cell viability 
PANC1 and BxPC3 were seeded in 6-well plates (Corning, Inc) for ~24 hours and post 
70% confluency, were treated with BMJ (2%, v/v) and followed from 72 to 144 hours to track 
changes in viability. Control wells were treated with media containing DMSO alone. Media was 
aspirated and fresh media with/without BMJ was added to the wells after every 72 hours till 
study completion. Cells were trypsinized, collected and counted using a Trypan blue dye 
exclusion method to determine viable and dead cells after BMJ treatment for various time points. 
Cells stained blue on the hemocytometer were recorded/counted as dead cells. All experiments 
were done in triplicates. 
Clonogenic assay 
PanC cells PANC1 and BxPC3 were seeded in clear 6-well plates (Corning, Inc.) at a 
density of ~ 2 x 103 cells/well. Caution was taken to plate single cells by thoroughly 
pipetting/breaking the cell pellet prior to seeding. Cells were allowed to grow and form colonies 
that were observed for 6 days when the cell colonies grew to ≥50 cells. Media containing fresh 
BMJ (2%, v/v) treatment was replaced every 72 hours till the end of study. On day 6 from BMJ 
treatment initiation, the media was aspirated, and the wells were washed with chilled 1X PBS. 
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Next, crystal violet dye was added to each well, enough to cover the well surface for about 1-2 
mins to stain the colonies. The dye was then removed, and the wells were gently rinsed with 
water and allowed to dry before proceeding to count the number of colonies (stained).  
Cell extraction and quantitative NMR analysis 
For NMR analysis, PANC1 (~1.3 X 106 cells/150mm3 culture dishes) and BxPC3 (~2 X 
106 cells/150mm3 culture dishes) cells were incubated with 5 mM [1-13C] glucose (Cat # CLM-
420-0, Cambridge Isotope Laboratories) for 72 hours with/without BMJ (2%, v/v) treatments, 
and then extracted with 12% perchloric acid; both water soluble and lipid extracts were then 
subjected to high resolution 1H- ,13C- and 31P-NMR experiments as described previously [262] 
(Fig. 3.1). Cell culture media were collected after 4 hours (data not shown) and 72 hours of BMJ 
treatment (last 4 hours in the presence of [1-13C] glucose) for glucose uptake/ lactate export 
studies. Experiments were performed partly at the Metabolomics NMR Core (University of 
Colorado Cancer Center).  
Immunofluorescence (Cells) 
PANC1 and BxPC3 were seeded at a density of ~8-10 x 103 cells/well, grown on 
coverslips and treated with BMJ (2%, v/v) for 72 hours. Formalin fixed cells were washed with 
0.1% triton X-100 in 1X PBS thrice, 5 min for each wash followed by permeabilization with 
0.3% Triton X-100 in 1X PBS for 1-2 hours. Next, cells were blocked with CAS block buffer 
(Invitrogen, 1:1 in 1X PBS) for an hour at room temperature. Post blocking, primary antibody 
was added to the dilution buffer (1% BSA in PBST) overnight at 4 ºC in a humidified chamber. 
Following day, cells were tagged with fluorochrome conjugated secondary antibody and 



























Sample preparation for NMR-spectroscopy 
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Finally, cells were washed with high salt PBS and subsequent washes with 0.1% triton X-100 in 
1X PBS. Lastly, the coverslips were mounted with Prolong® Gold Antifade Reagent /DAPI and 
allowed to dry. Olympus FV1000 FCS/RICS confocal microscope at Advanced Light 
Microscopy Core (ALMC) of University of Colorado Denver, Anschutz Medical Campus was 
used for imaging and analysis by FV-Viewer software was from Olympus. Fixing, 
permeabilization, blocking and antibody incubation was carried out as described in previous 
publications from our group [216]. 
Xenograft study 
All animal experiments were performed according to the IACUC-approved animal 
protocol (University of Colorado Denver). Athymic female nude mice were purchased from 
Charles River Laboratories and housed at the animal facility (University of Colorado Denver) for 
a week for acclimatization and fed AIN-76A diet (Envigo). Animals aged ~6 weeks were 
injected with PANC1 cells (2 x 106) suspended in 50 µL of serum-free medium (DMEM), mixed 
with 50 µL of Matrigel (1:1) s.c. into the dorsal right flanks of each mouse to initiate tumor 
growth. One group of the animals was initiated on BMJ treatment of 200mg/Kg, 5 days a week, 
in 100µl water, 24 hours post cell injection (Prevention approach: BMJ-1). The remaining tumor-
bearing animals were followed for 2.5-3 weeks until the tumors grew to a size of ~100mm3, and 
then divided into Control (untreated) and late BMJ (Intervention approach: BMJ-2) fed groups. 
Here, the animals were continued on BMJ treatment of 200mg/Kg for ~7 weeks. The tumor 
volume was measured using a digital caliper and calculated using the formula 0.5236 L1 (L2)
2, 
where L1 is the long axis and L
2 is the short axis of the tumor. At study completion, the animals 
were euthanized, and a part of the tumor was fixed in 10% phosphate-buffered formalin for IHC 
analyses. Tumor volumes and body weights of the animals were recorded biweekly. 
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[18F] FDG-PET, Magnetic Resonance Imaging for the in vivo xenograft model 
MRI was employed for non-invasively assessing tumor sizes in the animals. Bruker 4.7 
Tesla/ 16-cm MRI/MRS PharmaScan (Bruker Medical, Billerica, MA) with a mouse volume 
transmitter/ receiver coil (36 mm diameter) was used for all MRI studies at the Animal Imaging 
Shared Resources (AISR), University of Colorado Denver, employing the MRI protocol 
previously validated and published [263].  
For FDG-PET studies, 4 representative animals from each group (Control, BMJ-1 and 
BMJ-2) were fasted for 4 hours, blood glucose levels were monitored prior to injection of 250 
µCi of FDG (obtained from PetNet) as previously described [264]. After 60 mins of awake 
uptake, the animals were anesthetized with 2% isoflurane and a 10 min PET scan was acquired 
using Siemens Inveon μPET scanner and Inveon Acquisition Workplace software (IAW v1.5). 
All PET scans were acquired in a double-sampling mode to improve spatial resolution (1.2 mm). 
Regions of interest were manually drawn around the tumors on scan slides and total radioactivity 
of the ROI determined (in kBq/mL). The standardized uptake values (SUVs) were calculated as 
tissue activity [kBq/mL]/(corrected injected dose [kBq], where the corrected dose is calculated as 
C = C0*e(−0.006317*t) (18F decay constant of 0.006317). 
Immunohistochemistry 
Paraffin-embedded tumor sections (5 μm-thick) were deparaffinized and subjected to 
antigen retrieval using 10 mM citrate buffer (pH 6.0) in a microwave. Endogenous peroxidase 
activity was blocked with 3% H2O2 in methanol (v/v) for 10 min followed by incubation with 
CAS block for 1 hour at RT and incubated overnight at 4 ºC with the respective primary 
antibodies in a humidified chamber. Next day, the sections were incubated with biotin-
conjugated secondary antibodies for 1 hour at RT. Subsequently, sections were incubated with 
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conjugated horseradish peroxidase-streptavidin for another hour. The sections were then 
incubated with DAB, washed and counterstained with Harris hematoxylin and rinsed in Scott’s 
water. Percentage of positive cells was calculated by counting the number of positive stained 
cells (brown stained) and the total number of cells from eight arbitrarily selected fields per tumor 
section. For cytoplasmic staining/ scoring, arbitrary immunoreactivity scores were allotted based 
on intensity of brown staining as 0 (no staining), 1 (weak staining), 2 (moderate staining), 3 
(strong staining), 4 (very strong staining). Images were captured by AxioCam MrC5 camera at 
400x magnification.  
Immunofluorescence (Tissues) 
Paraffin embedded tissue slices (5 μm-thick) were deparaffinized in xylene and subjected 
to rehydration in a graded series of ethanol (100%-70%) with 5 min incubations. Antigen 
retrieval was performed using 10 mM citrate buffer (pH 6.0) in a microwave. Following antigen 
retrieval, the samples were allowed to cool down to RT and then processed as detailed above 
(immunofluorescence for cells). A1-HD confocal microscope from Nikon was used for tissue 
sample imaging, and NIS-Elements confocal microscope imaging software from Nikon was used 
for data analysis. 
Statistical analysis 
Statistical analyses excluding principal component and multivariate analysis (discussed 
later) were performed using Sigma Stat software (version 3.5, Jandel Scientific). Quantitative 
data are presented as mean±SEM. Statistical significance of difference between control and 
treatment groups was determined through one-way analysis of variance (ANOVA) followed by 
Tukey’s test for multiple comparisons. P<0.05 was considered significant. P value of p ≤ 0.05 is 
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Results 
BMJ induces cell death and inhibits cell growth and colony formation in human PanC cell 
lines 
Trypan blue exclusion assay was performed for determining cell growth and viability of 
PANC1 and BxPC3 cells (Fig. 3.2A). BMJ (2%, v/v) exposure for 72 - 144 hours caused a 
significant decrease in the total cell count through the course of the study for both cell lines; 
~95% decrease in total cell count for PANC1 cells and ~80% decrease in total cell count of 
BxPC3 cells post 144 hours of BMJ treatment. In parallel, BMJ showed an increase in cell death 
induction by 72 hours (~10% cell death for PANC1 and ~15% cell death for BxPC3 cells) which 
continued to increase significantly compared to the control until 144 hours (~50% cell death for 
PANC1 and ~55% cell death for BxPC3 cells). These results point to the ability of BMJ in 
efficiently targeting and inhibiting PanC cell growth and eliciting a time-based cell death 
response up to extended time points (144 hours). Note: Cell viability results from earlier 
treatment time points of 24 and 48 hours exhibited increased cell growth inhibition with no 





Figure 3.2: BMJ targets and decreases cell viability and clonogenic potential of PanC cells. 
(A) Represents the changes in total cell number and % death of PanC cells PANC1 (top) and 
BxPC3 (bottom) with BMJ (2%, v/v) treatment at 72, 96, 120 and 144 hours. (B) Changes in 
clonogenic potential of PanC cells PANC1 and BxPC3 with single exposure of BMJ (top) and 
multiple exposures of BMJ at every 72 hours (bottom), till the end of study, over a course of 6 
days. The pictures signify the changes in C (Control) and BMJ treated PanC cell colony numbers 
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Concurrently, the effect of BMJ (single and multiple exposures) on colony formation of 
PANC1 and BxPC3 cells was also determined. PanC cells seeded for colony formation assay 
were treated with/without BMJ (2%, v/v). One set of experiment incorporated the cells 
undergoing single BMJ exposure at study initiation. No fresh treatments were added to the 
treatment wells when media was replenished at 72 hours. Second set of experiment consisted of 
multiple BMJ exposures at every 72 hours till study end during fresh media replacement. On 
study completion, stained colonies were counted for both experimental conditions for PANC1 
and BxPC3 cells. Single BMJ treatment for PANC1 cells displayed ~87% decrease and BxPC3 
cells displayed ~73% decrease in total number of colonies compared to control wells. Meanwhile 
multiple BMJ exposures were more potent and exhibited ~99% and ~95% decrease in PANC1 
and BxPC3 colonies, respectively (Fig. 3.2B).  
BMJ modulates the metabolic profile of PanC cells 
KRAS mutation has been defined as a key player in ≥95% of PDACs, majorly 
contributing to their growth and progression. Previously published studies from our group have 
also established the role of BMJ in targeting and activating the master metabolic regulator 
AMPK causing apoptotic cell death in PanC [190]. Subsequently, here we investigated the 
comparative metabolic profiles of PanC cells with differential KRAS mutational statuses 
(PANC1; mutated KRAS and BxPC3; wild type KRAS), on BMJ exposure. The top panels for 
both cell lines depict the PCA (principal component analysis) of controls and BMJ treated groups 
(Fig 3.3A). The middle panels represent the PLS-DA (partial least square discriminant analysis) 
which highlights the metabolites with maximum significant changes between control and BMJ 
treated groups, and thereby helps enhance the estimation accuracy by identifying a subset of 




Figure 3.3: BMJ alters the PanC cell metabolome. (A) Principal component analysis and (B) 
Multivariate analysis- partial least squares discriminant analysis (PLS-DA) conducted on 
PANC1 (left panel) and BxPC3 (right panel) cells after 72- hour treatments with/without BMJ 
(2%, v/v) addition. The graphs were generated using Metaboanalyst software. (C) Depicts the 
endogenous metabolite comparative analysis between untreated and BMJ treated PanC cells 
PANC1 (left) and BxPC3 (right) generated from 1H, 13C and 31P NMR-spectroscopy. 
Endogenous metabolite concentrations are presented as nmol. g-1 cell wet weight. ***p≤0.001, 
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Of all the metabolites screened via 1H, 13C and 31P NMR-spectroscopy, a few key 
components of interest (glucose and lactate metabolic pathway components), highlighted from 
PLS-DA, were further examined and plotted to investigate their modified levels with BMJ 
treatment (Fig 3.3C). 13C- lactate was an interesting component which exhibited a significant 
build up within the cells with BMJ treatment for both PANC1 and BxPC3 cells, correlating with 
observed biological effect by 72 hours of BMJ treatment. This effect was accompanied by a 
significant decrease in lactate export with BMJ exposure for PANC1 cells, while no changes 
were observed in BxPC3 cells. Furthermore, increased intracellular glucose levels, along with a 
significant decrease in ATP/ADP ratios strongly pointed to cellular energy restriction with no 
new ATP generation by the cells with BMJ treatments; there was a complete dependence on the 
available intracellular glucose which was quickly being consumed as observed by increased 
intracellular glycolysis and lactate build up within the cells. More significant and robust results 
were observed for PANC1 cells in response to BMJ treatments, as opposed to BxPC3 cells where 
BMJ exhibited less significant metabolite changes compared to the untreated control cells. 
BMJ exposure modifies glucose and lactate transporter expression in PanC cells 
Results from 1H, 13C and 31P NMR-spectroscopy were validated in PanC cells PANC1 
and BxPC3 by IF analysis of glucose and lactate transporter expression status on treatment with 
BMJ. IF of GLUT1 and MCT4 transporters over a time-course of 4, 12 and 72 hours revealed the 
difference in expression between BMJ-treated versus control samples; GLUT1 and MCT4 are 
established to be upregulated and contribute to the aggressiveness of PanCs [265, 266]. Confocal 
microscopy images for GLUT1 in PANC1 cells depicted a decrease in expression at 4, 12 and 72 
hours after BMJ exposure compared to controls; however, the decrease, although still present, 
was less pronounced by 72 hours in BxPC3 cells (Fig. 3.4A). MCT4 also exhibited a sharp 
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decrease in its expression with BMJ treatments which followed a trend of decrease at 4 hours, 
dropped further by 12 hours and was barely present by 72 hours of BMJ exposure for both 
PANC1 and BxPC3 cells (Fig. 3.4B). Together, these results further support the notion of 
decreased glucose uptake and lactate export with BMJ treatments in PanC cells, as discussed in 
the previous section highlighting the NMR-spectroscopy data. 
FDG-PET and MRI demonstrate BMJ efficacy in PANC1 flank xenograft model 
To further investigate the relevance from our in vitro studies, we employed the PANC1 
xenograft mouse model for assessing BMJ efficacy against PanC in vivo. This model was chosen 
based on enhanced metabolic modifications in response to BMJ treatment, as inferred from our 
in vitro NMR-spectroscopy data. Animals were randomized into 3 groups: Control, BMJ-1 
(Prevention approach, BMJ- 200mg/Kg in 100µl water, initiated 24 hours post flank cell 
injection) and BMJ-2 (Intervention approach, BMJ- 200mg/Kg in 100µl water, dosing initiated 
after the xenografts grew to a size of ~100mm3). 4 mice from each cohort were analyzed by MRI 
and FDG-PET imaging at: baseline determination prior to animal randomization (day 0- when 
the tumors grew to ~100mm3) followed by Cycle 1 at day 6 and day 7 post randomization and 
BMJ-2 initiation, and Cycle 2 at study end (Fig. 3.5A).  
Animals from each cohort were followed in a time-course study using anatomical proton-
density MRI (Cycle 1 & 2) (Fig. 3.5B, left panel). Functional imaging end-points included (early 
time-point of day 6/7 post randomization and at study end): tumor cellularity by diffusion-
weighted DW-MRI and tumor metabolic activity by FDG-PET. A marked change was seen in 
imaging parameters within the BMJ treatment groups. Apparent diffusion coefficient (ADC), 
correlating with the extent of tissue cellularity and intact cell membranes, was shown to increase 




Figure 3.4: BMJ treatment downregulates glucose and lactate transporter expression in 
PanC cells. PanC cells were treated with BMJ (2%, v/v) and probed for (A) glucose transporter 
GLUT1 (green) and (B) lactate transporter MCT4 (red) in PANC1 and BxPC3 cells at 4, 12 and 
72-hour timepoints, in the presence or absence of BMJ. The transporter expression was analyzed 
by IF staining. DAPI is represented by blue stained nuclei. All images were captured at 100x 
magnification.  
BMJ downregulates GLUT1 and MCT4 expression in PanC cells 
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endpoints. ADC values for Control animals (1.05 ± 0.33, x 103mm2/s) in Cycle 1 increased with 
BMJ treatment in BMJ-1 (1.56 ± 0.03, x 103mm2/s) and BMJ-2 (1.48 ± 0.04, x 103mm2/s) 
groups. While the ADCs for Controls in Cycle 2 dropped (0.92 ± 0.11, x 103mm2/s) compared to 
Cycle 1 with accompanying increases in tumor volumes, BMJ treatment continued to maintain 
better ADCs in treated animals for both BMJ-1 (1.15 ± 0.08, x 103mm2/s) and BMJ-2 (1.12 ± 
0.25, x 103mm2/s) groups (Fig. 3.5B, right panel). 
As FDG uptake and accumulation marks the carbohydrate metabolism rate, reflecting the 
cellular metabolic activity, similar to regulated ADC levels, BMJ treatment decreased FDG 
uptake in the tumors, as presented by the SUV values and represented in the images (Fig. 3.5C). 
The SUVs recorded for Cycle 1 were higher in Controls (2.1 ± 0.11) compared to BMJ-1 (0.77 ± 
0.08) and BMJ-2 (1.42 ± 0.25) treated animals. For Cycle 2, the recorded SUVs for Controls 
were much higher than Cycle 1 (5.2 ± 1.04) while BMJ administered animals displayed 
decreased SUVs in BMJ-1 (2.57 ± 0.35) and BMJ-2 (4.27 ± 2.15) groups compared to Controls, 
as depicted in the images and bars (Fig. 3.5C). 
BMJ exhibits in vivo efficacy in inhibiting PANC1 xenograft growth in athymic nude mice 
Xenograft study findings presented a significant decrease, throughout the treatment 
protocols, in tumor volumes in BMJ-1 and BMJ-2 groups compared to control animals. BMJ 
administration caused a decrease in the tumor volumes in both BMJ-1 (~60mm3, p≤0.001) and 
BMJ-2 (~100mm3, p≤0.001) treatment groups compared to untreated controls (~450mm3) at 
study completion. Interestingly, BMJ-1 exhibited enhanced drug efficacy over BMJ-2; however, 
no statistical significance was observed within the BMJ treatment groups. Tumor volumes 
analyzed at study end displayed ~89% decrease in BMJ-1 group and ~80% decrease in BMJ-2 




Figure 3.5. MRI and FDG-PET scans depicting changes in PANC1 tumor bearing animals 
dosed with BMJ. (A) Schematic following the experimental regimen of control versus BMJ 
dosed PANC1 xenografts. The study involved chasing animals from 3 different treatment 
cohorts: Control (n=4, untreated), BMJ-1 (n=4, prevention approach, initiated 24 hours post 
PANC1 cell injection) and BMJ-2 (n=4, intervention approach, initiated when tumors grew to a 
size of ~100mm3), over a period of 73 days. FDG-PET scans and MRI imaging was performed 
first to set baselines (data not shown-at day 0, before randomizing animals into Control and 
BMJ-2 groups), next at Cycle1 (early timepoint of MRI at day 6 and FDG scans at day 7), and 
Cycle2 involving final set of scans (MRI at day 72 and FDG scans at day 73). (B) Left panel has 
representative proton density MRI scans of animals from each treatment cohort, from Cycle1 and 
Cycle2. Right panel shows quantitative imaging end points derived from DW-MRI and FDG-
PET of untreated and BMJ (1 and 2) treated animals. (C) Representative images of [18F] FDG 
uptake in PANC1 xenografts of Control, BMJ-1 and BMJ-2 groups at study end (Cycle2-day 
73). Tumors in MRI images are pointed out by arrows (white). Tumors in FDG-PET images are 






Figure 3.6: BMJ treatment decreases tumor volumes in PANC1 xenografts, and exerts 
efficacy via inhibiting cell proliferation, inducing apoptosis and decreasing the microvessel 
density. (A) Tumors volumes were plotted as a function of time for Control (untreated), BMJ-1 
(prevention approach) and BMJ-2 (intervention approach), followed by a difference in tumor 
volumes at the end of study (day 73- right panel). (B) Representative images from IHC analyses 
of Ki67, C-caspase3 and CD31 with a quantitative representation of the staining from each 
treatment group. All images were captured at 400x magnification. Data shown was a mean of 




the study for general signs of toxicity, such as primarily weight loss, where BMJ feeding did not 
show any observable toxicity in terms of no significant changes in body weights (data not 
shown). IHC analysis of efficacy markers was next performed for Ki67 (tumor cell proliferation 
maker), C-caspase 3 (apoptosis marker) and CD31 (microvessel density marker) in control and  
BMJ-fed animals (Fig. 3.6B). BMJ administration caused a significant decrease in cell 
proliferation as evidenced by Ki67 stained % positive cells for both BMJ-1 (~12%) and BMJ-2 
(~18%) groups compared to untreated controls (~38%). A marked increase in apoptosis 
induction was also observed in the tumor tissues from the animals with BMJ dosing where scores 
for C-caspase 3 drastically increased in BMJ-1 animals (3.5) compared to control animals (<1). 
However, not much effect on C-caspase 3 was observed in BMJ-2 group (1.5) which displayed a 
slight increase in staining from controls, although not significant. Regarding microvessel density 
of the xenografts, both BMJ treatments showed a strong and significant decrease, compared to 
controls, though at different levels. 
BMJ targets and modulates PanC cell metabolome in vivo  
Following BMJ efficacy investigation in PanC cells in vitro and in vivo we also assessed 
its effect on key metabolic components employing xenograft tissues from study detailed in Fig. 
3.6. Increased LDH levels have been associated with a poor prognostic outcome and increased 
PanC progression [267]. Also, results from our in vitro studies point to the involvement of lactate 
production and metabolism in BMJ-dependent PanC growth suppression. IHC staining 
demonstrated a significant decrease in LDH levels for BMJ-1 and BMJ-2 groups (≤1.5) 
compared to controls, thereby, supporting our in vitro findings (Fig. 3.7A). Consistent with our 
previous study showing that BMJ activates AMPK in PanC cells in culture and MiaPaCa2 mouse 





Figure 3.7: BMJ dosing modulates tumor LDH and pAMPK levels, and also decreases 
glucose and lactate transporter expression in vivo. (A) PANC1 xenografts were probed for 
LDH and pAMPK levels by IHC analysis and the positive brown staining was quantified. Images 
were acquired at 400x magnification. (B) Representative images from each treatment cohort 
depicting GLUT1 (green) and MCT4 (red) expression in PANC1 xenograft tissue of Control, 







in a significant increase (>3 fold) in pAMPK levels in both BMJ-1 and BMJ-2 groups (Fig. 
3.7A). 
Additionally, further studies were carried out in PANC1 xenograft tissues to support the 
BMJ-dependent metabolic changes observed in our in vitro findings. IF imaging showed a major 
decrease in GLUT1 expression in the tissues from both BMJ-1 and BMJ-2 groups compared to  
controls (Fig. 3.7B, left panel). Regarding MCT4, the decrease was more noticeable in its 
expression, where tissues from both BMJ-1 and BMJ-2 groups showed a marked reduction in 
this transporter protein levels compared to controls (Fig. 3.7B, right panel). Since an upregulated 
MCT4 expression is imperative in controlling intracellular pH and lactate-based metabolism, 
specifically lactate shuttling, to aid in tumor growth and survival under stressful  
conditions [268], our findings suggest that BMJ effectively targets and modulates PanC cell 
metabolism in vivo, with lactate being a major molecule of interest. 
Discussion 
PanC continues to be a highly aggressive form of malignancy, displaying poor response 
or proving non-responsive to the frontline chemotherapeutics in clinic. Minimal resulting 
survival benefits and improved efficacy accompany severe drug-associated side effects [269]. 
Recent studies provide an intriguing insight connecting AMPK activity loss and poor prognosis 
with increased desmoplasia in PDAC (pancreatic ductal adenocarcinoma), highlighting the 
importance of AMPK phosphorylation in inhibition of PanC cell migration and invasion 
potential [270, 271]. Established tumors are reported to possess a downregulated expression or a 
lack of functionally active AMPK and its targets [272, 273]. Numerous studies have confirmed 
the loss of AMPK activation as a frequent event in various cancers, especially in PanC 
promotion and progression [269, 274]. Tumor metabolism adapts for increased survival by 
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causing altered sensing, nutrient uptake and utilization, and efficient efflux of toxic byproducts 
[275]. Normal non-cancerous cells typically utilize nutrients via multiple nutrient-sensing 
pathways and increased sensitivity in response to minute changes in cellular nutrient levels, 
correlating with their abundance where their energy requirements are met by increasing 
mitochondrial oxidative phosphorylation and activating autophagy. However, cancer cell 
survival overrides the normal cell machinery by inducing a disbalance between biosynthetic and 
catabolic pathways that allows for rapid and uninhibited proliferation in unfavorable conditions 
of low nutrient and oxygen levels [275]. These studies suggest that targeting an aberrant cancer 
cell metabolism in PanC could be an effective strategy to manage this deadly malignancy. 
PanC cells like other tumor cells, undergo cellular reprograming to meet their bioenergetic and 
biosynthetic demands, with glycolytic shift emerging as the primary metabolic hallmark in the 
process of carcinogenesis [276]. The resulting malignant metabolic phenotype is programed to 
convert glucose into lactate, even in the presence of sufficient oxygen levels which drives the 
pathological requirements of cancerous cells, enabling rapid tumor growth and progression, as 
opposed to normal cells [276]. Over two-thirds of PanC patients deal with an impaired glucose 
tolerance as noted  by improved glucose levels post-surgical resection of PanC, suggesting a 
strong correlation between PanC and altered glucose metabolism [277]. Lactate homeostasis in 
cells, both normal and cancerous, occurs via facilitative and proton linked MCTs; these 
transporters are responsible for flushing the excess levels of lactate outside the plasma membrane 
and inhibiting continued glycolysis, thereby limiting the toxic buildup of lactate and intracellular 
acidification [278, 279]. Cells with an increasingly glycolytic phenotype use MCTs for 
transporting LDH generated lactate, thereby establishing MCTs as the key regulators of 
intracellular pH and lactate, where increased lactate export correlates with highly aggressive 
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PDACs [278]. For maintaining a higher rate of glycolysis, a characteristic feature of PDAC, the 
cells are required to secrete more lactate, since increased intracellular lactate accumulation 
causes inhibition of glycolysis by negative regulation of LDH activity [280]. Together, these 
findings recognize glycolysis and lactate pathways as important therapeutic targets for PanC 
management.  
Bitter melon is a widely consumed vegetable in Asia and Africa, and its various forms; 
aqueous extract, alkaline chloroform extract, pulp, aqueous extract powder, whole plant extract, 
are shown to possess antidiabetic and hypoglycemic activity in cell culture, animal and clinical 
studies [257, 281]. Notably, diabetes is an important risk factor for pancreatic cancer; almost half 
the PanC patient population are diabetic at diagnosis [282]. Our recent studies have reported an 
increased AMPK phosphorylation and activation with BMJ exposure in PanC cells in culture and 
mouse tumor xenografts [190]. This formed the basis to study BMJ-induced changes in PanC 
cell metabolome.  We utilized 1H, 13C and 31P NMR-spectroscopy associated metabolic profiling 
coupled with multivariate statistical analysis for an in-depth analysis of PanC cell metabolome 
status where BMJ exposure for 72 hours efficiently targeted the metabolic pathways, particularly 
glycolysis and lactate pathways. BMJ treatment induced a significant decrease in glucose uptake, 
lactate export and ATP/ADP ratios signifying restricted uptake of glucose in the energy deprived 
PanC cells. These results suggest a ‘metabolic switch’ from increased lactate export in PANC1 
cells with 4 hours of BMJ treatment (data not shown) representing cell growth inhibition to 
increased lactate build-up inside the PanC cells by 72 hours of BMJ treatment; a plausible cause 
of intracellular acidification leading to cell death initiation mediated by decreased transporter 
expression of GLUT1 and MCT4, both in vitro and in vivo [283]. 
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Oncogenic KRAS promotes glucose uptake by increased GLUT1 expression resulting in 
higher glycolytic activity, ATP generation and lactate synthesis leading to poor tumor prognosis 
and cancer progression, particularly reported in cancer cells harboring mutated/oncogenic KRAS, 
alluding to a possible reason for mutated KRAS-dependent improved response in PANC1 cells 
with BMJ treatment [284]. Additionally, PDAC cells demonstrate modified metabolism with 
increased aerobic glycolysis [284]. Furthermore, mutant KRAS also leads to enhanced expression 
of hexokinases 1 and 2, phosphofructokinase-1, and most importantly LDH, the genes encoding 
rate limiting enzymes of glycolytic pathway which results in elevated glycolytic flux [280]. LDH 
is responsible for catalyzing the conversion of pyruvate to lactate, was shown to decrease in 
PANC1 xenografts with BMJ feeding, thereby contributing in regulating the aberrant PanC cell 
metabolism in vivo. Our assumption is further supported by an increased pAMPK activity in 
PANC1 xenografts following BMJ treatment, as reported previously [190]. Furthermore, BMJ 
associated increase in ADCs (generated) from DW-MRI and decreased SUVs (generated from 
[18F] FDG uptake) reflected lower tissue cellularity and prolonged survival in comparison to 
control tumors where the aberrant ADC and SUV values corresponded with increased 
tumorigenesis and poor survival [285, 286]. Collectively, our findings employing the NMR-
metabolomics approach provide an in-depth account of underlying mechanism of BMJ efficacy 
in modulating PanC cell metabolism and identify altered lactate export as a key target of BMJ 








PROMISING INTERVENTION APPROACH EMPLOYING BITTER MELON JUICE 
IN COMBINATION WITH GEMCITABINE FOR ENHANCED ANTICANCER 
EFFICACY IN THE PATIENT DERIVED XENOGRAFT MODEL OF PANCREATIC 
CANCER 
Introduction 
Pancreatic cancer (PanC) accounts for the worst prognosis of all major malignancies with 
an even dismal survival rate; PanC has the lowest 5-year survival rate (<3%) of all major cancer 
types and projected to be the second leading cause of cancer-associated mortalities by the year 
2030, within the United States [1, 287]. PDACs (pancreatic ductal adenocarcinomas) are the 
most frequently encountered forms of PanC (~95%), with a symptomless progression to 
metastatic and invasive form of the disease [288]. Surgical resection is the main curative option; 
however, only 15-20% of PanC patients qualify for this procedure owing to the highly aggressive 
nature, complex spatial location of the pancreas and advancement of the disease at clinical 
diagnosis [289]. Unfortunately, surgery alone fails to suffice in a wide majority of patients where 
the disease relapse, in 70-80% of the resected tumors, is fatal without additional therapy [290]. 
PanC-associated frequently occurring genetic mutations are primarily KRAS, CDKN2A/p16, 
TP53 and SMAD4; none serving as a druggable target to date [291]. A highly complex genetic 
and metabolic profile with an increasing mutational list and pathway crosstalk render the disease 
a daunting challenge to treat [292]. Currently, of all the available treatment modalities for PanC, 
GEM is the standard of care frontline drug, with a moderate success rate in improving the 
median overall PanC patient survival by about 5.7-6.8 months[254, 293]. Though a modest 
improvement has been achieved using a combination therapy approach with FOLFIRINOX and 
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GEM+Nab-paclitaxel, the patient survival still remains less than 12 months with a poor quality 
of life due to the extensive side-effects [254, 293]. Moreover, chemoresistance to GEM is a 
major contributing factor for PanC patient’ lethality resulting from dysfunctional uptake and 
metabolism of GEM in cancer cells. This generates a caveat in chemotherapy demanding agents 
that could reverse GEM resistance and confer chemosensitivity in PanC.  
Lately, compounds derived from natural/dietary agents are gaining enormous attention 
due to their potency against numerous disease types, including anticancer efficacy [294-296]. 
Numerous epidemiological studies highlight the correlation between increased uptake of plant-
derived agents/nutraceuticals with lower cancer incidences in populations worldwide, including 
reduced PanC risk [231, 297]. Bitter melon (Momordica charantia), a dietary agent, has been 
used for its presumed anti-diabetic potential and other health benefits in Asia, Africa and parts of 
the Caribbean for several decades [188]. The pre-clinical efficacy studies with bitter melon show 
that it targets obesity/type II diabetes associated metabolic aberrations with improved glucose 
tolerance and lower blood glucose levels [187, 188, 298]. Bitter melon juice (BMJ) derived from 
the fruits of bitter melon has also been shown to possess anti-cancer efficacy in PanC, as 
demonstrated by us recently, which was mediated via phosphorylation and activation of 
metabolic fuel sensor, AMPK, in cells and animal models [190]. We have also reported BMJ 
efficacy in targeting molecular mechanisms associated with GEM resistance in PanC cells [192, 
261]. More recently, we have also shown BMJ potential to enhance GEM sensitivity in resistant 
PanC spheroids, in addition to targeting the PanC associated cancer stem cells and bulk tumor 
cell populations [192, 261]. Together, these studies provide compelling evidences regarding BMJ 
efficacy against PanC cells including those resistant to GEM, suggesting that it could be an 
effective natural intervention agent for PanC management, with minimal to no side effects. 
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Accordingly, utilizing PanC patient derived xenograft (PDX) mouse model, here we examined 
efficacy of BMJ and GEM alone and in combination, as well as underlying mechanisms.  
Materials and methods 
Cell lines and reagents 
Human pancreatic adenocarcinoma cells PANC1, AsPC1 and BxPC3 were purchased 
from ATCC (Manassas, VA, USA) and used at passage #10-15. PANC1 cells were grown under 
standard culture conditions (37°C, 95% humidified air and 5% CO2) with 10% FBS and 1% 
Penicillin-Streptomycin in Dulbecco’s Modified Eagle’s Medium (DMEM) with high glucose, 
from ATCC. BxPC3 cells were grown in RPMI 1640 (1X) with 10% FBS and 1% Penicillin-
Streptomycin while AsPC1 cells had additional essential amino acids. GEM (manufactured by 
Zydus Hospira) was provided by Dr. Wells Messersmith. Primary antibodies for IHC analysis 
were purchased from: Ki67 (#16667), CD31 (#28364), RRM1 (#81085) and hENT1 (#135756) 
from abcam (Cambridge, MA), VEGF (#152) and dCK (#393099) from Santa Cruz 
Biotechnology (Dallas, TX), and C-caspase3 from Cell Signaling Technology (#9661- Danvers, 
MA).  BMJ preparation, characterization and standardization were as reported by us recently 
[190]. For cell culture studies, BMJ was dissolved in DMSO (final concentration in media not 
exceeding 0.1%) and water, followed by mixing and centrifuging the solution at 3000 rpm for 3 
mins to remove any debris, as previously published [261].  
Cell viability assay  
PanC cell lines PANC1, AsPC1 and BxPC3 were seeded in 6-well plates (Corning, Inc.) 
for 24 hours and treated with either BMJ (0.5-2%, v/v), GEM (2-25 µM) or a combination of 
BMJ+GEM (Combo) where the cells were pre-exposed to BMJ for 1 hour before exogenous 
GEM addition. For the control group, media with DMSO alone was added to the wells. Cell 
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viability was determined post 72 hours of drug incubation by trypan blue exclusion assay. All 
experiments were done in triplicates. For determining the nature of drug interactions of varying 
dose ranges in Combo group, CompuSyn software program based on Chou-Talalay method, was 
utilized to calculate the combination indices of BMJ (0.5-2%, v/v) and GEM (2-25 µM) in 
PANC1, AsPC1 and BxPC3 cells [299]. 
Patient derived xenograft study 
All animal studies were conducted in accordance with IACUC-approved animal protocol 
(University of Colorado Denver). Athymic female nude mice (Harlan Labs, Indianapolis, IN) 
aged ~8-10 weeks housed at the animal facility (University of Colorado Denver) were switched 
to AIN76A pellet diet (Envigo) for a week prior to study initiation for acclimatization. Utilizing 
a trocar, the animals were subcutaneously injected with ~3mm3 of PanC patient tumor tissue 
designated PDX272, PDX266 and PDX271, covered in Matrigel as previously described [300, 
301]. Animals were implanted with tumor tissue in both flanks, enough to generate ~10 tumors 
per treatment cohort for each PDX explant. Once the tumors achieved a size of ~200mm3, the 
animals were randomized into four treatment cohorts per PDX explant: Controls, BMJ 
(200mg/Kg in water, 5 days a week via oral gavage), GEM (50mg/Kg in saline, biweekly, i.p.) 
and Combo (combination of BMJ and GEM). The animals were maintained on an active drug 
treatment regimen for 32 (PDX272) and 35 (PDX266 and PDX271) days. Post completion of 
active dosing, part of the animals per group were sacrificed and tumors harvested. The remaining 
animals were allowed to continue for another 30-33 days until end of study (day 64) without any 
drug treatments to examine the changes in tumor volumes/tumor regrowth post treatment 
termination. Since tumor take rate for PDX271 was low, we only recorded tumor volume at end 
of active dosing period (35 days) but did not sacrifice any mouse to collect explants; all animals 
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were continued without any treatments in washout study (day 35 to 64). At study end following 
completion of treatment washout period, all of the remaining animals were euthanized, and the 
harvested tumors were formalin fixed or snap frozen for further analysis. H&E, PSR was 
performed at the Histology Shared Resource, Dept. of Pathology (University of Colorado 
Denver) and analyzed/quantified by a histopathologist and images were captured using Olympus 
BX51, 17mp high-definition camera employing Olympus CellSens software (Olympus, 
Waltham, MA). Polarized light images of PSR staining were quantified using SlideBook V.6.0 
(Intelligent Imaging Innovations, Denver, CO). 
Immunohistochemistry 
Paraffin-embedded tumor sections (5 μm-thick) were deparaffinized in xylene and graded 
series of anhydrous alcohol, then subjected to antigen retrieval using 10 mM citrate buffer (pH 
6.0) in a microwave or a pressure cooker for 15 mins. Endogenous peroxidase activity was 
blocked using 3% H2O2 in methanol (v/v) for 10 mins followed by incubation with CAS block 
for 1 hour at RT. Tissue section bearing slides were incubated overnight at 4 ºC with their 
respective primary antibodies in a humidified chamber. Following day, the sections were 
incubated with biotin-conjugated secondary antibodies for 1 hour at RT and incubated with 
conjugated horseradish peroxidase-streptavidin for another hour. This followed incubation with 
DAB, washes, counterstaining with Harris hematoxylin and rinses in Scott’s water. Percentage of 
positive cells was calculated by counting the number of positive stained cells (brown stained) 
and the total number of cells from 8 arbitrarily selected fields per tumor section. For cytoplasmic 
staining/ scoring, arbitrary immunoreactivity scores were allotted based on intensity of brown 
staining allotted as 0 (no staining), 1 (weak staining), 2 (moderate staining), 3 (strong staining), 4 




Statistical analyses were performed using Sigma Stat software (version 3.5, Jandel 
Scientific). Quantitative data are presented as mean±SEM. Statistical significance of difference 
between control and treatment groups was determined through one-way analysis of variance 
(ANOVA) followed by Tukey’s test for multiple comparisons. Graphpad prism was exclusively 
used for analyzing tumor volumes only. p ≤ 0.05 was considered significant. P value of p ≤ 0.05 
is denoted by *, p ≤ 0.01 is denoted by ** and p ≤ 0.001 is denoted by ***. 
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Results 
BMJ in combination with GEM induces enhanced efficacy in PanC cells  
In vitro drug efficacy was determined using trypan blue exclusion assay to study the 
combinatorial effects of BMJ+GEM on cell viability of human PanC cells BxPC3, AsPC1 and 
PANC1. BxPC3 cells displayed the best and most significant decrease in total cell number for 
Combo groups (1% & 2% BMJ with 2µM GEM) compared to GEM and BMJ alone, together 
with a significant increase in % dead cells; ≥50% cell death was observed in 2% BMJ with 25 
µM GEM, as opposed to only ~25% with 25 µM GEM alone (Fig. 4.1A). AsPC1 cells showed 
similar increased efficacy with Combo compared to GEM alone where a pronounced effect of 
~30% cell death was observed with a combination of 2% BMJ and 25 µM GEM; combination 
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doses showed no additional effect on the total cell number (Fig. 4.1B). BMJ and GEM 
combinations failed to elicit any improved response over BMJ and GEM alone treatments in 
PANC1 cells, where no difference was observed in the total cell number and % dead cells with 
different combinations of drug doses (Fig. 4.1C).    
Use of CompuSyn software employing Chou Talalay method to determine the nature of 
drug combinations in PanC cells revealed a highly synergistic effect in BxPC3 cells with BMJ 
and GEM combinations; combination indices (CIs) in the range of ~0.02-1.00. The effect in 
AsPC1 cells was comparable to that seen in BxPC3 cells, with CI range of ~0.6-1.0. However, 
PANC1 cells revealed an antagonistic effect resulting from BMJ and GEM combinations where 
the CIs were ranging between ~2.6-22.1 (way over the threshold for synergism), thereby 
supporting the results obtained from the cell viability assay (Fig. 4.1D). 
Histological characterization of PanC- PDX272, PDX266 and PDX271 explants  
The H&E (hematoxylin and eosin) stained tumor tissue images differentiate between 
different PDX explant types. Histological classification of tumors with higher magnification 
insets (40x), particularly highlights the progression/clinical stage of PanC, as seen by the ductal 
morphology (Fig. 4.2A). H&E analysis represented PDX272 as classical PDAC while PDX266 
and PDX271 had a mucinous appearance, where PDX271 had the most mucinous morphology. 
A summary is provided corresponding to the criteria for PDX classification, including 
differences based on PanC grade/stage, extent of metastasis, inflammation, epithelial hyperplasia 







Figure 4.1: In vitro efficacy of BMJ and GEM in PanC cells. Changes in total cell number and 
percent dead cells of (A) BxPC3, (B) AsPC1 and (C) PANC1 cells with varying drug doses of 
BMJ, GEM and a combination of BMJ+GEM for 72 hours. (D) Represents the combination 
indices for BMJ+GEM for BxPC3, AsPC1 and PANC1 cells using CompuSyn software. Fa 





Figure 4.2: Characterization and comparison of PanC-PDX272, PDX266 and PDX271 
explants. (A) Representative images from H&E staining of PDX272, PDX266 and PDX271 
depicting the differences in histological grades at 20x objective (magnified insets were captured 











Combination dosing of BMJ with GEM induces increased anticancer efficacy in PanC-
PDX model 
The drug efficacy trends of individual drug treatments compared to combination 
regimens were highly comparable in all three PanC-PDX explants for the active treatment phase 
and treatment washout periods (Fig. 4.3A-4.3C). With active drug treatments, all PDX explants 
displayed a significant inhibition in tumor growth (measured as tumor volume) with BMJ alone 
compared to controls (50% inhibition in PDX272 and PDX271, 60% inhibition in PDX266), 
while GEM and Combo groups had a better efficacy over BMJ (76%, 80% inhibition in 
PDX272; 83%, 85% inhibition in PDX266; and 68% inhibition for both in PDX271, with GEM 
and Combo treatments, respectively). Treatment washout period (extending from treatment 
termination up to day 64) caused a change in the tumor volume (recorded at day 32 for PDX272 
and at day 35 for PDX266 and PDX271), where a sharp tumor regrowth was observed in GEM 
alone group, which was close to that observed in controls (Fig. 4.3A-4.3C). Combo and BMJ 
group displayed extended efficacy with sustained inhibition in tumor growth, post treatment 
termination (Fig. 4.3A-4.3C).  
When tumor volumes where compared as a fold change between the end of active drug 
dosing (day 32 for PDX272 and day 35 for PDX266 and PDX271) versus the end of study 
following completion of tumor regrowth (if any) during washout phase day 64) (Fig. 4.3D),  
PanC-PDXs 272, PDX266 and PDX271 from GEM alone group showed the maximum fold 
change (8-fold increase in PDX272 and 2-fold increase in PDX266 and PDX271). Notably, fold 
increases in PanC-PDX explants were more profound compared to even those in control groups 
(Fig. 4.3D). However, negligible fold changes were observed in PanC-PDX explants in BMJ 




Figure 4.3: Drug efficacy in PanC-PDX xenografts determined by altered tumor volumes 
with BMJ or GEM alone, and combination therapy (BMJ+GEM).  Tumor volumes (mm3) 
were measured biweekly and plotted as a function of time with active treatment administration 
(until day 32 for PDX272 and day 35 for PDX266 and PDX271, left panel) and tumor regrowth 
was measured post treatment termination until study end (day 64, right panels) in (A) PDX272, 
(B) PDX266 and (C) PDX271 in Control (black), BMJ (green), GEM (blue) and Combo 
(yellow) groups. (D) Represents fold change in tumor volumes for each treatment cohort from 
day 32/day 35 (solid fill bars) and day 64 (pattern fill bars), for PDX272, PDX266 and PDX271.  
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BMJ- and GEM-induced histological changes in PanC- PDX272, PDX266 and PDX271 
explants 
PDX272 (Fig. 4.4A): Initiated as PanIN-1B, basally located nuclei with minimal changes 
and abundant supranuclear mucin. There was a little evidence of metastasis either at day 32 or 
64. BMJ treatment for 32 days induced cell death and sloughing into gland lumens with 
inflammatory cells present outside the cancer mass. By day 64, lots of inflammatory cells 
(lymphocytes, PMNs & macrophages) were present throughout with cell death but less mucin 
secretion and thicker glandular epithelium. GEM treatment for 32 days induced cell death & 
sloughing into gland lumens with inflammation, but no increase in glandular epithelium. By day 
64, mucin production was reduced with presence of glandular epithelial thickening (few glands 
were filled with necrotic debris) and inflammatory cells present throughout. Combo treatment for 
32 days displayed way less mucin and lower epithelium with increased collagen & connective 
tissue deposition around the glands.  By day 64, mucin secretion decreased but the epithelium 
was piled up with increased cell death and sloughing into gland lumens. Also, an increased 
number of inflammatory cells, pigmented macrophages and non-degranulated mast cells were 
observed with collagen deposition in connective tissue around glands (Fig. 4.4A). 
PDX266 (Fig. 4.4B): It initiated as PanIN-3, small acini with a low cuboidal cancer cell, 
pleomorphic, increased metastatic cells in the connective tissue with lots of cells pinching off 
into the gland lumens. BMJ treatment for 35 days induced large patches of necrosis, which were 
intensified by day 64. GEM dosing for 35 days caused an increase in the number of smaller 
glands with lots of fibrotic connective tissue deposition and lymphocytes around the cancer mass 
(some calcification of materials in the gland lumens was observed). By day 64, further increase 
was seen in smaller glands (no calcification) with increased collagen connective tissue between 
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glands. Very evident metastatic cell groups migrating out through the outer rim of connective 
tissue around the cancer mass were present. Combo treatment for 35 days increased the number 
of small glands and connective tissue. There was also increased cell death with reduced 
lymphocytes around the cancer mass.  By day 64, way fewer glands were present, replaced by 
small masses of single/few cells but a marked increase in collagen deposits was seen with more 
PMNs and non-degranulated mast cells in connective tissue surrounding the cancer mass (Fig. 
4.4B).  
PDX271 (Fig. 4.4C): Initiated as PanIN-2, lots of larger glands with pseudostratified as 
well as columnar epithelium, lots of mucin (presumably even some goblet cells). Increased 
metastasis with cells budding off into the gland lumen. BMJ treatment exhibited glands of highly 
mucinous looking simple columnar epithelium and low nuclei flattened against the basement 
membrane. GEM displayed characteristics similar to BMJ group. Combo had two main cell 
populations: one with abundant mucin as for BMJ/GEM alone and other population containing 
much less mucin and dense glands with increased number of inflammatory cells including 
pigmented macrophages and traces of local metastasis (Fig. 4.4C). 
GEM and Combo treatments increase fibrosis in PanC- PDX272, PDX266 and PDX271 
explants  
Picrosirius red (PSR) staining for determining the extent of fibrosis/collagen deposition 
in PanC-PDXs was performed (Fig. 4.5A). The fibrosis content was similar for PanC-PDX272 at 
day 32 (end of active drug treatment) and day 64 (end of study post treatment washout period), 
where increased fibrosis was observed in GEM and Combo groups at both timepoints, compared 
to control and BMJ groups (Fig. 4.5A). In PDX266, increased fibrosis deposition was seen 





Figure 4.4: Representative H&E images at 20x objective from (A) PDX272, (B) PDX266 and 
(C) PDX271 explants at day 32/day 35 (active treatments) and day 64 (tumor regrowth, end of 
study) depicting histological changes in each PDX with different treatment cohorts; Control, 







in Combo at day 35 of treatment. By day 64, there was a further increase in fibrosis with GEM 
and Combo, while BMJ had the lowest content (Fig. 4.5A). PDX271 exhibited a trend similar to 
that observed for PDX266 where GEM and Combo had the most fibrosis by the end of study, 
while BMJ had the least (Fig. 4.5A). Overall, PDX266 had the highest fibrotic deposition in 
GEM and Combo groups, as determined by the percent positive pixels. 
Based on the results from histological characterization of the PDX explants, we further 
investigated the mucinous PDX266 and PDX271 by MUC1 staining (Fig. 4.5B), a marker for 
PanC aggressiveness and GEM resistance [302, 303]. IHC analysis of PDX266 exhibited a 
significant increase in MUC1 expression following active treatment with GEM for 35 days. By 
the end of study at day 64 (a 30-day washout period), GEM MUC1 levels were still higher than 
BMJ and Combo groups; BMJ and Combo displayed MUC1 levels lower than those of control 
group following treatment washout period. Similarly, for PDX271, MUC1 levels were elevated 
in GEM group while BMJ and Combo MUC1 expression was lower than the control (Fig. 4.5B).  
Combination of BMJ and GEM targets the efficacy markers and GEM metabolism 
pathway molecules to display elevated antitumor potential in PanC- PDX272, PDX266 and 
PDX271 
Various drug efficacy markers were analyzed by IHC staining to determine the effect of 
BMJ and GEM alone and in combination in PanC-PDX272, PDX266 and PDX271 with active 
drug treatments and extended efficacies post treatment termination; qualitative IHC staining for 
these markers is shown in supplementary Fig. 4.1. Quantitative IHC analysis (Fig. 4.6A) of cell 
proliferation marker Ki67 revealed a significant decrease in proliferative cells with BMJ, GEM 
and Combo treatments where Combo treatment was the most significant with active drug dosing 




Figure 4.5: Combination of BMJ+GEM increases fibrosis and decreases MUC1 expression 
in PanC-PDX explants. (A) Polarized light images from PSR staining of PDX272, PDX266 and 
PDX271 from different treatment cohorts; Control(C), BMJ (B), GEM (G) and Combo (B+G), at 
day 32/day 35 and day 64. Fibrosis quantification represented as percent positive pixels using 
SlideBook V.6.0 (right panel). (B) Representative IHC images of MUC1 expression in the 
mucinous PDX266 and PDX271, with quantification of the immunoreactivity score. ***p≤0.001, 
**p≤0.01 and *p≤0.05. 
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BMJ, GEM and Combo, respectively). However; this trend shifted post treatment termination by 
day 64 where GEM explants displayed a significant increase in Ki67 (+) cells, even when 
compared to controls (except PDX272), while BMJ and Combo groups remained effective in 
inhibiting proliferation (Fig. 4.6A).  
Next, apoptosis induction was analyzed by C-caspase 3 staining where PDX272 explants 
showed a significant increase in apoptosis with GEM and Combo groups, while no changes were 
seen in PDX266 with active dosing regimen (Fig. 4.6A). By the end of study at day 64, Combo 
continued to display increased apoptosis in PDX272, while BMJ and Combo both induced 
apoptosis in PDX266; similar trend was observed in PDX271 but not statistically significant 
(Fig. 4.6A).  
Vascular endothelial growth factor (VEGF) and CD31 were also employed to determine 
treatment induced changes in angiogenesis and microvessel density (Fig. 4.6A). PDX272 and 
PDX266 exhibited significantly decreased VEGF immunoreactivity scores CD31/microvessel 
density (non-significant for PDX266) with all treatments but GEM and Combo had better effects 
in samples from active dosing. Interestingly, by day 64, GEM’s effect was lost, and it was now 
comparable to control VEGF and CD31 expression, while both BMJ and Combo exhibited 
sustained decrease in VEGF and CD31 levels for all PanC-PDX explants (Fig. 4.6A). 
Based on the results from the efficacy markers suggesting lost drug sensitivity for failed 
GEM efficacy post treatment termination in PanC-PDX272, PDX266 and PDX271, we also 
investigated GEM resistance pathway molecules in these explants by IHC analysis (Fig. 4.6B, 
IHC images are presented in supplementary Fig. 4.1). RRM1 is mainly known as a marker of 
poor survival in PanC patients undergoing GEM-based chemotherapy [304]. All drug exposures 
led to a decreased RRM1 expression with active treatments in PanC-PDX272 and PDX266, 
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although the decrease was not strong in PDX272 GEM group. At the end of treatment washout 
period (day 64), PDX272 and PDX271 displayed increased RRM1 levels in GEM group but a 
sustained decrease in BMJ and Combo groups, while PDX266 had a contrasting effect with 
GEM showing the most decrease in RRM1 expression; BMJ and Combo RRM1 expression 
levels were significantly higher than untreated controls on day 64 but still less than day 35 (Fig. 
4.6B).  
Investigation into hENT1 (human equilibrative nucleoside transporter 1) expression, 
responsible for bidirectional GEM trafficking [305], revealed increased transporter levels in 
GEM and Combo groups at the end of active treatments for both PDX272 and PDX261. 
However, at study end (day 64), Combo was the only group that continued to express high levels 
of hENT1 for all three explants, while GEM showed poor hENT1 expression based on a marked 
decrease in its expression compared to active dosing (PDX272, PDX266 and PDX271). Lastly, 
IHC analysis for deoxycytidine kinase (dCK), enzyme responsible for GEM metabolism, 
revealed increased levels of dCK with active GEM treatment, but Combo had the most 
augmented dCK expression levels by study end. GEM metabolism pathway molecules analysis 
depicted their partial involvement in GEM resistance of PanC-PDX272, PDX266 and PDX271 
following treatment termination period, where the GEM metabolism pathway molecules in GEM 
exposed tumors were significantly altered by study end, conferring a loss of drug sensitivity in 
tumor cells towards GEM whereas BMJ and mainly Combo groups displayed sustained 
efficacies, possibly by overcoming the GEM resistance and conferring extended drug sensitivity 






Figure 4.6: Combination treatment of BMJ+GEM targets key molecules involved in PanC 
progression to impart improved efficacy. (A) IHC quantification of drug efficacy markers 
involved in proliferation (Ki67), apoptosis (C-caspase3) and angiogenesis (VEGF, CD31) and 
(B) GEM metabolism pathway molecules; RRM1, hENT1 and dCK, with Control (C-black), 
BMJ (B-green), GEM (G-blue) and Combo (B+G-yellow) treatments  in PDX272 (day 32 and 





PDXs are routinely generated by engrafting tumor tissue derived straight from the patient 
into an immunodeficient mouse and passaged in vivo for efficacy studies of various 
chemotherapeutics [306]. Lack of efficient predictive preclinical models is often responsible for 
the drugs previously exhibiting remarkable anticancer potential to eventually fail in clinical 
settings [307]. Although the availability of immunodeficient mouse models is helpful regarding 
the ease of xenograft establishment using cancer cell lines, it harbors little resemblance with the 
true nature of patient tumor complexity and heterogeneity resulting in differential treatment 
responses between preclinical and clinical evaluations [307]. Therefore, high reliability owing to 
the preservation of overall patient genomic profile, including tumor histology and stromal 
component as well as enhanced correlation with patient response pattern to standard 
chemotherapeutic agents compared to cell line derived xenografts, make PDX an ideal model for 
preclinical drug efficacy testing [308, 309].  
PanC severity continues to rise with no significant improvements in treatment schemes 
and a poor therapy response. Ever since the initial reports in late 1990s, GEM has been the most 
widely utilized first-line chemotherapeutic for PanC patients regardless of nominal increase in 
patient survival [293]. While patient survival and increased toxicity due to repeated high dosages 
with GEM treatments still remain a challenge, the rising cases of inherited or acquired GEM 
resistance worsen the current state of PanC therapeutics and pose serious concerns [81, 310]. 
Based on the synergistic effects of GEM in treatment combinations with other 
chemotherapeutics, recent strategies expanded the PDAC treatment horizon by using 
combinatorial treatments like FOLFIRNOX or GEM+Nab-paclitaxel, however, availing no 
significant benefits but increased rates of toxicities, thereby limiting the use of these approaches 
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[311, 312]. Instead, combination approaches are readily including natural agents with 
mainstream chemotherapeutics to target PanC by exploiting their promising anticancer potential 
with manageable toxicities [313, 314]. 
Previous works from our group have alluded to the anticancer potential of BMJ in PanC 
mediated via AMPK activation, targeting CSC and bulk tumor cells and contextually more 
relevant, by imparting sensitivity to GEM resistant PanC cells and spheroids [190, 192, 261]. We 
therefore focused on an approach using BMJ in combination with GEM in PanC-PDX mouse 
model to further understand and establish the underlying mechanisms responsible of elevated 
anticancer efficacy and validate BMJ induced PanC cell sensitivity to GEM in vivo. Following 
the nature of drug combination (BMJ+GEM) in vitro, in vivo investigation of BMJ+GEM in 
PanC-PDX explants resulted in highest efficacies with active dosing for GEM and Combo 
groups, which was reversed following treatment washout; GEM tumors exhibited tumor 
regrowth hinting at loss of GEM sensitivity post dosing termination while Combo and BMJ (to a 
greater extent), demonstrated sustained efficacy by inhibiting tumor regrowth. Overall, the trends 
were consistent, and Combo emerged as the ultimate winner by study end, displaying the most 
significant anticancer potential. While stromal remodeling and collagen degradation have been 
associated with improved drug delivery, certain studies also report these elements to act by 
restraining PDAC [315, 316]. Hence, this remains of great interest and subject to deeper 
investigation because contrary to the popular belief associating higher fibrotic content with 
PDAC aggressiveness, GEM and Combo treatments indeed resulted in increased fibrosis, albeit 
accompanying the most significant anticancer efficacy in Combo group. IHC analysis of PDX 
explants revealed inhibition of tumor cell proliferation and angiogenesis alongside apoptosis 
induction, and sustained efficacy post treatment termination in BMJ and Combo groups. The 
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subtle differences between treatment response of PDX explants warrant further histological 
analysis and interpretation of our findings but can be partly attributed to the differential tumor 
histological grade and classification of each PDX explant; PDX272 (classical PDAC), PDX266 
and PDX271 (highly mucinous). The switch in GEM efficacy from being highly effective with 
active dosing to lost drug sensitivity post treatment washout pointed at the involvement of 
aberrant GEM metabolism, verified in PDX tumors by reduced hENT1, dCK and increased 
RRM1 levels directly correlating with GEM resistance and dismal patient survival [304, 317, 
318]. Excess lactate synthesis and export to the extracellular space increases acidic environment 
favoring PanC aggressiveness by providing a thriving niche for drug resistant cancer stem cells 
[319]. Highly acidic extracellular environment, in turn, could negatively impact cellular GEM 
uptake since GEM is a weak base with a pKa of 3.58 [320]. Interestingly, we have observed BMJ 
efficacy by modulation of PanC cell metabolome where BMJ treatment caused intracellular 
lactate accumulation and decreased lactate dehydrogenase (LDH) levels in xenograft tumors, 
thus explaining the enhanced efficacy of Combo to be contributed mainly by BMJ in improved 
GEM uptake and metabolism in PanC cells where GEM alone failed to elucidate treatment 
response after treatment termination (unpublished data; Dhar, et al.). Additional studies for GEM 
uptake in combination with BMJ are needed to confirm our findings. Taken together, 
aforementioned results highlight the efficacy of BMJ in combination with GEM in a high fidelity 
preclinical PDX mouse model of PanC, by modifying and regulating the key players of GEM 
uptake and metabolism thereby providing a promising approach for future clinical investigations 







Supplementary Figure 4.1: IHC images of drug efficacy markers  
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Supplementary Figure 4.1: IHC images of GEM metabolism pathway molecules 
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Supplementary Figure 4.1: IHC images of drug efficacy markers; Ki67, C-caspase3, VEGF 
and CD31, and GEM metabolism pathway molecules; RRM1, hENT1 and dCK, in Control, 
BMJ, GEM and Combo treatments for PDX272 (day 32 and day 64), PDX266 (day 35 and day 














EVALUATING BITTER MELON JUICE EFFICACY IN PROGRESSION BASED 
TRANSGENIC MOUSE MODEL OF PANCREATIC CANCER 
Introduction 
Pancreatic cancer (PanC) remains the most aggressive of major solid tumor types within 
the United States in the modern era, yielding the worst diagnosis and prognosis rates. Surgical 
resection is the foremost curative option with dismal rates; over 80% of patient population 
present unresectable tumors at diagnosis, thereby limiting the expected overall survival to ≤6 
months [321]. Pancreatic ductal adenocarcinoma (PDAC) is the most frequently encountered 
class of PanC, originating as adenocarcinoma in ductal cells of exocrine pancreas, accounting for 
the majority (>90%) of PanC malignancies [322]. Increased metastasis and local invasion add to 
the disease severity, dragging down the 5-year survival rate to a mere 3% [1]. It is estimated to 
be the primary type of gastrointestinal cancers, and second leading cause of cancer related 
fatalities by 2030, trailing only lung cancer [287]. Principal concern inhibiting PanC early 
intervention and diagnosis is the asymptomatic progression of the disease to its advanced 
stages/higher grades rendering most therapies futile [321]. Past two decades bear witness to 
limited advances in development of better directed strategies for PanC management [323]. 
Ultimately, highly aggressive disease state coupled with inadequate tools for timely diagnosis 
and limited treatment opportunities, requires improved therapeutic approaches to address this 
challenge efficiently.  
PDACs possess a repertoire of genetic mutations responsible for establishment of a 
disease progression model where serial accumulation of multiple inherited or acquired mutations 
over time lead to the development of highly invasive adenocarcinomas [324]. Mutated KRAS, the 
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proto-oncogenic driver, is the most frequent and prevalently mutated gene present in ≥90% 
PDACs; an early occurrence in PDAC progression to invasive forms [325]. Successive 
inactivation mutations in CDKN2A, TP53 and SMAD4 also contribute to the generation of 
precursor lesions prior to succumbing to the invasive disease form [326-328]. PanC progression 
initiates with the generation of precursor lesions, commonly referred to as pancreatic 
intraepithelial neoplasia (PanIN), ranging from low-grade (PanIN-1A/B), intermediate grade 
(PanIN-2) or high-grade (PanIN-3) lesions [329-331]. Due to the severity of PanC, timely 
diagnosis and intervention can prove to be of immense therapeutic value for prolonged and 
disease-free patient survival. Therefore, utilizing various transgenic mouse models of PanC can 
provide an exceptional platform for drug efficacy studies targeting stage-specific disease 
intervention. Development and inclusion of highly reliable genetically engineered mouse models 
(GEMMs) in cancer research has helped improve our understanding of PanC pathogenesis [332]. 
LSLKRASG12D/+;p48Cre/+ transgenic mouse model used in this study has been extensively 
characterized and shown to recapitulate human PanC progression scheme involving different 
early to late PanIN stages before advancing to PDAC [333]. Additionally, this transgenic mouse 
model was originally generated with KRASG12D/+ mediated PanIN initiation specific to pancreas, 
as observed in the human disease state with spontaneous somatic cell KRAS mutation facilitating 
disease initiation [334]. Ptf1α/p48 driven targeted oncogenic KRASG12D/+ expression in pancreatic 
epithelial cells leads to widespread premalignant PanIN development in GEMMs [335]. GEMMs 
offer a great alternative to cancer cell and xenograft models and are widely incorporated in tumor 
biology and drug response analysis at various timepoints in cancer progression. Collectively, 
transgenic animals represent the current standard of preclinical setting for therapeutic and 
intervention strategy with PanC tumorigenesis similar to that observed in patients.  
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Marginal advances in PanC management employ synthetic agents/chemotherapeutics 
accompanying dismal patient overall survival owing to the extreme associated side effects and 
patient distress. This necessitates the incorporation of natural agents harboring potential 
anticancer efficacies and minimal toxicities to be evaluated in preclinical disease models for 
increased translational relevance. Recent years witnessed numerous studies investigating the 
potential of nutraceuticals in cancer therapy and their associated mechanisms [231]. Current 
study employed a natural agent bitter melon juice (BMJ), derived from the fruits of bitter melon 
(Momordica charantia). Results from numerous preclinical and clinical studies report BMJ 
consumption associated health benefits including  antidiabetic, anthelmintic, abortifacient-
effects, etc. [181]. Importantly, BMJ exhibits strong anticancer potential against different cancer 
types; skin, breast, stomach, prostate, colon, and several others [188]. The relevance to current 
disease form is further highlighted from our previously published studies showing strong 
anticancer efficacy of BMJ in PanC via multiple targets and pathways. We have reported AMPK 
activation led nutrient stress in PanC cells and animal models, improved sensitivity to 
gemcitabine resistant PanC cells, and PanC associated cancer stem cell and bulk tumor cell 
regulation with BMJ exposures [190, 192, 261]. Moreover, BMJ displays heightened efficacy 
and modulates the PanC cell metabolome, primarily by restricting lactate transport from the cell 
to extracellular space besides exhibiting anticancer potential in patient derived xenografts of 
PanC involving overcoming gemcitabine resistance in the tumors, when used in combination 
therapy (Unpublished data, Dhar et al.). Together, these finding further supported current study 





Materials and methods 
BMJ preparation 
Chinese variety of bitter melon (commercially available at local Asian grocery stores) 
was used for BMJ preparation as detailed recently, together with quality control and 
standardization. For efficacy studies, BMJ powder was suspended in water, and 100 mg/Kg and 
200mg/Kg doses were used, as previously published [261]. 
In vivo study 
All animal studies were conducted in accordance with IACUC-approved animal protocol 
at University of Colorado Denver, Anschutz Medical campus. LSLKRASG12D/+ male mice and 
p48Cre/+ female mice were procured from Prof. C.V. Rao, University of Oklahoma Health 
Science Center [336]. LSLKRASG12D/+ and p48Cre/+ animals developed on a pure C57BL/6 
background, were cross-bred with non-transgenic C57BL/6 (Jackson laboratory, Bar harbor, 
ME) wild type breeder females and males, respectively, to expand the parent colonies. On 
acquiring enough parent numbers, LSLKRASG12D/+ males were bred with p48Cre/+ female animals 
to generate the desired colony of LSLKRASG12D/+;p48Cre/+  transgenic experimental mice (Fig. 
5.1A). Genotyping was performed at Transnetyx, Inc. (Cordova, TN) using ear-snips from ~3-4-
week old littermates. Both male and female LSLKRASG12D/+;p48Cre/+  transgenic mice were used 
in the study.  
During the study, animals had free access to drinking water and food (AIN76A diet from 
Envigo). General signs of toxicity were monitored daily and animal body weights were recorded 
on a biweekly basis. At the time of each sacrifice/study endpoint, the animals were euthanized by 
carbon dioxide asphyxiation followed by exsanguination. For necropsy, mice were individually 
weighed and examined for gross pathology, and pancreas along with other major organs, mainly 
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lung, liver, kidney and spleen were harvested. Harvested pancreas from each animal was divided 
in to pancreas-head (P-Head) and pancreas-tail (P-Tail) sections and processed separately. 
Collected tissues were fixed overnight in 10% (v/v) phosphate-buffered formalin, processed 
conventionally and paraffin embedded. Sections (5 µm thick) were stained with hematoxylin and 
eosin (H&E) for histopathological assessment.  
Experimental plan for various treatment regimens 
LSLKRASG12D/+ males were bred with p48Cre/+ female animals to generate the desired 
colony of LSLKRASG12D/+;p48Cre/+  transgenic experimental mice. The progression model follows 
initiation of early PanIN-1A by ~6 weeks of age, followed by PanIN-1B close to ~15 weeks. 
PanIN-2 arise post 15 weeks and PanIN-3 develop by the age of ~30-31 weeks prior to ~41 
weeks when the PDAC stage sets in [333, 337] (Fig. 5.1B). The animals (untreated) were 
followed as a function of time to determine the histological differences between the male and 
female animals at different stages of PanC progression; the chosen timepoints included animals 
at the ages of (1) week 4, (2) week 10, (3) week 15, (4) week 20, and (5) week 25. Additionally, 
BMJ dosing was tested in the following treatment cohorts comprising of additional untreated 
control animals from both male and female sexes, for each cohort. For 200mg/Kg dose of BMJ, 
treatment timepoints included were; (1) BMJ dosing from week 4-10 of age and (2) BMJ dosing 
from week 6-15 of age (Fig. 5.1C). For 100mg/Kg dose of BMJ, similar treatment timepoints 
were included. BMJ was administered 5 days a week via oral gavage. At the completion of each 
timepoint, animals were euthanized, pancreas harvested, frozen/fixed and processed for further 
molecular analysis. Sample size of 8 animals per treatment group was included for controls and 
BMJ treated animals combined (4 males and 4 females/cohort). All histological analysis was 
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performed using hematoxylin and eosin (H & E) staining and images were captured using 
AxioCam MrC5 camera. 
Masson trichrome staining 
Masson trichrome staining kit was purchased from Thermo Fisher Scientific (#87019, 
Waltham, MA). Pancreas were fixed in 10% phosphate-buffered formalin for 24 h and processed 
conventionally. The paraffin-embedded tumor sections (5 μm-thick) were deparaffinized using 
xylene (3 incubations for 5 mins each) and rehydrated in a graded series of ethanol (100%-70%). 
The slides were rinsed in water and proceeded for the trichrome staining protocol. Briefly, the 
tissue sections were incubated with Bouin’s fluid (30 sec in a microwave) followed by 
incubation with Weigert’s Iron Hematoxylin stain (10 mins at RT). Sections were rinsed in 
deionized water and placed in Biebrich Scarlet-Acid Fuchsin solution (~10 mins, until desired 
intensity). Next, the sections were rinsed and placed in Phosphotungstic-Phosphomolybdic Acid 
solution (~5 mins) followed by incubation with Aniline Blue stain (~10 mins, until desired 
intensity). Lastly, the sections were incubated with 1% Acetic Acid solution (1min), rinsed and 
dehydrated in ethanol (70-100% in a graded series), cleared in xylene and covered with 
mounting media (Permaslip mounting media, Alban Scientific Inc, St. Louis, MO) for further 
analysis. 
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Figure 5.1: BMJ efficacy in LSLKRASG12D/+;p48Cre/+ transgenic mouse model. (A) Scheme 
representing development of LSLKRASG12D/+;p48Cre/+ transgenic line from parents colonies of 
LSLKRASG12D/+ bearing males and p48Cre/+ bearing females. (B) Age based PanC progression 
through various stages of PanINs to PDAC. (C) Experimental plan for intervention stages with 
100 and 200mg/Kg BMJ dose. Each BMJ treatment group had their respective untreated control 





PanC progression in male and female LSLKRASG12D/+;p48Cre/+  transgenic animals  
We followed the progression of PanC in male and female LSLKRASG12D/+;p48Cre/+  mice 
for a comparative analysis over a course of 25 weeks. Male animals at week 4 of age witnessed 
an initiation of early stage PanINs, mostly PanIN-1As, as represented by normal pancreatic ducts 
with enlarged nuclei. Similar patterns were seen for female animals at week 4 of age. Following 
timepoint of week 10 displayed increase in the lesions and formation of papillary structures in 
the ducts of both male and female mice. At week 15, male animals had more ductal papillae with 
epithelium shifting to columnar type and initiation of nuclear atypia representing PanIN-1B/2 
stage. The females at week 15 had a higher degree of nuclear atypia, loss of polarity, enlarged 
nuclei and epithelial thickening with increase number of mitotic figures depicting advanced 
PanIN-2. By week 20, male mice had extensive nuclear crowding and atypia with papillary 
epithelial lesions. The epithelial cell clusters were budding off into the ductal lumen pointing to 
initiation of PanIN-3. Further progression with advanced PanIN-3 was observed in the female 
counterparts where cribriform progressed to the extent of ductal collapse, a loss of ductal 
integrity was evident. Besides, cribriform growth with luminal necrotic cell content was apparent 
in addition to severe atypia, nuclear pleiomorphism and increased basement membrane 
infiltration. At the final study timepoint of week 25, both male and female animals exhibited 
classic PDAC morphology with a glandular phenotype and random organization of ducts at 
various degrees of differentiation accompanying severe nuclear atypia and increased luminal 
necrotic debris. Invasion of basement membrane with migrating tumor cell/clusters were 
observed next to the blood vessels. Although the progression to advanced PDAC was seen in 




Figure 5.2: Progression based histological changes in LSLKRASG12D/+;p48Cre/+ mice 
pancreata. Pancreas from each animal was divided into pancreas head (P-Head) and pancreas 
tail (P-Tail) and processed separately. H&E staining was used for histological analysis at weeks 
(Wk) - 4, 10, 15, 20 and 25 of age in male and female animals. Histological changes are 
represented by colored arrows: enlarged nuclei (white), papillary structures/cribriform (yellow), 
epithelial thickening (black), necrotic cells in ductal lumen (green), collapsed duct (red) and 
infiltration of basement membrane (cyan). Images were captured by AxioCam MrC5 camera at 





Figure 5.3: Trichrome staining in various progression stages of PanC. Pancreas, both 
pancreas head (P-Head) and pancreas tail (P-Tail) from male and female animals in the age-
based progression scheme were stained for collagen deposition (collagen is stained blue) using 
Masson trichrome stain at weeks (Wk) - 4, 10, 15, 20 and 25 of age. Images were captured by 




replaced and infiltrated by PDAC morphology (Fig. 5.2). Trichrome staining for assessment of 
tissue collagen accumulation which is associated with more aggressive and metastatic PanC 
phenotype, revealed a gradual  increase in collagen deposition with PanC progression upto week 
25 in both male and female LSLKRASG12D/+;p48Cre/+  transgenic mice; a marginal increase in 
collagen deposition was observed from week 4 to week 25, with the maximum collagen 
accumulation seen in the pancreas at week 25 (Fig 5.3) [338].    
LSLKRASG12D/+;p48Cre/+  transgenic animals exhibited disease progression with 200mg/Kg 
BMJ administration 
Following results from age based progression of Panc in LSLKRASG12D/+;p48Cre/+  
transgenic mice, we examined BMJ based intervention approach at two stages of the disease, 
mainly from early onset of low grade PanINs: week 4-10 (Fig. 5.4A), and from PanIN1B/2 
initiation: week 6-15 (Fig. 5.4B). 200 mg/Kg BMJ dosing increased the number and area of 
PanIN lesions compared to the untreated controls in LSLKRASG12D/+;p48Cre/+  transgenic mice 
(data not shown). The trend was similar for BMJ treated animals in all study cohorts; BMJ 
dosing from week 4-10 and week 6-15 of age caused the disease to progress, as observed by the 
changes in ductal morphology. For the treatment group of week 4-10 of age, while the control 
animals displayed a lower ductal epithelium and maintained a relatively normal/intact ductal 
morphology, BMJ fed animals had a thickened/columnar ductal epithelium with nuclear atypia 
and pleiomorphism where the nuclei were shoved towards the basement membrane, commonly 
seen in PanIN-1A/B [333, 339]. Disease progressed to PanIN-2 with BMJ administration from 
week 6-15 of age where loss of nuclear polarity with nuclear enlargement and crowding was 
seen [333, 339]. Overall, PDAC seemed to initiate early on (as early as week 10), where the 





Figure 5.4: 200mg/Kg BMJ induced histological changes in LSLKRASG12D/+;p48Cre/+ mice 
pancreata. H&E analysis of pancreas head (P-Head) and pancreas tail (P-Tail) in control and 
200 mg/Kg BMJ dosed animals from (A) Wk 4-10 and (B) Wk 6-15 of age, in male and female 
mice. Images were captured by AxioCam MrC5 camera at 10x objective. The magnified insets 









Figure 5.5: Trichrome staining in pancreata of LSLKRASG12D/+;p48Cre/+ mice dosed with 
200mg/Kg BMJ. Pancreas head (P-Head) and pancreas tail (P-Tail) in control and 200 mg/Kg 
BMJ dosed animals were stained with Masson trichrome stain to study the changes in collagen 
deposition (collagen is stained blue) in male and female mice in (A) Wk 4-10 and (B) Wk 6-15 






Results from trichrome staining disclosed no changes within the groups (Fig 5.5A, 5.5B). No 
apparent changes in animal body weights were observed with BMJ administration compared to 
the untreated controls (data not shown). 
LSLKRASG12D/+;p48Cre/+  transgenic animals exhibited no distinct histological changes with 
100mg/Kg BMJ administration 
Based on the dismal results from 200mg/Kg BMJ dosing in LSLKRASG12D/+;p48Cre/+  
animals, we tested a lower dose of BMJ in these transgenic animals. The experimental mice were 
now administered a lower dose of 100mg/Kg BMJ from week 4-10 of age (Fig. 5.6A), and from 
week 6-15 of age (Fig. 5.6B). While the extent of PDAC was higher with BMJ administration 
where most of the pancreatic tissue was replaced by adenocarcinoma infiltration, no major 
changes in ductal morphology were observed within the untreated control and BMJ treated 
animals. By the end of week 10, both control and BMJ treated animals had loss of nuclear 
polarity and elongated columnar cells. However, at the completion of week 15, control and BMJ 
treated animals both exhibited micropapillary structures with thickening of ductal epithelium and 
further nuclear atypia. Yet again, female animals had a more aggressive disease state with greater 
degree of PDAC and cribriforming along with necrosis in the ductal lumen, a distinct 
characteristic of PanIN-3 [333, 339]. Trichrome staining in all cohorts revealed no significant 






Figure 5.6: 100mg/Kg BMJ induced histological changes in LSLKRASG12D/+;p48Cre/+ mice 
pancreata. H&E analysis of pancreas head (P-Head) and pancreas tail (P-Tail) in control and 
100 mg/Kg BMJ dosed animals from (A) Wk 4-10 and (B) Wk 6-15 of age, in male and female 
mice. Images were captured by AxioCam MrC5 camera at 10x objective. The magnified insets 










Figure 5.7: Trichrome staining in pancreata of LSLKRASG12D/+;p48Cre/+ mice dosed with 
100mg/Kg BMJ. Pancreas head (P-Head) and pancreas tail (P-Tail) in control and 100 mg/Kg 
BMJ dosed animals were stained with Masson trichrome stain to study the changes in collagen 
deposition (collagen is stained blue) in male and female mice in (A) Wk 4-10 and (B) Wk 6-15 








It is well documented that vast majority of PDACs express mutated KRAS; it is also 
considered a critical initiating event in PDAC [340]. Mutated KRAS is a frequent occurrence in > 
90% of PanINs and PDACs where single nucleotide mutations at codon 12 are the most common 
feature [334]. Presence of KRASG12D is well associated with significantly decreased overall 
survival in PanC patient populations [341]. KRAS encodes a small GTPase located on the shorter 
arm of chromosome 12, which actively contributes to cellular differentiation, proliferation, 
migration and apoptosis, thereby facilitating cancer signaling pathways [342]. EGFR activation 
mediated key downstream signaling pathway molecules of KRAS are initiated and include RAF, 
MEK and MAPK cascade, responsible for cancer cell proliferation and motility alongside 
activated PI3K/AKT/mTOR pathway mediated inhibition on apoptosis [343]. Oncogenic KRAS 
alters cancer cell metabolism to sustain carcinogenesis under unfavorable conditions of 
increasingly fibrotic tumor microenvironment and limited nutrient supply [280, 284, 344]. 
Therefore, the incorporation of mutated KRAS based LSLKRASG12D/+;p48Cre/+  transgenic mouse 
model was highly imperative and required for deeper investigation into PanC tumorigenesis and 
progression. In addition to KRASG12D dependent PanC initiation and p48Cre mediated pancreatic 
origin of the disease (tumor initiation localized exclusively to pancreas and plays a role in 
mammalian pancreatic development), this model recapitulates the course of PanC progression 
including different stages of PanINs to ultimately PDAC, as understood in human PanC [333]. 
LSLKRASG12D/+;p48Cre/+  transgenic mouse model displays a series of four well-characterized 
PanIN grades before succumbing to invasive PDAC form within a year [333]. PanINs are 
subclassified into PanIN-1A, PanIN-1B, PanIN2 and PanIN3 based on the degree of architectural 
atypia where PanIN-1A/B represent complete absence or slight atypia (low grade), PanIN-2 for 
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moderate atypia (intermediate grade), and PanIN-3 presence suggests severe atypia (high grade) 
[332]. High grade PanINs are detected with amplified frequency in older mice where the 
typically existing acinar parenchyma is replaced extensively by stromal/desmoplastic fibroblasts 
and high influx of inflammatory cells [337].  
Transgenic mouse models are being routinely used for multiple drug efficacy studies 
involving synthetic and natural agents, alone or in combination therapy [336, 345-347]. Though 
nutrients by themselves offer an effective strategy in cancer chemoprevention, mainstream 
chemotherapy is gradually shifting gears to include multidrug/combination therapies with 
nutrients and dietary agents for improved efficacy and negate the detrimental side-effects of 
synthetic antineoplastic agents [348-350]. Our study was initiated by following the PanIN 
progression to PDAC using LSLKRASG12D/+;p48Cre/+  transgenic mouse model over a course of 4-
25 weeks in male and female mice. Early stage PanINs were seen in both males and females by 
week 4 of age. By week 20, the PanINs gradually progressed to PanIN3 in both sexes. Traces of 
PDAC infiltration were evident in male animals by week 15, however, female animals depicted 
onset of PDAC by as early as week 10 with a much higher degree of PDAC infiltration. Gravity 
of the disease increased by week 20 and 25 when majority of the pancreatic parenchyma was 
infiltrated by PDAC; female pancreas had near complete replacement of pancreatic parenchyma 
by PDAC, reflecting a more aggressive disease progression. Based on the age dependent PanC 
progression pattern, intervention time points of week 4-10 and week 6-15 were selected for BMJ 
efficacy studies. 200mg/Kg BMJ dosing in LSLKRASG12D/+;p48Cre/+  animals caused further 
disease progression to moderately advanced stages, more aggressive than what was observed in 
their untreated control counterparts. A lower dose of 100mg/Kg BMJ dosing demonstrated no 
rescue from PanC progression where BMJ was administered from weeks 4-10 and 6-15, of age. 
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Trichrome staining exhibited no significant collagen deposition, originally thought to aid in 
PanC aggressiveness [351]. Interestingly, BMJ has demonstrated outstanding anticancer efficacy 
in PanC cell flank xenografts and patient derived xenografts of PanC in our previous studies. 
However, a probable cause of failed BMJ potential observed in LSLKRASG12D/+;p48Cre/+ mouse 
model could be explained by the loss of BMJ activity in early stage PanC tumors. For our drug 
efficacy studies utilizing PanC cell line derived and patient derived xenografts, the tumors were 
high grade PanC or PDAC with no hint of intact tissue/ductal morphology where BMJ feeding 
resulted in an increased anticancer efficacy, whereas the tissue architecture was comparatively 
better preserved in the transgenic mouse model demonstrating pancreatic ducts with moderate 
atypia and PanIN2, an intermediate stage of PanC progression. Additionally, numerous studies 
performed in normal and diabetic pancreatic tissue have reported BMJ intake to be associated 
with an increased cell proliferation rate of insulin (β cells) and somatostatin (δ cells) positive 
cells, and induction of cell repair in the pancreatic islets [352-355]. This partially describes the 
reason behind dismal BMJ efficacy in initial stages of PanC where potentially, the drug identifies 
and recognizes the intact pancreatic tissue/ductal morphology and in turn, acts via increasing the 
pancreatic cell mass. Henceforth, the current batch of studies are in preliminary stages and the 
results obtained do not necessarily reflect the complete BMJ efficacy mechanism. Therefore, 
these results require further inclusion of additional experimental time points at advanced PanC 
stages with a stronger sample size for both male and female animals. Future studies entail 
incorporation of later time points of week 20 and week 25 in PanC progression, where BMJ 
might display improved anticancer efficacy upon encountering poorly differentiated advanced 
tumor grades, mainly PanIN3 and PDAC. Taken together, a more comprehensive and extended 
analysis of BMJ dosing including several intervention time points in LSLKRASG12D/+;p48Cre/+ 
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transgenic animals is needed to establish the true potential of this natural agent in a progression 




















SUMMARY AND FUTURE DIRECTIONS 
Increased incidences, asymptomatic progression to invasive forms, poor diagnostic 
techniques, limited treatment options, extensive debilitating side-effects, therapeutic resistance 
and high probability of disease relapse deem PanC as one of the worst cancer types. PanC is 
estimated to be the second leading cause of cancer related fatalities by 2030 [356]. A repertoire 
of intricate genetic mutations and dysregulated pathways result in a miserable 5-year survival 
rate coupled with scarcity of efficient treatment modalities and poor overall survival (~6-12 
months), add fuel to the fire, making PanC a highly complex disease state. Hence, current dismal 
state of PanC management demands therapeutic agents with improved anticancer efficacy and 
minimal unwanted secondary effects bringing nutraceuticals/phytochemicals to mainstream 
chemotherapy. Bitter melon (crude juice/ extracts/ derivatives) is a natural agent possessing 
several health benefits against a variety of disease forms, including diabetes and cancer, via 
multiple mechanisms [357-359]. Certain bioactive compounds derived from bitter melon, known 
to possess anticancer effects are BG-4, kuguaglycoside C, kuguacin J, recombinant anti-HIV and 
antitumor protein MAP30, and α-momorcharin [360]. For facilitating its anticancer activity, 
bitter melon has been reported to target cell proliferation/apoptosis, metastasis, cell cycle and 
signaling pathways, metabolic pathway intermediates/transporter proteins, etc. [194, 360]. Yet, 
mechanistic insights detailing anticancer potential and underlying pathway targets of bitter 
melon are very limited, necessitating further analysis. Results from our studies have elucidated 
the anticancer mechanisms of bitter melon juice (BMJ) in its efficacy against PanC where it 
targets the PanC-CSC and bulk tumor cells, modulates PanC cell metabolism for improved 
activity and proves highly successful as a combination agent by improving drug-response of 
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resistant tumor cells in preclinical mouse models of PanC-PDX, although its potential remains to 
be fully tested in a transgenic mouse model of PanC progression.  
The primary goal of Chapter II was to understand the role of BMJ in inhibiting PanC-
CSC pool and the associated molecular targets. This was vital since CSCs have been extensively 
linked with cancer initiation, progression, metastasis and chemoresistance in turn facilitating 
their continuous self-renewal and PanC progression [356]. FACS sorted human PanC-CSC 
derived spheroids were equally responsive to BMJ treatment as the bulk tumor cells/unsorted 
population. PanC spheroids subjected to a range of BMJ doses displayed a higher efficacy in 
spheroid formation compared to untreated controls, by responding with decreased number and 
size of spheroids. Subsequent assays in PanC cell monolayers and spheroids were performed to 
determine PanC-CSC associated molecular markers. Of all the tested molecules, transcription 
factor SOX2 and cell surface adhesion marker CD44 were found to be the most downregulated 
with BMJ treatments, thereby identifying them as candidate targets. In vivo tumor tissue analysis 
from BMJ-fed nude mice carrying MiaPaCa2 tumor xenograft further validated the in vitro 
findings with addition of PDX1, a transcription factor involved in PanC progression. 
Interestingly, we were also able to show that BMJ exposure conferred drug sensitivity in PanC 
cells previously resistant to gemcitabine (GEM) by decreasing PanC stemness in spheroid 
assays, where monotherapy with GEM alone is reported to cause CSC enrichment [361, 362]. 
This suggests targeting and inhibiting PanC-CSC dependent disease progression as one of the 
mechanisms in BMJ linked anticancer potential for PanC management. 
Future studies in this chapter will include deeper investigation of the underlying 
pathways activated in PanC-CSCs, with BMJ treatment. Several signaling pathways like 
hedgehog (Hh), Notch and Wnt pathways have been implicated in CSC initiation responsible for 
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tumorigenesis, where these pathway aberrations lead to dysregulated CSC self-renewal, 
proliferation and differentiation [363]. Additionally, studies have also pointed to enrichment of 
CSC pool following monotherapeutic treatment regimens with GEM, while promising outcomes 
with better curative results were achieved using a combination of CSC inhibitors coupled with 
conventional chemotherapeutics with decreased tumor burden due to CSC depletion and 
improved survival, in PanC [361, 362]. Therefore, it will be an interesting approach to use a 
combination of BMJ+GEM for revealing the PanC-CSC associated targets/molecular markers 
and pathways modulated post BMJ exposures in cell and animal models of PanC. Furthermore, it 
will be important to test the in vivo extended efficacy of BMJ on PanC-CSC derived xenografts 
since CSCs are known to be involved in tumor relapse. Ideally, BMJ fed nude mice xenografts 
initiated from PanC-CSC FACS sorted cells, will be subjected to magnetic activated cell sorting 
(MACS) dissociation and isolation of CSC population which will be reinjected in nude animals 
to test their reduced ability of tumor formation in second generation tumors and beyond.  
For Chapter III, we tested BMJ efficacy in modulation and regulation of PanC cell 
metabolism. Our previous studies report the phosphorylation and activation of AMPK, the 
master metabolic regulator, in response to BMJ treatment, causing apoptotic death in PanC cells 
[190]. Extensive metabolic reprograming is considered a hallmark of cancer progression 
whereby cancer cells undergo changes in their metabolic routes to fulfil the constant bioenergetic 
requirements of rapidly proliferating cells to support tumorigenesis [364]. Several anticancer 
drug discovery approaches include pharmacological AMPK activators, identifying AMPK as a 
suitable target for cancer chemotherapeutics [365]. In this aim, BMJ mediated modulation of 
PanC cell metabolome was investigated by NMR-spectroscopy, which highlighted significant 
changes in glucose and lactate metabolism. PanC generally displays enhanced lactate levels in 
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the extracellular space, resulting in failed cancer therapies due to reduced drug uptake; however, 
BMJ treatment caused a significant increase in intracellular lactate levels denoting lactate build-
up within the cells [320]. Further validation studies showed BMJ led a decrease in GLUT1 and 
MCT4 transporter expression in PanC cells thereby possibly affecting cellular uptake and export 
of glucose and lactate for cell growth and proliferation. These results were further confirmed in 
PANC1 xenograft animals where the transporter expression decreased with BMJ exposure in 
addition to significantly decreased LDH and AMPK levels, all supporting lactate export as a 
major target of BMJ mediated alteration of PanC cell metabolome in exerting its anticancer 
efficacy. 
Future studies for this chapter will include NMRS metabolomics on frozen tumor 
sections from BMJ-treated animals for a better correlation of results observed with in vitro PanC 
models. Additionally, an enzymatic assay for LDH activity using BMJ treated tumor tissue 
would further strengthen the results from expression levels of LDH in tumor tissues, as seen by 
immunohistochemistry. Varying KRAS statuses have differential treatment outcomes in PanC 
patient populations undergoing chemotherapy [366, 367]. Therefore, it would be interesting to 
study BMJ treatment responses in PanC types differing in their KRAS mutational statuses to 
better understand the drug efficacy mechanisms regarding KRAS dependence/independence, as 
observed in vitro with PANC1 (mutated KRAS) and BxPC3 (wild type KRAS) cells. 
Chapter IV discussed improved drug efficacy employing a combination of BMJ+GEM 
over GEM monotherapy in PanC. Growing rates of treatment resistance leading to dismal overall 
survival in cancer patients remains a prime challenge [52]. GEM, although a widely used 
standard of care drug for locally advanced and metastatic PanC therapy, develops rapid 
resistance within weeks of treatment initiation [368]. Hence, various drug combinations are 
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promptly being screened for improved drug sensitivity over single-agent chemotherapy [369]. 
We tested a range of BMJ doses in combination with GEM in multiple PanC cells lines to 
determine the nature of drug combinations. Encouraging results of BMJ+GEM treatment on 
PanC cell viability were further confirmed in PanC-PDX mouse models. BMJ in combination 
with GEM proved to be highly successful in decreasing PanC-PDX tumor volumes and 
displayed sustained efficacy by inhibiting tumor regrowth; even post treatment termination 
validated by immunohistochemistry of drug efficacy markers. Underlying pathway analysis for 
GEM resistance confirmed BMJ mediated improved treatment response in tumors exposed to 
BMJ+GEM compared to GEM alone. BMJ caused increased drug sensitivity by regulating the 
aberrant GEM metabolic pathway, assisting improved GEM uptake and metabolism by cancer 
cells as represented by hENT1, RRM1 and dCK analysis. Collectively, these results support the 
use of BMJ as an efficacious combination agent for overcoming GEM resistance in PanC, 
thereby providing an opportunity for reduced patient distress by minimizing GEM associated 
side-effects and heightened translational relevance using PDX models. 
Regulation of GEM transport and metabolism markers by BMJ was a novel finding from 
this chapter. We can further elucidate other mechanisms and potential pathway crosstalk 
involved in combination-based treatments of BMJ+GEM, including changes in PanC metabolic 
components similar to chapter III. It will be of great significance to test the combination of BMJ 
with several other PanC therapeutics like 5-FU, nab-paclitaxel, FOLFIRINOX, abraxane, etc., 
for efficacy studies and molecular pathways. Additionally, the frozen PanC-PDX tumor tissues 
can be further analyzed for biomarker discovery and pathway targets, including CSC and 
metabolic markers. This can involve derivation of cell lines and organoids from PanC-PDX 
tumors for combination treatments and other mechanistic studies. Also, gene expression profiling 
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from the different PDX explants used in this study will add to better characterization of the 
tumor explants and explain their treatment response. Furthermore, incorporation of PanC-PDX 
explants with differing KRAS mutational statuses can provide a deeper insight into BMJ based 
anti-cancer efficacy in combination therapy. 
In Chapter V, we sought to establish BMJ efficacy in a transgenic mouse model of PanC. 
The LSLKRASG12D/+;p48Cre/+ model was carefully chosen based on its potential to effectively 
mimic human PanC progression with development of various grades of PanINs before advancing 
to the metastatic and invasive PDAC [333]. We sought to explore the role of BMJ as a 
chemoprevention and intervention agent by initiating BMJ treatments in these animals as early as 
4/5 weeks of age. The idea was to investigate BMJ efficacy in inhibiting PanC progression from 
early to intermediate lesions (PanIN1A/B to PanIN2). Alongside age-based progression, we also 
evaluated multiple BMJ doses (100 and 200mg/Kg) for our studies. While H & E analysis of 
pancreas tissues from male and female animals exhibited a much aggressive disease progression 
in females, a stronger sample size will be required to verify this finding. Also, whereas 
200mg/Kg BMJ dose proved detrimental in inhibiting disease progression, a lower dose of 
100mg/Kg BMJ displayed no apparent changes between control and treated animals.  
The results obtained from this chapter are just preliminary studies providing a basis for more 
elaborate evaluation of BMJ efficacy in various progression time points for this transgenic 
mouse model. Future studies will include more male and female experimental animals added per 
group (control and BMJ treated) for desired study time-points until higher grade PDAC develop. 
Additionally, pancreata from control animals followed as a function of time will be analyzed for 
histological and molecular differences within male and female counterparts at different stages of 
PanC advancement.  
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Overall, the aforementioned results from exhaustive investigation into various 
mechanisms of PanC carcinogenesis highlights BMJ potential as a resourceful natural agent 
capable of regulating PanC via multiple mechanisms, alone or in combination with clinical 
chemotherapeutic agents. Nevertheless, more studies are needed to reveal several other aspects 
of BMJ mediated efficacy in PanC. Increasing evidence supports the involvement of tumor 
microenvironment (TME) in aiding PanC progression. This comprises of various TME 
components like tumor cells, stroma, immune component, adaptive metabolism, invasive EMT 
and CSC pool [370]. Extensive desmoplasia is commonly associated with PanC aggressiveness 
and chemoresistance; however, this theory remains debatable [315, 371]. Combination of 
BMJ+GEM displayed an increase in fibrosis in PanC-PDX tumors, which can be subjected to 
further analysis of stromal components, mainly collagen, hyaluronic acid (HA) content, laminin 
and fibronectin. PanC stroma contributes to hypoperfusion, hypoxia and consists of infiltrative 
macrophages and inflammatory cells, all involved in inhibition of drug delivery to tumor cells 
and assist tumor-stroma interactions [372]. This can be evaluated in both PanC-PDX and 
transgenic tumors with BMJ alone or in combination with leading immunotherapeutic agents 
consisting of cancer vaccines, immune modulators, monoclonal antibodies, etc [373]. 
Consequently, BMJ dosing will need to be optimized for its efficient bioavailability before 







Very few preliminary studies, including those from our group, have alluded to the 
anticancer efficacy of bitter melon juice (BMJ), extracts and its components, mainly cucurbitane 
triterpenoids and cucurbitane type triterpene glycosides, which act by causing inhibition of 
cancer stem cells, induction of cell death, and modulation of cancer cell metabolism by 
activation of principal metabolic regulators like AMPK and PPARγ [190, 193, 357, 374]. 
Although various health benefits are associated with bitter melon intake, ours is the first group to 
successfully decipher and report the therapeutic potential of BMJ in PanC initiation and 
progression, and to further explain the underlying mechanisms of action and BMJ targets 
involved in the observed efficacy. BMJ emerged as a potent natural agent exhibiting promising 
anticancer potential in PanC management. Its potential was first tested in several human PanC 
cells and spheroids, primarily mediating its anticancer effects by targeting both PanC-CSCs and 
bulk tumor cell populations. CSCs have been routinely implicated in cancer initiation, 
progression, relapse and treatment resistance thereby proving as ideal therapeutic targets [375]. 
We showed BMJ-facilitated decrease in expression of PanC-CSC associated molecular markers 
including SOX2, OCT4, NANOG and CD44. BMJ treatment modulated the PanC cell 
metabolome for improved efficacy by altering lactate and glucose transport. BMJ decreased 
glucose uptake and lactate export in PanC cells and tissues, thereby identifying lactate and 
glucose transporters as the prime targets involved in altered metabolism of cancerous cells. BMJ 
elicited an enhanced treatment response and sustained efficacy in three different PanC-PDX 
explants when used in combination with GEM where GEM alone failed to demonstrate extended 
sensitivity and displayed initiation of treatment resistance where dismal results are commonly 
indicated by development of drug resistance to GEM monotherapy in PanC patients. These 
findings hold immense importance regarding the lack of significant improvements in PanC 
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patient survival for the past several decades [376, 377]. MiaPaCa2 and PANC1 xenograft studies 
employing BMJ administration exhibited significant efficacy over untreated controls. Only a 
slight variation in the treatment outcomes between different PanC-PDX explants was seen, 
which can be attributed to the widely heterogeneous nature of the disease, thus explaining the 
differential response to treatments [378]. Additionally, LSLKRASG12D/+;p48Cre/+  transgenic 
mouse model of PanC was employed for determining BMJ potential as an effective intervention 
agent in an age-based progression model of PanC which requires additional investigation and 
inclusion of several timepoints to confirm BMJ efficacy at various stages of PanC progression. 
Taken together, aforementioned results clearly state the importance of BMJ as an efficient 
anticancer agent and define the fundamental mechanisms of action involved in PanC regulation, 
displaying immense potential with minimal accompanying side-effects when used alone or in 
combination with widespread chemotherapeutic GEM. These studies present a solid foundation 
for further investigating the potential of this natural agent in the clinic based on the improved 
translational relevance exhibited in the preclinical nude mice flank xenografts and PanC-PDX 
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